id	sid	tid	token	lemma	pos
easat-4305	1	1	edelweiss	edelweiss	PROPN
easat-4305	1	2	applied	apply	VERB
easat-4305	1	3	science	science	NOUN
easat-4305	1	4	and	and	CCONJ
easat-4305	1	5	technology	technology	NOUN
easat-4305	1	6	issn	issn	PROPN
easat-4305	1	7	:	:	PUNCT
easat-4305	1	8	2576	2576	NUM
easat-4305	1	9	-	-	SYM
easat-4305	1	10	8484	8484	NUM
easat-4305	1	11	vol	vol	NOUN
easat-4305	1	12	.	.	PROPN
easat-4305	2	1	9	9	NUM
easat-4305	2	2	,	,	PUNCT
easat-4305	2	3	no	no	INTJ
easat-4305	2	4	.	.	NOUN
easat-4305	2	5	1	1	NUM
easat-4305	2	6	,	,	PUNCT
easat-4305	2	7	1010	1010	NUM
easat-4305	2	8	-	-	SYM
easat-4305	2	9	1018	1018	NUM
easat-4305	2	10	2025	2025	NUM
easat-4305	2	11	publisher	publisher	NOUN
easat-4305	2	12	:	:	PUNCT
easat-4305	2	13	learning	learn	VERB
easat-4305	2	14	gate	gate	NOUN
easat-4305	2	15	doi	doi	PROPN
easat-4305	2	16	:	:	PUNCT
easat-4305	2	17	10.55214/25768484.v9i1.4305	10.55214/25768484.v9i1.4305	NUM
easat-4305	2	18	©	©	PROPN
easat-4305	2	19	2025	2025	NUM
easat-4305	2	20	by	by	ADP
easat-4305	2	21	the	the	DET
easat-4305	2	22	authors	author	NOUN
easat-4305	2	23	;	;	PUNCT
easat-4305	2	24	licensee	licensee	PROPN
easat-4305	2	25	learning	learning	NOUN
easat-4305	2	26	gate	gate	NOUN
easat-4305	3	1	©	©	PROPN
easat-4305	3	2	2025	2025	NUM
easat-4305	3	3	by	by	ADP
easat-4305	3	4	the	the	DET
easat-4305	3	5	authors	author	NOUN
easat-4305	3	6	;	;	PUNCT
easat-4305	3	7	licensee	licensee	PROPN
easat-4305	3	8	learning	learning	NOUN
easat-4305	3	9	gate	gate	NOUN
easat-4305	3	10	history	history	NOUN
easat-4305	3	11	:	:	PUNCT
easat-4305	3	12	received	receive	VERB
easat-4305	3	13	:	:	PUNCT
easat-4305	3	14	21	21	NUM
easat-4305	3	15	november	november	PROPN
easat-4305	3	16	2024	2024	NUM
easat-4305	3	17	;	;	PUNCT
easat-4305	3	18	revised	revise	VERB
easat-4305	3	19	:	:	PUNCT
easat-4305	3	20	3	3	NUM
easat-4305	3	21	january	january	NOUN
easat-4305	3	22	2025	2025	NUM
easat-4305	3	23	;	;	PUNCT
easat-4305	3	24	accepted	accept	VERB
easat-4305	3	25	:	:	PUNCT
easat-4305	3	26	10	10	NUM
easat-4305	3	27	january	january	PROPN
easat-4305	3	28	2025	2025	NUM
easat-4305	3	29	;	;	PUNCT
easat-4305	3	30	published	publish	VERB
easat-4305	3	31	:	:	PUNCT
easat-4305	4	1	17	17	NUM
easat-4305	4	2	january	january	NOUN
easat-4305	4	3	2025	2025	NUM
easat-4305	4	4	*	*	PUNCT
easat-4305	4	5	correspondence	correspondence	NOUN
easat-4305	4	6	:	:	PUNCT
easat-4305	5	1	thuytbvo.igr@gmail.com	thuytbvo.igr@gmail.com	X
easat-4305	5	2	evaluation	evaluation	NOUN
easat-4305	5	3	of	of	ADP
easat-4305	5	4	the	the	DET
easat-4305	5	5	sensitivity	sensitivity	NOUN
easat-4305	5	6	and	and	CCONJ
easat-4305	5	7	specificity	specificity	NOUN
easat-4305	5	8	of	of	ADP
easat-4305	5	9	monoclonal	monoclonal	NOUN
easat-4305	5	10	antibodies	antibody	NOUN
easat-4305	5	11	for	for	ADP
easat-4305	5	12	detecting	detect	VERB
easat-4305	5	13	the	the	DET
easat-4305	5	14	thioredoxin	thioredoxin	PROPN
easat-4305	5	15	antigen	antigen	NOUN
easat-4305	5	16	in	in	ADP
easat-4305	5	17	hepatocellular	hepatocellular	ADJ
easat-4305	5	18	carcinoma	carcinoma	NOUN
easat-4305	5	19	patients	patient	NOUN
easat-4305	5	20	duong	duong	VERB
easat-4305	5	21	quang	quang	PROPN
easat-4305	6	1	huy1,2	huy1,2	PROPN
easat-4305	6	2	,	,	PUNCT
easat-4305	6	3	ho	ho	PROPN
easat-4305	6	4	truong	truong	PROPN
easat-4305	6	5	giang2,3	giang2,3	PROPN
easat-4305	6	6	,	,	PUNCT
easat-4305	6	7	nguyen	nguyen	PROPN
easat-4305	6	8	thi	thi	PROPN
easat-4305	6	9	diem1	diem1	PROPN
easat-4305	6	10	,	,	PUNCT
easat-4305	6	11	vo	vo	PROPN
easat-4305	6	12	thi	thi	VERB
easat-4305	6	13	bich	bich	PROPN
easat-4305	6	14	thuy1,3	thuy1,3	PROPN
easat-4305	6	15	*	*	PROPN
easat-4305	6	16	1institute	1institute	NUM
easat-4305	6	17	of	of	ADP
easat-4305	6	18	genome	genome	NOUN
easat-4305	6	19	research	research	NOUN
easat-4305	6	20	,	,	PUNCT
easat-4305	6	21	vietnam	vietnam	PROPN
easat-4305	6	22	academy	academy	PROPN
easat-4305	6	23	of	of	ADP
easat-4305	6	24	science	science	PROPN
easat-4305	6	25	and	and	CCONJ
easat-4305	6	26	technology,18	technology,18	PROPN
easat-4305	6	27	hoang	hoang	PROPN
easat-4305	6	28	quoc	quoc	PROPN
easat-4305	6	29	viet	viet	PROPN
easat-4305	6	30	,	,	PUNCT
easat-4305	6	31	cau	cau	PROPN
easat-4305	6	32	giay	giay	PROPN
easat-4305	6	33	,	,	PUNCT
easat-4305	6	34	hanoi	hanoi	PROPN
easat-4305	6	35	100000	100000	NUM
easat-4305	6	36	,	,	PUNCT
easat-4305	6	37	vietnam	vietnam	PROPN
easat-4305	6	38	.	.	PUNCT
easat-4305	6	39	2103	2103	NUM
easat-4305	6	40	military	military	ADJ
easat-4305	6	41	hospital	hospital	NOUN
easat-4305	6	42	,	,	PUNCT
easat-4305	6	43	vietnam	vietnam	PROPN
easat-4305	6	44	military	military	PROPN
easat-4305	6	45	medical	medical	PROPN
easat-4305	6	46	university	university	PROPN
easat-4305	6	47	,	,	PUNCT
easat-4305	6	48	hanoi	hanoi	PROPN
easat-4305	6	49	100000	100000	NUM
easat-4305	6	50	,	,	PUNCT
easat-4305	6	51	vietnam	vietnam	PROPN
easat-4305	6	52	.	.	PUNCT
easat-4305	7	1	3graduate	3graduate	NUM
easat-4305	7	2	university	university	NOUN
easat-4305	7	3	of	of	ADP
easat-4305	7	4	science	science	NOUN
easat-4305	7	5	and	and	CCONJ
easat-4305	7	6	technology	technology	NOUN
easat-4305	7	7	,	,	PUNCT
easat-4305	7	8	vietnam	vietnam	PROPN
easat-4305	7	9	academy	academy	PROPN
easat-4305	7	10	of	of	ADP
easat-4305	7	11	science	science	NOUN
easat-4305	7	12	and	and	CCONJ
easat-4305	7	13	technology	technology	NOUN
easat-4305	7	14	,	,	PUNCT
easat-4305	7	15	18	18	NUM
easat-4305	7	16	hoang	hoang	PROPN
easat-4305	7	17	quoc	quoc	PROPN
easat-4305	7	18	viet	viet	PROPN
easat-4305	7	19	,	,	PUNCT
easat-4305	7	20	cau	cau	PROPN
easat-4305	7	21	giay	giay	PROPN
easat-4305	7	22	,	,	PUNCT
easat-4305	7	23	hanoi	hanoi	PROPN
easat-4305	7	24	100000	100000	NUM
easat-4305	7	25	,	,	PUNCT
easat-4305	7	26	vietnam	vietnam	PROPN
easat-4305	7	27	;	;	PUNCT
easat-4305	7	28	thuytbvo.igr@gmail.com	thuytbvo.igr@gmail.com	X
easat-4305	7	29	(	(	PUNCT
easat-4305	7	30	v.t.b.t	v.t.b.t	PROPN
easat-4305	7	31	.	.	PUNCT
easat-4305	7	32	)	)	PUNCT
easat-4305	7	33	.	.	PUNCT
easat-4305	8	1	abstract	abstract	ADV
easat-4305	8	2	:	:	PUNCT
easat-4305	8	3	the	the	DET
easat-4305	8	4	objective	objective	NOUN
easat-4305	8	5	of	of	ADP
easat-4305	8	6	this	this	DET
easat-4305	8	7	study	study	NOUN
easat-4305	8	8	was	be	AUX
easat-4305	8	9	to	to	PART
easat-4305	8	10	evaluate	evaluate	VERB
easat-4305	8	11	the	the	DET
easat-4305	8	12	sensitivity	sensitivity	NOUN
easat-4305	8	13	and	and	CCONJ
easat-4305	8	14	specificity	specificity	NOUN
easat-4305	8	15	of	of	ADP
easat-4305	8	16	the	the	DET
easat-4305	8	17	monoclonal	monoclonal	NOUN
easat-4305	8	18	antibody	antibody	NOUN
easat-4305	8	19	of	of	ADP
easat-4305	8	20	thioredoxin	thioredoxin	PROPN
easat-4305	8	21	(	(	PUNCT
easat-4305	8	22	mab	mab	NOUN
easat-4305	8	23	-	-	PUNCT
easat-4305	8	24	txn	txn	NOUN
easat-4305	8	25	)	)	PUNCT
easat-4305	8	26	for	for	ADP
easat-4305	8	27	detecting	detect	VERB
easat-4305	8	28	the	the	DET
easat-4305	8	29	thioredoxin	thioredoxin	PROPN
easat-4305	8	30	(	(	PUNCT
easat-4305	8	31	txn	txn	NOUN
easat-4305	8	32	)	)	PUNCT
easat-4305	8	33	antigen	antigen	NOUN
easat-4305	8	34	in	in	ADP
easat-4305	8	35	serum	serum	NOUN
easat-4305	8	36	samples	sample	NOUN
easat-4305	8	37	from	from	ADP
easat-4305	8	38	patients	patient	NOUN
easat-4305	8	39	with	with	ADP
easat-4305	8	40	hepatocellular	hepatocellular	ADJ
easat-4305	8	41	carcinoma	carcinoma	NOUN
easat-4305	8	42	(	(	PUNCT
easat-4305	8	43	hcc	hcc	PROPN
easat-4305	8	44	)	)	PUNCT
easat-4305	8	45	.	.	PUNCT
easat-4305	9	1	to	to	PART
easat-4305	9	2	achieve	achieve	VERB
easat-4305	9	3	this	this	PRON
easat-4305	9	4	,	,	PUNCT
easat-4305	9	5	the	the	DET
easat-4305	9	6	mab	mab	NOUN
easat-4305	9	7	-	-	PUNCT
easat-4305	9	8	txn	txn	NOUN
easat-4305	9	9	,	,	PUNCT
easat-4305	9	10	generated	generate	VERB
easat-4305	9	11	from	from	ADP
easat-4305	9	12	hybridoma	hybridoma	NOUN
easat-4305	9	13	cells	cell	NOUN
easat-4305	9	14	,	,	PUNCT
easat-4305	9	15	was	be	AUX
easat-4305	9	16	utilized	utilize	VERB
easat-4305	9	17	to	to	PART
easat-4305	9	18	optimize	optimize	VERB
easat-4305	9	19	the	the	DET
easat-4305	9	20	conditions	condition	NOUN
easat-4305	9	21	for	for	ADP
easat-4305	9	22	an	an	DET
easat-4305	9	23	indirect	indirect	ADJ
easat-4305	9	24	elisa	elisa	NOUN
easat-4305	9	25	immunoassay	immunoassay	PROPN
easat-4305	9	26	.	.	PUNCT
easat-4305	10	1	the	the	DET
easat-4305	10	2	sensitivity	sensitivity	NOUN
easat-4305	10	3	,	,	PUNCT
easat-4305	10	4	specificity	specificity	NOUN
easat-4305	10	5	,	,	PUNCT
easat-4305	10	6	positive	positive	ADJ
easat-4305	10	7	predictive	predictive	ADJ
easat-4305	10	8	value	value	NOUN
easat-4305	10	9	,	,	PUNCT
easat-4305	10	10	and	and	CCONJ
easat-4305	10	11	negative	negative	ADJ
easat-4305	10	12	predictive	predictive	ADJ
easat-4305	10	13	value	value	NOUN
easat-4305	10	14	of	of	ADP
easat-4305	10	15	the	the	DET
easat-4305	10	16	assay	assay	NOUN
easat-4305	10	17	were	be	AUX
easat-4305	10	18	evaluated	evaluate	VERB
easat-4305	10	19	on	on	ADP
easat-4305	10	20	the	the	DET
easat-4305	10	21	basis	basis	NOUN
easat-4305	10	22	of	of	ADP
easat-4305	10	23	stored	store	VERB
easat-4305	10	24	patient	patient	ADJ
easat-4305	10	25	medical	medical	ADJ
easat-4305	10	26	records	record	NOUN
easat-4305	10	27	.	.	PUNCT
easat-4305	11	1	the	the	DET
easat-4305	11	2	results	result	NOUN
easat-4305	11	3	showed	show	VERB
easat-4305	11	4	that	that	SCONJ
easat-4305	11	5	indirect	indirect	ADJ
easat-4305	11	6	elisa	elisa	NOUN
easat-4305	11	7	using	use	VERB
easat-4305	11	8	mab	mab	NOUN
easat-4305	11	9	-	-	PUNCT
easat-4305	11	10	txn	txn	NOUN
easat-4305	11	11	exhibited	exhibit	VERB
easat-4305	11	12	a	a	DET
easat-4305	11	13	sensitivity	sensitivity	NOUN
easat-4305	11	14	of	of	ADP
easat-4305	11	15	93.61	93.61	NUM
easat-4305	11	16	%	%	NOUN
easat-4305	11	17	,	,	PUNCT
easat-4305	11	18	a	a	DET
easat-4305	11	19	specificity	specificity	NOUN
easat-4305	11	20	of	of	ADP
easat-4305	11	21	96	96	NUM
easat-4305	11	22	%	%	NOUN
easat-4305	11	23	,	,	PUNCT
easat-4305	11	24	a	a	DET
easat-4305	11	25	positive	positive	ADJ
easat-4305	11	26	predictive	predictive	ADJ
easat-4305	11	27	value	value	NOUN
easat-4305	11	28	of	of	ADP
easat-4305	11	29	97.77	97.77	NUM
easat-4305	11	30	%	%	NOUN
easat-4305	11	31	,	,	PUNCT
easat-4305	11	32	and	and	CCONJ
easat-4305	11	33	a	a	DET
easat-4305	11	34	negative	negative	ADJ
easat-4305	11	35	predictive	predictive	ADJ
easat-4305	11	36	value	value	NOUN
easat-4305	11	37	of	of	ADP
easat-4305	11	38	88	88	NUM
easat-4305	11	39	%	%	NOUN
easat-4305	11	40	.	.	PUNCT
easat-4305	12	1	in	in	ADP
easat-4305	12	2	conclusion	conclusion	NOUN
easat-4305	12	3	,	,	PUNCT
easat-4305	12	4	mab	mab	NOUN
easat-4305	12	5	-	-	PUNCT
easat-4305	12	6	txn	txn	NOUN
easat-4305	12	7	is	be	AUX
easat-4305	12	8	a	a	DET
easat-4305	12	9	valuable	valuable	ADJ
easat-4305	12	10	tool	tool	NOUN
easat-4305	12	11	for	for	ADP
easat-4305	12	12	detecting	detect	VERB
easat-4305	12	13	txn	txn	NOUN
easat-4305	12	14	antigens	antigen	NOUN
easat-4305	12	15	in	in	ADP
easat-4305	12	16	serum	serum	NOUN
easat-4305	12	17	samples	sample	NOUN
easat-4305	12	18	from	from	ADP
easat-4305	12	19	hcc	hcc	PROPN
easat-4305	12	20	patients	patient	NOUN
easat-4305	12	21	,	,	PUNCT
easat-4305	12	22	offering	offer	VERB
easat-4305	12	23	high	high	ADJ
easat-4305	12	24	sensitivity	sensitivity	NOUN
easat-4305	12	25	and	and	CCONJ
easat-4305	12	26	specificity	specificity	NOUN
easat-4305	12	27	for	for	ADP
easat-4305	12	28	clinical	clinical	ADJ
easat-4305	12	29	application	application	NOUN
easat-4305	12	30	.	.	PUNCT
easat-4305	13	1	keywords	keyword	NOUN
easat-4305	13	2	:	:	PUNCT
easat-4305	13	3	hepatocellular	hepatocellular	ADJ
easat-4305	13	4	carcinoma	carcinoma	NOUN
easat-4305	13	5	,	,	PUNCT
easat-4305	13	6	indirect	indirect	ADJ
easat-4305	13	7	elisa	elisa	NOUN
easat-4305	13	8	,	,	PUNCT
easat-4305	13	9	monoclonal	monoclonal	NOUN
easat-4305	13	10	antibodies	antibody	NOUN
easat-4305	13	11	,	,	PUNCT
easat-4305	13	12	sensitivity	sensitivity	NOUN
easat-4305	13	13	,	,	PUNCT
easat-4305	13	14	specificity	specificity	NOUN
easat-4305	13	15	.	.	PUNCT
easat-4305	14	1	1	1	X
easat-4305	14	2	.	.	X
easat-4305	14	3	introduction	introduction	NOUN
easat-4305	14	4	hepatocellular	hepatocellular	ADJ
easat-4305	14	5	carcinoma	carcinoma	NOUN
easat-4305	14	6	is	be	AUX
easat-4305	14	7	the	the	DET
easat-4305	14	8	sixth	sixth	ADJ
easat-4305	14	9	most	most	ADV
easat-4305	14	10	common	common	ADJ
easat-4305	14	11	cancer	cancer	NOUN
easat-4305	14	12	worldwide	worldwide	ADV
easat-4305	14	13	and	and	CCONJ
easat-4305	14	14	the	the	DET
easat-4305	14	15	third	third	ADJ
easat-4305	14	16	leading	lead	VERB
easat-4305	14	17	cause	cause	NOUN
easat-4305	14	18	of	of	ADP
easat-4305	14	19	cancer	cancer	NOUN
easat-4305	14	20	-	-	PUNCT
easat-4305	14	21	related	relate	VERB
easat-4305	14	22	mortality	mortality	NOUN
easat-4305	14	23	[	[	X
easat-4305	14	24	1	1	NUM
easat-4305	14	25	]	]	PUNCT
easat-4305	14	26	.	.	PUNCT
easat-4305	15	1	in	in	ADP
easat-4305	15	2	2022	2022	NUM
easat-4305	15	3	,	,	PUNCT
easat-4305	15	4	there	there	PRON
easat-4305	15	5	were	be	VERB
easat-4305	15	6	over	over	ADP
easat-4305	15	7	866,000	866,000	NUM
easat-4305	15	8	new	new	ADJ
easat-4305	15	9	cases	case	NOUN
easat-4305	15	10	globally	globally	ADV
easat-4305	15	11	,	,	PUNCT
easat-4305	15	12	with	with	ADP
easat-4305	15	13	the	the	DET
easat-4305	15	14	highest	high	ADJ
easat-4305	15	15	incidence	incidence	NOUN
easat-4305	15	16	rates	rate	NOUN
easat-4305	15	17	observed	observe	VERB
easat-4305	15	18	in	in	ADP
easat-4305	15	19	east	east	PROPN
easat-4305	15	20	asia	asia	PROPN
easat-4305	15	21	,	,	PUNCT
easat-4305	15	22	southeast	southeast	PROPN
easat-4305	15	23	asia	asia	PROPN
easat-4305	15	24	and	and	CCONJ
easat-4305	15	25	north	north	PROPN
easat-4305	15	26	africa	africa	PROPN
easat-4305	15	27	.	.	PUNCT
easat-4305	16	1	the	the	DET
easat-4305	16	2	primary	primary	ADJ
easat-4305	16	3	risk	risk	NOUN
easat-4305	16	4	factors	factor	NOUN
easat-4305	16	5	for	for	ADP
easat-4305	16	6	hcc	hcc	PROPN
easat-4305	16	7	include	include	VERB
easat-4305	16	8	viral	viral	ADJ
easat-4305	16	9	hepatitis	hepatitis	NOUN
easat-4305	16	10	(	(	PUNCT
easat-4305	16	11	hepatitis	hepatitis	PROPN
easat-4305	16	12	b	b	PROPN
easat-4305	16	13	virus	virus	NOUN
easat-4305	16	14	(	(	PUNCT
easat-4305	16	15	hbv	hbv	NOUN
easat-4305	16	16	)	)	PUNCT
easat-4305	16	17	and	and	CCONJ
easat-4305	16	18	hepatitis	hepatitis	PROPN
easat-4305	16	19	c	c	PROPN
easat-4305	16	20	virus	virus	NOUN
easat-4305	16	21	(	(	PUNCT
easat-4305	16	22	hcv	hcv	PROPN
easat-4305	16	23	)	)	PUNCT
easat-4305	16	24	)	)	PUNCT
easat-4305	16	25	,	,	PUNCT
easat-4305	16	26	a	a	DET
easat-4305	16	27	history	history	NOUN
easat-4305	16	28	of	of	ADP
easat-4305	16	29	alcohol	alcohol	NOUN
easat-4305	16	30	consumption	consumption	NOUN
easat-4305	16	31	,	,	PUNCT
easat-4305	16	32	and	and	CCONJ
easat-4305	16	33	aflatoxin	aflatoxin	NOUN
easat-4305	16	34	exposure	exposure	NOUN
easat-4305	16	35	[	[	X
easat-4305	16	36	1	1	NUM
easat-4305	16	37	]	]	PUNCT
easat-4305	16	38	.	.	PUNCT
easat-4305	17	1	globally	globally	ADV
easat-4305	17	2	,	,	PUNCT
easat-4305	17	3	the	the	DET
easat-4305	17	4	burden	burden	NOUN
easat-4305	17	5	of	of	ADP
easat-4305	17	6	liver	liver	NOUN
easat-4305	17	7	cancer	cancer	NOUN
easat-4305	17	8	is	be	AUX
easat-4305	17	9	projected	project	VERB
easat-4305	17	10	to	to	PART
easat-4305	17	11	increase	increase	VERB
easat-4305	17	12	by	by	ADP
easat-4305	17	13	55	55	NUM
easat-4305	17	14	%	%	NOUN
easat-4305	17	15	by	by	ADP
easat-4305	17	16	2040	2040	NUM
easat-4305	17	17	,	,	PUNCT
easat-4305	17	18	emphasizing	emphasize	VERB
easat-4305	17	19	the	the	DET
easat-4305	17	20	need	need	NOUN
easat-4305	17	21	for	for	ADP
easat-4305	17	22	effective	effective	ADJ
easat-4305	17	23	measures	measure	NOUN
easat-4305	17	24	to	to	PART
easat-4305	17	25	improve	improve	VERB
easat-4305	17	26	region	region	NOUN
easat-4305	17	27	-	-	PUNCT
easat-4305	17	28	specific	specific	ADJ
easat-4305	17	29	prevention	prevention	NOUN
easat-4305	17	30	and	and	CCONJ
easat-4305	17	31	treatment	treatment	NOUN
easat-4305	17	32	strategies	strategy	NOUN
easat-4305	17	33	[	[	X
easat-4305	17	34	2	2	NUM
easat-4305	17	35	]	]	PUNCT
easat-4305	17	36	.	.	PUNCT
easat-4305	18	1	vietnam	vietnam	PROPN
easat-4305	18	2	ranks	rank	VERB
easat-4305	18	3	seventh	seventh	ADV
easat-4305	18	4	globally	globally	ADV
easat-4305	18	5	in	in	ADP
easat-4305	18	6	terms	term	NOUN
easat-4305	18	7	of	of	ADP
easat-4305	18	8	hcc	hcc	PROPN
easat-4305	18	9	incidence	incidence	NOUN
easat-4305	18	10	,	,	PUNCT
easat-4305	18	11	with	with	ADP
easat-4305	18	12	approximately	approximately	ADV
easat-4305	18	13	24,500	24,500	NUM
easat-4305	18	14	new	new	ADJ
easat-4305	18	15	cases	case	NOUN
easat-4305	18	16	reported	report	VERB
easat-4305	18	17	in	in	ADP
easat-4305	18	18	2022	2022	NUM
easat-4305	18	19	.	.	PUNCT
easat-4305	19	1	this	this	DET
easat-4305	19	2	cancer	cancer	NOUN
easat-4305	19	3	is	be	AUX
easat-4305	19	4	particularly	particularly	ADV
easat-4305	19	5	prevalent	prevalent	ADJ
easat-4305	19	6	and	and	CCONJ
easat-4305	19	7	concerning	concern	VERB
easat-4305	19	8	in	in	ADP
easat-4305	19	9	men	man	NOUN
easat-4305	19	10	,	,	PUNCT
easat-4305	19	11	who	who	PRON
easat-4305	19	12	exhibit	exhibit	VERB
easat-4305	19	13	the	the	DET
easat-4305	19	14	highest	high	ADJ
easat-4305	19	15	age	age	NOUN
easat-4305	19	16	-	-	PUNCT
easat-4305	19	17	specific	specific	ADJ
easat-4305	19	18	incidence	incidence	NOUN
easat-4305	19	19	rates	rate	NOUN
easat-4305	19	20	worldwide	worldwide	ADV
easat-4305	20	1	[	[	X
easat-4305	20	2	2	2	NUM
easat-4305	20	3	]	]	PUNCT
easat-4305	20	4	.	.	PUNCT
easat-4305	21	1	imaging	imaging	NOUN
easat-4305	21	2	modalities	modality	NOUN
easat-4305	21	3	such	such	ADJ
easat-4305	21	4	as	as	ADP
easat-4305	21	5	ultrasound	ultrasound	NOUN
easat-4305	21	6	,	,	PUNCT
easat-4305	21	7	computed	compute	VERB
easat-4305	21	8	tomography	tomography	NOUN
easat-4305	21	9	(	(	PUNCT
easat-4305	21	10	ct	ct	NOUN
easat-4305	21	11	)	)	PUNCT
easat-4305	21	12	,	,	PUNCT
easat-4305	21	13	and	and	CCONJ
easat-4305	21	14	magnetic	magnetic	ADJ
easat-4305	21	15	resonance	resonance	NOUN
easat-4305	21	16	imaging	imaging	NOUN
easat-4305	21	17	(	(	PUNCT
easat-4305	21	18	mri	mri	NOUN
easat-4305	21	19	)	)	PUNCT
easat-4305	21	20	have	have	AUX
easat-4305	21	21	long	long	ADV
easat-4305	21	22	been	be	AUX
easat-4305	21	23	regarded	regard	VERB
easat-4305	21	24	as	as	ADP
easat-4305	21	25	essential	essential	ADJ
easat-4305	21	26	tools	tool	NOUN
easat-4305	21	27	for	for	ADP
easat-4305	21	28	detecting	detect	VERB
easat-4305	21	29	hcc	hcc	PROPN
easat-4305	21	30	.	.	PUNCT
easat-4305	22	1	these	these	DET
easat-4305	22	2	techniques	technique	NOUN
easat-4305	22	3	provide	provide	VERB
easat-4305	22	4	detailed	detailed	ADJ
easat-4305	22	5	information	information	NOUN
easat-4305	22	6	about	about	ADP
easat-4305	22	7	tumor	tumor	NOUN
easat-4305	22	8	size	size	NOUN
easat-4305	22	9	,	,	PUNCT
easat-4305	22	10	location	location	NOUN
easat-4305	22	11	,	,	PUNCT
easat-4305	22	12	and	and	CCONJ
easat-4305	22	13	invasiveness	invasiveness	VERB
easat-4305	22	14	[	[	X
easat-4305	22	15	3	3	NUM
easat-4305	22	16	]	]	PUNCT
easat-4305	22	17	.	.	PUNCT
easat-4305	23	1	however	however	ADV
easat-4305	23	2	,	,	PUNCT
easat-4305	23	3	imaging	imaging	NOUN
easat-4305	23	4	methods	method	NOUN
easat-4305	23	5	are	be	AUX
easat-4305	23	6	often	often	ADV
easat-4305	23	7	costly	costly	ADJ
easat-4305	23	8	,	,	PUNCT
easat-4305	23	9	limited	limit	VERB
easat-4305	23	10	in	in	ADP
easat-4305	23	11	detecting	detect	VERB
easat-4305	23	12	small	small	ADJ
easat-4305	23	13	tumors	tumor	NOUN
easat-4305	23	14	,	,	PUNCT
easat-4305	23	15	incapable	incapable	ADJ
easat-4305	23	16	of	of	ADP
easat-4305	23	17	characterizing	characterize	VERB
easat-4305	23	18	early	early	ADJ
easat-4305	23	19	-	-	PUNCT
easat-4305	23	20	stage	stage	NOUN
easat-4305	23	21	lesions	lesion	NOUN
easat-4305	23	22	,	,	PUNCT
easat-4305	23	23	and	and	CCONJ
easat-4305	23	24	require	require	VERB
easat-4305	23	25	highly	highly	ADV
easat-4305	23	26	skilled	skilled	ADJ
easat-4305	23	27	operators	operator	NOUN
easat-4305	23	28	to	to	PART
easat-4305	23	29	manage	manage	VERB
easat-4305	23	30	advanced	advanced	ADJ
easat-4305	23	31	equipment	equipment	NOUN
easat-4305	23	32	.	.	PUNCT
easat-4305	24	1	biomarkers	biomarker	NOUN
easat-4305	24	2	such	such	ADJ
easat-4305	24	3	as	as	ADP
easat-4305	24	4	alpha	alpha	NOUN
easat-4305	24	5	-	-	PUNCT
easat-4305	24	6	fetoprotein	fetoprotein	ADJ
easat-4305	24	7	(	(	PUNCT
easat-4305	24	8	afp	afp	NOUN
easat-4305	24	9	)	)	PUNCT
easat-4305	24	10	,	,	PUNCT
easat-4305	24	11	afp	afp	PROPN
easat-4305	24	12	-	-	PUNCT
easat-4305	24	13	l3	l3	PROPN
easat-4305	24	14	and	and	CCONJ
easat-4305	24	15	des	des	PROPN
easat-4305	24	16	-	-	ADJ
easat-4305	24	17	gamma	gamma	NOUN
easat-4305	24	18	-	-	PUNCT
easat-4305	24	19	carboxy	carboxy	ADJ
easat-4305	24	20	prothrombin	prothrombin	NOUN
easat-4305	24	21	(	(	PUNCT
easat-4305	24	22	dcp	dcp	NOUN
easat-4305	24	23	)	)	PUNCT
easat-4305	24	24	play	play	VERB
easat-4305	24	25	critical	critical	ADJ
easat-4305	24	26	roles	role	NOUN
easat-4305	24	27	and	and	CCONJ
easat-4305	24	28	are	be	AUX
easat-4305	24	29	widely	widely	ADV
easat-4305	24	30	used	use	VERB
easat-4305	24	31	in	in	ADP
easat-4305	24	32	diagnosing	diagnose	VERB
easat-4305	24	33	hcc	hcc	PROPN
easat-4305	24	34	.	.	PUNCT
easat-4305	25	1	among	among	ADP
easat-4305	25	2	these	these	PRON
easat-4305	25	3	,	,	PUNCT
easat-4305	25	4	afp	afp	PROPN
easat-4305	25	5	is	be	AUX
easat-4305	25	6	the	the	DET
easat-4305	25	7	most	most	ADV
easat-4305	25	8	commonly	commonly	ADV
easat-4305	25	9	used	use	VERB
easat-4305	25	10	biomarker	biomarker	NOUN
easat-4305	25	11	,	,	PUNCT
easat-4305	25	12	although	although	SCONJ
easat-4305	25	13	its	its	PRON
easat-4305	25	14	sensitivity	sensitivity	NOUN
easat-4305	25	15	is	be	AUX
easat-4305	25	16	limited	limit	VERB
easat-4305	25	17	,	,	PUNCT
easat-4305	25	18	particularly	particularly	ADV
easat-4305	25	19	for	for	ADP
easat-4305	25	20	early	early	ADJ
easat-4305	25	21	-	-	PUNCT
easat-4305	25	22	stage	stage	NOUN
easat-4305	25	23	hcc	hcc	PROPN
easat-4305	25	24	.	.	PUNCT
easat-4305	26	1	combining	combine	VERB
easat-4305	26	2	afp	afp	PROPN
easat-4305	26	3	with	with	ADP
easat-4305	26	4	afp	afp	PROPN
easat-4305	26	5	-	-	PUNCT
easat-4305	26	6	l3	l3	NOUN
easat-4305	26	7	,	,	PUNCT
easat-4305	26	8	which	which	PRON
easat-4305	26	9	is	be	AUX
easat-4305	26	10	associated	associate	VERB
easat-4305	26	11	with	with	ADP
easat-4305	26	12	malignancy	malignancy	NOUN
easat-4305	26	13	,	,	PUNCT
easat-4305	26	14	and	and	CCONJ
easat-4305	26	15	dcp	dcp	NOUN
easat-4305	26	16	,	,	PUNCT
easat-4305	26	17	which	which	PRON
easat-4305	26	18	is	be	AUX
easat-4305	26	19	linked	link	VERB
easat-4305	26	20	to	to	ADP
easat-4305	26	21	coagulation	coagulation	NOUN
easat-4305	26	22	abnormalities	abnormality	NOUN
easat-4305	26	23	in	in	ADP
easat-4305	26	24	hcc	hcc	PROPN
easat-4305	26	25	,	,	PUNCT
easat-4305	26	26	enhances	enhance	VERB
easat-4305	26	27	diagnostic	diagnostic	ADJ
easat-4305	26	28	accuracy	accuracy	NOUN
easat-4305	27	1	[	[	X
easat-4305	27	2	4	4	NUM
easat-4305	27	3	]	]	PUNCT
easat-4305	27	4	.	.	PUNCT
easat-4305	28	1	in	in	ADP
easat-4305	28	2	recent	recent	ADJ
easat-4305	28	3	years	year	NOUN
easat-4305	28	4	,	,	PUNCT
easat-4305	28	5	txn	txn	PROPN
easat-4305	28	6	has	have	AUX
easat-4305	28	7	emerged	emerge	VERB
easat-4305	28	8	as	as	ADP
easat-4305	28	9	a	a	DET
easat-4305	28	10	potential	potential	ADJ
easat-4305	28	11	biomarker	biomarker	NOUN
easat-4305	28	12	for	for	ADP
easat-4305	28	13	diagnosing	diagnose	VERB
easat-4305	28	14	hcc	hcc	PROPN
easat-4305	28	15	.	.	PUNCT
easat-4305	29	1	serum	serum	PROPN
easat-4305	29	2	txn	txn	PROPN
easat-4305	29	3	levels	level	NOUN
easat-4305	29	4	are	be	AUX
easat-4305	29	5	often	often	ADV
easat-4305	29	6	elevated	elevate	VERB
easat-4305	29	7	in	in	ADP
easat-4305	29	8	hcc	hcc	PROPN
easat-4305	29	9	patients	patient	NOUN
easat-4305	29	10	,	,	PUNCT
easat-4305	29	11	suggesting	suggest	VERB
easat-4305	29	12	its	its	PRON
easat-4305	29	13	utility	utility	NOUN
easat-4305	29	14	in	in	ADP
easat-4305	29	15	distinguishing	distinguish	VERB
easat-4305	29	16	hcc	hcc	PROPN
easat-4305	29	17	from	from	ADP
easat-4305	29	18	benign	benign	ADJ
easat-4305	29	19	liver	liver	NOUN
easat-4305	29	20	diseases	disease	NOUN
easat-4305	29	21	and	and	CCONJ
easat-4305	29	22	healthy	healthy	ADJ
easat-4305	29	23	conditions	condition	NOUN
easat-4305	29	24	[	[	X
easat-4305	29	25	5	5	NUM
easat-4305	29	26	]	]	PUNCT
easat-4305	29	27	.	.	PUNCT
easat-4305	30	1	compared	compare	VERB
easat-4305	30	2	with	with	ADP
easat-4305	30	3	afp	afp	PROPN
easat-4305	30	4	alone	alone	ADV
easat-4305	30	5	,	,	PUNCT
easat-4305	30	6	combining	combine	VERB
easat-4305	30	7	txn	txn	NOUN
easat-4305	30	8	with	with	ADP
easat-4305	30	9	traditional	traditional	ADJ
easat-4305	30	10	https://orcid.org/0009-0003-4490-1839	https://orcid.org/0009-0003-4490-1839	PROPN
easat-4305	30	11	https://orcid.org/0009-0000-0534-3764	https://orcid.org/0009-0000-0534-3764	PROPN
easat-4305	30	12	https://orcid.org/0009-0002-2923-8867	https://orcid.org/0009-0002-2923-8867	VERB
easat-4305	30	13	https://orcid.org/0000-0001-6746-9573	https://orcid.org/0000-0001-6746-9573	AUX
easat-4305	30	14	1011	1011	NUM
easat-4305	30	15	edelweiss	edelweiss	PROPN
easat-4305	30	16	applied	apply	VERB
easat-4305	30	17	science	science	NOUN
easat-4305	30	18	and	and	CCONJ
easat-4305	30	19	technology	technology	NOUN
easat-4305	30	20	issn	issn	PROPN
easat-4305	30	21	:	:	PUNCT
easat-4305	30	22	2576	2576	NUM
easat-4305	30	23	-	-	SYM
easat-4305	30	24	8484	8484	NUM
easat-4305	30	25	vol	vol	NOUN
easat-4305	30	26	.	.	PROPN
easat-4305	31	1	9	9	NUM
easat-4305	31	2	,	,	PUNCT
easat-4305	31	3	no	no	INTJ
easat-4305	31	4	.	.	NOUN
easat-4305	31	5	1	1	NUM
easat-4305	31	6	:	:	PUNCT
easat-4305	31	7	1010	1010	NUM
easat-4305	31	8	-	-	SYM
easat-4305	31	9	1018	1018	NUM
easat-4305	31	10	,	,	PUNCT
easat-4305	31	11	2025	2025	NUM
easat-4305	31	12	doi	doi	NOUN
easat-4305	31	13	:	:	PUNCT
easat-4305	31	14	10.55214/25768484.v9i1.4305	10.55214/25768484.v9i1.4305	NUM
easat-4305	31	15	©	©	PROPN
easat-4305	31	16	2025	2025	NUM
easat-4305	31	17	by	by	ADP
easat-4305	31	18	the	the	DET
easat-4305	31	19	authors	author	NOUN
easat-4305	31	20	;	;	PUNCT
easat-4305	31	21	licensee	licensee	PROPN
easat-4305	31	22	learning	learn	VERB
easat-4305	31	23	gate	gate	NOUN
easat-4305	31	24	biomarkers	biomarker	NOUN
easat-4305	31	25	such	such	ADJ
easat-4305	31	26	as	as	ADP
easat-4305	31	27	afp	afp	PROPN
easat-4305	31	28	may	may	AUX
easat-4305	31	29	improve	improve	VERB
easat-4305	31	30	early	early	ADJ
easat-4305	31	31	-	-	PUNCT
easat-4305	31	32	stage	stage	NOUN
easat-4305	31	33	diagnostic	diagnostic	ADJ
easat-4305	31	34	accuracy	accuracy	NOUN
easat-4305	31	35	,	,	PUNCT
easat-4305	31	36	enhancing	enhance	VERB
easat-4305	31	37	both	both	DET
easat-4305	31	38	sensitivity	sensitivity	NOUN
easat-4305	31	39	and	and	CCONJ
easat-4305	31	40	specificity	specificity	NOUN
easat-4305	31	41	.	.	PUNCT
easat-4305	32	1	txn	txn	PROPN
easat-4305	32	2	offers	offer	VERB
easat-4305	32	3	several	several	ADJ
easat-4305	32	4	advantages	advantage	NOUN
easat-4305	32	5	over	over	ADP
easat-4305	32	6	afp	afp	NOUN
easat-4305	32	7	for	for	ADP
easat-4305	32	8	early	early	ADJ
easat-4305	32	9	hcc	hcc	PROPN
easat-4305	32	10	detection	detection	NOUN
easat-4305	32	11	,	,	PUNCT
easat-4305	32	12	including	include	VERB
easat-4305	32	13	its	its	PRON
easat-4305	32	14	ability	ability	NOUN
easat-4305	32	15	to	to	PART
easat-4305	32	16	reflect	reflect	VERB
easat-4305	32	17	oxidative	oxidative	ADJ
easat-4305	32	18	stress	stress	NOUN
easat-4305	32	19	and	and	CCONJ
easat-4305	32	20	other	other	ADJ
easat-4305	32	21	physiological	physiological	ADJ
easat-4305	32	22	changes	change	NOUN
easat-4305	32	23	,	,	PUNCT
easat-4305	32	24	higher	high	ADJ
easat-4305	32	25	sensitivity	sensitivity	NOUN
easat-4305	32	26	for	for	ADP
easat-4305	32	27	small	small	ADJ
easat-4305	32	28	tumors	tumor	NOUN
easat-4305	32	29	,	,	PUNCT
easat-4305	32	30	and	and	CCONJ
easat-4305	32	31	its	its	PRON
easat-4305	32	32	applicability	applicability	NOUN
easat-4305	32	33	in	in	ADP
easat-4305	32	34	patients	patient	NOUN
easat-4305	32	35	with	with	ADP
easat-4305	32	36	underlying	underlie	VERB
easat-4305	32	37	liver	liver	NOUN
easat-4305	32	38	conditions	condition	NOUN
easat-4305	32	39	such	such	ADJ
easat-4305	32	40	as	as	ADP
easat-4305	32	41	cirrhosis	cirrhosis	NOUN
easat-4305	32	42	or	or	CCONJ
easat-4305	32	43	chronic	chronic	ADJ
easat-4305	32	44	hepatitis	hepatitis	NOUN
easat-4305	32	45	.	.	PUNCT
easat-4305	33	1	in	in	ADP
easat-4305	33	2	contrast	contrast	NOUN
easat-4305	33	3	,	,	PUNCT
easat-4305	33	4	afp	afp	PROPN
easat-4305	33	5	typically	typically	ADV
easat-4305	33	6	exhibits	exhibit	VERB
easat-4305	33	7	high	high	ADJ
easat-4305	33	8	sensitivity	sensitivity	NOUN
easat-4305	33	9	only	only	ADV
easat-4305	33	10	in	in	ADP
easat-4305	33	11	advanced	advanced	ADJ
easat-4305	33	12	hcc	hcc	NOUN
easat-4305	33	13	stages	stage	NOUN
easat-4305	33	14	and	and	CCONJ
easat-4305	33	15	has	have	VERB
easat-4305	33	16	low	low	ADJ
easat-4305	33	17	specificity	specificity	NOUN
easat-4305	33	18	in	in	ADP
easat-4305	33	19	chronic	chronic	ADJ
easat-4305	33	20	liver	liver	NOUN
easat-4305	33	21	diseases	disease	NOUN
easat-4305	33	22	[	[	X
easat-4305	33	23	5	5	NUM
easat-4305	33	24	]	]	PUNCT
easat-4305	33	25	.	.	PUNCT
easat-4305	34	1	2	2	X
easat-4305	34	2	.	.	X
easat-4305	34	3	materials	material	NOUN
easat-4305	34	4	and	and	CCONJ
easat-4305	34	5	methods	method	NOUN
easat-4305	34	6	2.1	2.1	NUM
easat-4305	34	7	.	.	PUNCT
easat-4305	35	1	study	study	NOUN
easat-4305	35	2	subjects	subject	NOUN
easat-4305	35	3	,	,	PUNCT
easat-4305	35	4	materials	material	NOUN
easat-4305	35	5	and	and	CCONJ
easat-4305	35	6	equipment	equipment	NOUN
easat-4305	35	7	the	the	DET
easat-4305	35	8	study	study	NOUN
easat-4305	35	9	subjects	subject	NOUN
easat-4305	35	10	included	include	VERB
easat-4305	35	11	serum	serum	NOUN
easat-4305	35	12	samples	sample	NOUN
easat-4305	35	13	collected	collect	VERB
easat-4305	35	14	from	from	ADP
easat-4305	35	15	patients	patient	NOUN
easat-4305	35	16	diagnosed	diagnose	VERB
easat-4305	35	17	with	with	ADP
easat-4305	35	18	hcc	hcc	PROPN
easat-4305	35	19	at	at	ADP
easat-4305	35	20	the	the	DET
easat-4305	35	21	108	108	NUM
easat-4305	35	22	military	military	ADJ
easat-4305	35	23	central	central	ADJ
easat-4305	35	24	hospital	hospital	NOUN
easat-4305	35	25	.	.	PUNCT
easat-4305	36	1	the	the	DET
easat-4305	36	2	samples	sample	NOUN
easat-4305	36	3	were	be	AUX
easat-4305	36	4	preserved	preserve	VERB
easat-4305	36	5	at	at	ADP
easat-4305	36	6	4	4	NUM
easat-4305	36	7	°	°	ADP
easat-4305	36	8	c	c	NOUN
easat-4305	36	9	and	and	CCONJ
easat-4305	36	10	promptly	promptly	ADV
easat-4305	36	11	processed	process	VERB
easat-4305	36	12	within	within	ADP
easat-4305	36	13	48	48	NUM
easat-4305	36	14	hours	hour	NOUN
easat-4305	36	15	for	for	ADP
easat-4305	36	16	immunoassays	immunoassay	NOUN
easat-4305	36	17	.	.	PUNCT
easat-4305	37	1	a	a	DET
easat-4305	37	2	total	total	NOUN
easat-4305	37	3	of	of	ADP
easat-4305	37	4	72	72	NUM
easat-4305	37	5	serum	serum	NOUN
easat-4305	37	6	samples	sample	NOUN
easat-4305	37	7	were	be	AUX
easat-4305	37	8	divided	divide	VERB
easat-4305	37	9	into	into	ADP
easat-4305	37	10	three	three	NUM
easat-4305	37	11	groups	group	NOUN
easat-4305	37	12	on	on	ADP
easat-4305	37	13	the	the	DET
easat-4305	37	14	basis	basis	NOUN
easat-4305	37	15	of	of	ADP
easat-4305	37	16	medical	medical	ADJ
easat-4305	37	17	records	record	NOUN
easat-4305	37	18	:	:	PUNCT
easat-4305	37	19	(	(	PUNCT
easat-4305	37	20	1	1	X
easat-4305	37	21	)	)	PUNCT
easat-4305	37	22	hcc	hcc	PROPN
easat-4305	37	23	group	group	NOUN
easat-4305	37	24	:	:	PUNCT
easat-4305	37	25	8	8	NUM
easat-4305	37	26	samples	sample	NOUN
easat-4305	37	27	from	from	ADP
easat-4305	37	28	patients	patient	NOUN
easat-4305	37	29	with	with	ADP
easat-4305	37	30	early	early	ADJ
easat-4305	37	31	-	-	PUNCT
easat-4305	37	32	stage	stage	NOUN
easat-4305	37	33	hcc	hcc	NOUN
easat-4305	37	34	and	and	CCONJ
easat-4305	37	35	39	39	NUM
easat-4305	37	36	samples	sample	NOUN
easat-4305	37	37	from	from	ADP
easat-4305	37	38	patients	patient	NOUN
easat-4305	37	39	with	with	ADP
easat-4305	37	40	intermediate-	intermediate-	NUM
easat-4305	37	41	,	,	PUNCT
easat-4305	37	42	advanced-	advanced-	ADJ
easat-4305	37	43	,	,	PUNCT
easat-4305	37	44	or	or	CCONJ
easat-4305	37	45	terminal	terminal	ADJ
easat-4305	37	46	-	-	PUNCT
easat-4305	37	47	stage	stage	NOUN
easat-4305	37	48	hcc	hcc	PROPN
easat-4305	37	49	,	,	PUNCT
easat-4305	37	50	collectively	collectively	ADV
easat-4305	37	51	referred	refer	VERB
easat-4305	37	52	to	to	ADP
easat-4305	37	53	as	as	ADP
easat-4305	37	54	late	late	ADJ
easat-4305	37	55	-	-	PUNCT
easat-4305	37	56	stage	stage	NOUN
easat-4305	37	57	hcc	hcc	PROPN
easat-4305	37	58	.	.	PUNCT
easat-4305	38	1	(	(	PUNCT
easat-4305	38	2	2	2	X
easat-4305	38	3	)	)	PUNCT
easat-4305	38	4	liver	liver	NOUN
easat-4305	38	5	disease	disease	NOUN
easat-4305	38	6	group	group	NOUN
easat-4305	38	7	:	:	PUNCT
easat-4305	38	8	this	this	DET
easat-4305	38	9	group	group	NOUN
easat-4305	38	10	included	include	VERB
easat-4305	38	11	10	10	NUM
easat-4305	38	12	serum	serum	NOUN
easat-4305	38	13	samples	sample	NOUN
easat-4305	38	14	from	from	ADP
easat-4305	38	15	individuals	individual	NOUN
easat-4305	38	16	diagnosed	diagnose	VERB
easat-4305	38	17	with	with	ADP
easat-4305	38	18	liverrelated	liverrelate	VERB
easat-4305	38	19	conditions	condition	NOUN
easat-4305	38	20	(	(	PUNCT
easat-4305	38	21	e.g.	e.g.	ADV
easat-4305	38	22	,	,	PUNCT
easat-4305	38	23	positive	positive	ADJ
easat-4305	38	24	for	for	ADP
easat-4305	38	25	hbv	hbv	NOUN
easat-4305	38	26	or	or	CCONJ
easat-4305	38	27	hcv	hcv	VERB
easat-4305	38	28	or	or	CCONJ
easat-4305	38	29	exhibiting	exhibit	VERB
easat-4305	38	30	cirrhosis	cirrhosis	NOUN
easat-4305	38	31	)	)	PUNCT
easat-4305	38	32	but	but	CCONJ
easat-4305	38	33	without	without	ADP
easat-4305	38	34	confirmed	confirm	VERB
easat-4305	38	35	hcc	hcc	PROPN
easat-4305	38	36	.	.	PUNCT
easat-4305	39	1	(	(	PUNCT
easat-4305	39	2	3	3	X
easat-4305	39	3	)	)	PUNCT
easat-4305	39	4	healthy	healthy	ADJ
easat-4305	39	5	control	control	NOUN
easat-4305	39	6	group	group	NOUN
easat-4305	39	7	:	:	PUNCT
easat-4305	39	8	this	this	DET
easat-4305	39	9	group	group	NOUN
easat-4305	39	10	consisted	consist	VERB
easat-4305	39	11	of	of	ADP
easat-4305	39	12	15	15	NUM
easat-4305	39	13	serum	serum	NOUN
easat-4305	39	14	samples	sample	NOUN
easat-4305	39	15	from	from	ADP
easat-4305	39	16	healthy	healthy	ADJ
easat-4305	39	17	individuals	individual	NOUN
easat-4305	39	18	confirmed	confirm	VERB
easat-4305	39	19	to	to	PART
easat-4305	39	20	have	have	VERB
easat-4305	39	21	no	no	DET
easat-4305	39	22	liver	liver	NOUN
easat-4305	39	23	-	-	PUNCT
easat-4305	39	24	related	relate	VERB
easat-4305	39	25	diseases	disease	NOUN
easat-4305	39	26	.	.	PUNCT
easat-4305	40	1	the	the	DET
easat-4305	40	2	materials	material	NOUN
easat-4305	40	3	and	and	CCONJ
easat-4305	40	4	equipment	equipment	NOUN
easat-4305	40	5	used	use	VERB
easat-4305	40	6	in	in	ADP
easat-4305	40	7	this	this	DET
easat-4305	40	8	study	study	NOUN
easat-4305	40	9	included	include	VERB
easat-4305	40	10	a	a	DET
easat-4305	40	11	purified	purified	ADJ
easat-4305	40	12	recombinant	recombinant	ADJ
easat-4305	40	13	antigen	antigen	NOUN
easat-4305	40	14	of	of	ADP
easat-4305	40	15	txn	txn	NOUN
easat-4305	40	16	(	(	PUNCT
easat-4305	40	17	rag	rag	NOUN
easat-4305	40	18	-	-	PUNCT
easat-4305	40	19	txn	txn	NOUN
easat-4305	40	20	,	,	PUNCT
easat-4305	40	21	0.85	0.85	NUM
easat-4305	40	22	mg	mg	NUM
easat-4305	40	23	/	/	SYM
easat-4305	40	24	ml	ml	NOUN
easat-4305	40	25	)	)	PUNCT
easat-4305	40	26	and	and	CCONJ
easat-4305	40	27	a	a	DET
easat-4305	40	28	specific	specific	ADJ
easat-4305	40	29	monoclonal	monoclonal	NOUN
easat-4305	40	30	antibody	antibody	NOUN
easat-4305	40	31	of	of	ADP
easat-4305	40	32	txn	txn	PROPN
easat-4305	40	33	(	(	PUNCT
easat-4305	40	34	mab	mab	NOUN
easat-4305	40	35	-	-	PUNCT
easat-4305	40	36	txn	txn	NOUN
easat-4305	40	37	,	,	PUNCT
easat-4305	40	38	1.2	1.2	NUM
easat-4305	40	39	mg	mg	NUM
easat-4305	40	40	/	/	SYM
easat-4305	40	41	ml	ml	NOUN
easat-4305	40	42	)	)	PUNCT
easat-4305	40	43	,	,	PUNCT
easat-4305	40	44	both	both	PRON
easat-4305	40	45	of	of	ADP
easat-4305	40	46	which	which	PRON
easat-4305	40	47	were	be	AUX
easat-4305	40	48	supplied	supply	VERB
easat-4305	40	49	by	by	ADP
easat-4305	40	50	the	the	DET
easat-4305	40	51	vietnam‒germany	vietnam‒germany	PROPN
easat-4305	40	52	cooperative	cooperative	ADJ
easat-4305	40	53	scientific	scientific	ADJ
easat-4305	40	54	research	research	NOUN
easat-4305	40	55	project	project	NOUN
easat-4305	40	56	(	(	PUNCT
easat-4305	40	57	code	code	NOUN
easat-4305	40	58	:	:	PUNCT
easat-4305	40	59	nđt.102	nđt.102	NOUN
easat-4305	40	60	.	.	PUNCT
easat-4305	40	61	ger/21	ger/21	NOUN
easat-4305	40	62	)	)	PUNCT
easat-4305	40	63	and	and	CCONJ
easat-4305	40	64	developed	develop	VERB
easat-4305	40	65	by	by	ADP
easat-4305	40	66	the	the	DET
easat-4305	40	67	microbial	microbial	ADJ
easat-4305	40	68	genomics	genomic	NOUN
easat-4305	40	69	laboratory	laboratory	NOUN
easat-4305	40	70	,	,	PUNCT
easat-4305	40	71	institute	institute	NOUN
easat-4305	40	72	of	of	ADP
easat-4305	40	73	genome	genome	NOUN
easat-4305	40	74	research	research	NOUN
easat-4305	40	75	,	,	PUNCT
easat-4305	40	76	vietnam	vietnam	PROPN
easat-4305	40	77	academy	academy	PROPN
easat-4305	40	78	of	of	ADP
easat-4305	40	79	science	science	NOUN
easat-4305	40	80	and	and	CCONJ
easat-4305	40	81	technology	technology	NOUN
easat-4305	40	82	.	.	PUNCT
easat-4305	41	1	the	the	DET
easat-4305	41	2	secondary	secondary	PROPN
easat-4305	41	3	goat	goat	PROPN
easat-4305	41	4	anti	anti	PROPN
easat-4305	41	5	-	-	ADJ
easat-4305	41	6	mouse	mouse	ADJ
easat-4305	41	7	igg	igg	NOUN
easat-4305	41	8	(	(	PUNCT
easat-4305	41	9	h+l	h+l	PROPN
easat-4305	41	10	)	)	PUNCT
easat-4305	41	11	hrpconjugated	hrpconjugate	VERB
easat-4305	41	12	antibody	antibody	NOUN
easat-4305	41	13	was	be	AUX
easat-4305	41	14	purchased	purchase	VERB
easat-4305	41	15	from	from	ADP
easat-4305	41	16	invitrogen	invitrogen	PROPN
easat-4305	41	17	(	(	PUNCT
easat-4305	41	18	usa	usa	PROPN
easat-4305	41	19	)	)	PUNCT
easat-4305	41	20	.	.	PUNCT
easat-4305	42	1	various	various	ADJ
easat-4305	42	2	solutions	solution	NOUN
easat-4305	42	3	were	be	AUX
easat-4305	42	4	used	use	VERB
easat-4305	42	5	,	,	PUNCT
easat-4305	42	6	including	include	VERB
easat-4305	42	7	0.2	0.2	NUM
easat-4305	42	8	m	m	NOUN
easat-4305	42	9	bicarbonate	bicarbonate	NOUN
easat-4305	42	10	buffer	buffer	NOUN
easat-4305	42	11	at	at	ADP
easat-4305	42	12	ph	ph	PROPN
easat-4305	42	13	9.4	9.4	NUM
easat-4305	42	14	(	(	PUNCT
easat-4305	42	15	thermo	thermo	NOUN
easat-4305	42	16	fisher	fisher	PROPN
easat-4305	42	17	,	,	PUNCT
easat-4305	42	18	usa	usa	PROPN
easat-4305	42	19	)	)	PUNCT
easat-4305	42	20	,	,	PUNCT
easat-4305	42	21	blocking	block	VERB
easat-4305	42	22	buffer	buffer	NOUN
easat-4305	42	23	(	(	PUNCT
easat-4305	42	24	tbst	tbst	NOUN
easat-4305	42	25	containing	contain	VERB
easat-4305	42	26	5	5	NUM
easat-4305	42	27	%	%	NOUN
easat-4305	42	28	bsa	bsa	NOUN
easat-4305	42	29	;	;	PUNCT
easat-4305	42	30	thermo	thermo	PROPN
easat-4305	42	31	fisher	fisher	PROPN
easat-4305	42	32	,	,	PUNCT
easat-4305	42	33	usa	usa	PROPN
easat-4305	42	34	)	)	PUNCT
easat-4305	42	35	,	,	PUNCT
easat-4305	42	36	dilution	dilution	NOUN
easat-4305	42	37	buffer	buffer	NOUN
easat-4305	42	38	(	(	PUNCT
easat-4305	42	39	tbst	tbst	NOUN
easat-4305	42	40	containing	contain	VERB
easat-4305	42	41	1	1	NUM
easat-4305	42	42	%	%	NOUN
easat-4305	42	43	bsa	bsa	NOUN
easat-4305	42	44	;	;	PUNCT
easat-4305	42	45	thermo	thermo	PROPN
easat-4305	42	46	fisher	fisher	PROPN
easat-4305	42	47	,	,	PUNCT
easat-4305	42	48	usa	usa	PROPN
easat-4305	42	49	)	)	PUNCT
easat-4305	42	50	,	,	PUNCT
easat-4305	42	51	washing	washing	NOUN
easat-4305	42	52	buffer	buffer	NOUN
easat-4305	42	53	(	(	PUNCT
easat-4305	42	54	tbst	tbst	ADJ
easat-4305	42	55	;	;	PUNCT
easat-4305	42	56	thermo	thermo	NOUN
easat-4305	42	57	fisher	fisher	PROPN
easat-4305	42	58	,	,	PUNCT
easat-4305	42	59	usa	usa	PROPN
easat-4305	42	60	)	)	PUNCT
easat-4305	42	61	,	,	PUNCT
easat-4305	42	62	and	and	CCONJ
easat-4305	42	63	1	1	NUM
easat-4305	42	64	m	m	NOUN
easat-4305	42	65	hcl	hcl	NOUN
easat-4305	42	66	stop	stop	NOUN
easat-4305	42	67	solution	solution	NOUN
easat-4305	42	68	(	(	PUNCT
easat-4305	42	69	sigma	sigma	PROPN
easat-4305	42	70	aldrich	aldrich	PROPN
easat-4305	42	71	,	,	PUNCT
easat-4305	42	72	usa	usa	PROPN
easat-4305	42	73	)	)	PUNCT
easat-4305	42	74	.	.	PUNCT
easat-4305	43	1	additional	additional	ADJ
easat-4305	43	2	reagents	reagent	NOUN
easat-4305	43	3	included	include	VERB
easat-4305	43	4	bovine	bovine	NOUN
easat-4305	43	5	serum	serum	NOUN
easat-4305	43	6	albumin	albumin	PROPN
easat-4305	43	7	(	(	PUNCT
easat-4305	43	8	bsa	bsa	PROPN
easat-4305	43	9	,	,	PUNCT
easat-4305	43	10	merck	merck	PROPN
easat-4305	43	11	,	,	PUNCT
easat-4305	43	12	usa	usa	PROPN
easat-4305	43	13	)	)	PUNCT
easat-4305	43	14	and	and	CCONJ
easat-4305	43	15	tmb	tmb	NOUN
easat-4305	43	16	substrate	substrate	NOUN
easat-4305	43	17	solution	solution	NOUN
easat-4305	43	18	(	(	PUNCT
easat-4305	43	19	thermo	thermo	NOUN
easat-4305	43	20	fisher	fisher	PROPN
easat-4305	43	21	,	,	PUNCT
easat-4305	43	22	usa	usa	PROPN
easat-4305	43	23	)	)	PUNCT
easat-4305	43	24	.	.	PUNCT
easat-4305	44	1	elisas	elisas	PROPN
easat-4305	44	2	were	be	AUX
easat-4305	44	3	conducted	conduct	VERB
easat-4305	44	4	in	in	ADP
easat-4305	44	5	96	96	NUM
easat-4305	44	6	-	-	PUNCT
easat-4305	44	7	well	well	NOUN
easat-4305	44	8	plates	plate	NOUN
easat-4305	44	9	(	(	PUNCT
easat-4305	44	10	costar	costar	NOUN
easat-4305	44	11	assay	assay	NOUN
easat-4305	44	12	plate	plate	NOUN
easat-4305	44	13	,	,	PUNCT
easat-4305	44	14	corning	corning	NOUN
easat-4305	44	15	,	,	PUNCT
easat-4305	44	16	usa	usa	PROPN
easat-4305	44	17	)	)	PUNCT
easat-4305	44	18	,	,	PUNCT
easat-4305	44	19	and	and	CCONJ
easat-4305	44	20	the	the	DET
easat-4305	44	21	results	result	NOUN
easat-4305	44	22	were	be	AUX
easat-4305	44	23	measured	measure	VERB
easat-4305	44	24	with	with	ADP
easat-4305	44	25	a	a	DET
easat-4305	44	26	biotek	biotek	NOUN
easat-4305	44	27	elx808	elx808	PROPN
easat-4305	44	28	plate	plate	NOUN
easat-4305	44	29	reader	reader	NOUN
easat-4305	44	30	(	(	PUNCT
easat-4305	44	31	biotek	biotek	PROPN
easat-4305	44	32	,	,	PUNCT
easat-4305	44	33	usa	usa	PROPN
easat-4305	44	34	)	)	PUNCT
easat-4305	44	35	.	.	PUNCT
easat-4305	45	1	pipettes	pipette	NOUN
easat-4305	45	2	(	(	PUNCT
easat-4305	45	3	single	single	ADJ
easat-4305	45	4	-	-	PUNCT
easat-4305	45	5	channel	channel	NOUN
easat-4305	45	6	and	and	CCONJ
easat-4305	45	7	multichannel	multichannel	PROPN
easat-4305	45	8	)	)	PUNCT
easat-4305	45	9	and	and	CCONJ
easat-4305	45	10	various	various	ADJ
easat-4305	45	11	types	type	NOUN
easat-4305	45	12	of	of	ADP
easat-4305	45	13	pipette	pipette	NOUN
easat-4305	45	14	tips	tip	NOUN
easat-4305	45	15	were	be	AUX
easat-4305	45	16	employed	employ	VERB
easat-4305	45	17	during	during	ADP
easat-4305	45	18	the	the	DET
easat-4305	45	19	experiments	experiment	NOUN
easat-4305	45	20	.	.	PUNCT
easat-4305	46	1	data	datum	NOUN
easat-4305	46	2	analysis	analysis	NOUN
easat-4305	46	3	was	be	AUX
easat-4305	46	4	performed	perform	VERB
easat-4305	46	5	via	via	ADP
easat-4305	46	6	graphpad	graphpad	NOUN
easat-4305	46	7	prism	prism	NOUN
easat-4305	46	8	9	9	NUM
easat-4305	46	9	software	software	NOUN
easat-4305	46	10	(	(	PUNCT
easat-4305	46	11	graphpad	graphpad	PROPN
easat-4305	46	12	software	software	PROPN
easat-4305	46	13	inc	inc	PROPN
easat-4305	46	14	.	.	PROPN
easat-4305	46	15	,	,	PUNCT
easat-4305	46	16	la	la	PROPN
easat-4305	46	17	jolla	jolla	PROPN
easat-4305	46	18	,	,	PUNCT
easat-4305	46	19	ca	ca	NOUN
easat-4305	46	20	)	)	PUNCT
easat-4305	46	21	.	.	PUNCT
easat-4305	47	1	2.2	2.2	NUM
easat-4305	47	2	.	.	PUNCT
easat-4305	48	1	research	research	NOUN
easat-4305	48	2	methods	method	NOUN
easat-4305	48	3	the	the	DET
easat-4305	48	4	indirect	indirect	ADJ
easat-4305	48	5	elisa	elisa	NOUN
easat-4305	48	6	was	be	AUX
easat-4305	48	7	optimized	optimize	VERB
easat-4305	48	8	for	for	ADP
easat-4305	48	9	detecting	detect	VERB
easat-4305	48	10	the	the	DET
easat-4305	48	11	txn	txn	NOUN
easat-4305	48	12	antigen	antigen	ADV
easat-4305	48	13	in	in	ADP
easat-4305	48	14	serum	serum	NOUN
easat-4305	48	15	samples	sample	NOUN
easat-4305	48	16	.	.	PUNCT
easat-4305	49	1	each	each	DET
easat-4305	49	2	component	component	NOUN
easat-4305	49	3	of	of	ADP
easat-4305	49	4	the	the	DET
easat-4305	49	5	reaction	reaction	NOUN
easat-4305	49	6	was	be	AUX
easat-4305	49	7	systematically	systematically	ADV
easat-4305	49	8	optimized	optimize	VERB
easat-4305	49	9	.	.	PUNCT
easat-4305	50	1	the	the	DET
easat-4305	50	2	positive	positive	ADJ
easat-4305	50	3	control	control	NOUN
easat-4305	50	4	consisted	consist	VERB
easat-4305	50	5	of	of	ADP
easat-4305	50	6	recombinant	recombinant	ADJ
easat-4305	50	7	rag	rag	NOUN
easat-4305	50	8	-	-	PUNCT
easat-4305	50	9	txn	txn	NOUN
easat-4305	50	10	antigen	antigen	NOUN
easat-4305	50	11	diluted	dilute	VERB
easat-4305	50	12	in	in	ADP
easat-4305	50	13	bicarbonate	bicarbonate	NOUN
easat-4305	50	14	buffer	buffer	NOUN
easat-4305	50	15	at	at	ADP
easat-4305	50	16	serial	serial	ADJ
easat-4305	50	17	dilutions	dilution	NOUN
easat-4305	50	18	of	of	ADP
easat-4305	50	19	1:2	1:2	NUM
easat-4305	50	20	,	,	PUNCT
easat-4305	50	21	1:4	1:4	NUM
easat-4305	50	22	,	,	PUNCT
easat-4305	50	23	1:8	1:8	NUM
easat-4305	50	24	,	,	PUNCT
easat-4305	50	25	1:16	1:16	NUM
easat-4305	50	26	,	,	PUNCT
easat-4305	50	27	1:32	1:32	NUM
easat-4305	50	28	,	,	PUNCT
easat-4305	50	29	1:64	1:64	NUM
easat-4305	50	30	,	,	PUNCT
easat-4305	50	31	and	and	CCONJ
easat-4305	50	32	1:128	1:128	NUM
easat-4305	50	33	.	.	PUNCT
easat-4305	51	1	the	the	DET
easat-4305	51	2	monoclonal	monoclonal	NOUN
easat-4305	51	3	antibody	antibody	NOUN
easat-4305	51	4	mab	mab	NOUN
easat-4305	51	5	-	-	PUNCT
easat-4305	51	6	txn	txn	NOUN
easat-4305	51	7	was	be	AUX
easat-4305	51	8	diluted	dilute	VERB
easat-4305	51	9	in	in	ADP
easat-4305	51	10	dilution	dilution	NOUN
easat-4305	51	11	buffer	buffer	NOUN
easat-4305	51	12	at	at	ADP
easat-4305	51	13	ratios	ratio	NOUN
easat-4305	51	14	of	of	ADP
easat-4305	51	15	1:8	1:8	NUM
easat-4305	51	16	,	,	PUNCT
easat-4305	51	17	1:16	1:16	NUM
easat-4305	51	18	,	,	PUNCT
easat-4305	51	19	1:32	1:32	NUM
easat-4305	51	20	,	,	PUNCT
easat-4305	51	21	1:64	1:64	NUM
easat-4305	51	22	,	,	PUNCT
easat-4305	51	23	1:128	1:128	NUM
easat-4305	51	24	,	,	PUNCT
easat-4305	51	25	1:256	1:256	NUM
easat-4305	51	26	and	and	CCONJ
easat-4305	51	27	1:512	1:512	NUM
easat-4305	51	28	.	.	PUNCT
easat-4305	52	1	the	the	DET
easat-4305	52	2	hrp	hrp	PROPN
easat-4305	52	3	-	-	PUNCT
easat-4305	52	4	conjugated	conjugate	VERB
easat-4305	52	5	goat	goat	PROPN
easat-4305	52	6	anti	anti	ADJ
easat-4305	52	7	-	-	ADJ
easat-4305	52	8	mouse	mouse	ADJ
easat-4305	52	9	igg	igg	NOUN
easat-4305	52	10	(	(	PUNCT
easat-4305	52	11	h+l	h+l	NOUN
easat-4305	52	12	)	)	PUNCT
easat-4305	52	13	secondary	secondary	ADJ
easat-4305	52	14	antibody	antibody	NOUN
easat-4305	52	15	was	be	AUX
easat-4305	52	16	diluted	dilute	VERB
easat-4305	52	17	according	accord	VERB
easat-4305	52	18	to	to	ADP
easat-4305	52	19	the	the	DET
easat-4305	52	20	manufacturer	manufacturer	NOUN
easat-4305	52	21	's	's	PART
easat-4305	52	22	recommendations	recommendation	NOUN
easat-4305	52	23	at	at	ADP
easat-4305	52	24	ratios	ratio	NOUN
easat-4305	52	25	of	of	ADP
easat-4305	52	26	1:5000	1:5000	NUM
easat-4305	52	27	,	,	PUNCT
easat-4305	52	28	1:10000	1:10000	NUM
easat-4305	52	29	,	,	PUNCT
easat-4305	52	30	1:15000	1:15000	NUM
easat-4305	52	31	,	,	PUNCT
easat-4305	52	32	1:20000	1:20000	NUM
easat-4305	52	33	and	and	CCONJ
easat-4305	52	34	1:25000	1:25000	NUM
easat-4305	52	35	.	.	PUNCT
easat-4305	53	1	the	the	DET
easat-4305	53	2	procedure	procedure	NOUN
easat-4305	53	3	for	for	ADP
easat-4305	53	4	detecting	detect	VERB
easat-4305	53	5	the	the	DET
easat-4305	53	6	txn	txn	NOUN
easat-4305	53	7	antigen	antigen	ADV
easat-4305	53	8	in	in	ADP
easat-4305	53	9	the	the	DET
easat-4305	53	10	serum	serum	NOUN
easat-4305	53	11	was	be	AUX
easat-4305	53	12	conducted	conduct	VERB
easat-4305	53	13	as	as	SCONJ
easat-4305	53	14	follows	follow	VERB
easat-4305	53	15	.	.	PUNCT
easat-4305	54	1	patient	patient	ADJ
easat-4305	54	2	serum	serum	NOUN
easat-4305	54	3	was	be	AUX
easat-4305	54	4	diluted	dilute	VERB
easat-4305	54	5	in	in	ADP
easat-4305	54	6	0.2	0.2	NUM
easat-4305	54	7	m	m	NOUN
easat-4305	54	8	bicarbonate	bicarbonate	NOUN
easat-4305	54	9	buffer	buffer	NOUN
easat-4305	54	10	at	at	ADP
easat-4305	54	11	ph	ph	PROPN
easat-4305	54	12	9.4	9.4	NUM
easat-4305	54	13	at	at	ADP
easat-4305	54	14	a	a	DET
easat-4305	54	15	ratio	ratio	NOUN
easat-4305	54	16	of	of	ADP
easat-4305	54	17	1:1	1:1	NUM
easat-4305	54	18	.	.	PUNCT
easat-4305	55	1	a	a	DET
easat-4305	55	2	total	total	NOUN
easat-4305	55	3	of	of	ADP
easat-4305	55	4	100	100	NUM
easat-4305	55	5	μl	μl	ADP
easat-4305	55	6	of	of	ADP
easat-4305	55	7	diluted	diluted	ADJ
easat-4305	55	8	serum	serum	NOUN
easat-4305	55	9	was	be	AUX
easat-4305	55	10	added	add	VERB
easat-4305	55	11	to	to	ADP
easat-4305	55	12	each	each	PRON
easat-4305	55	13	well	well	ADV
easat-4305	55	14	,	,	PUNCT
easat-4305	55	15	and	and	CCONJ
easat-4305	55	16	the	the	DET
easat-4305	55	17	plate	plate	NOUN
easat-4305	55	18	was	be	AUX
easat-4305	55	19	sealed	seal	VERB
easat-4305	55	20	with	with	ADP
easat-4305	55	21	specialized	specialized	ADJ
easat-4305	55	22	adhesive	adhesive	ADJ
easat-4305	55	23	film	film	NOUN
easat-4305	55	24	and	and	CCONJ
easat-4305	55	25	incubated	incubate	VERB
easat-4305	55	26	at	at	ADP
easat-4305	55	27	room	room	NOUN
easat-4305	55	28	temperature	temperature	NOUN
easat-4305	55	29	for	for	ADP
easat-4305	55	30	2	2	NUM
easat-4305	55	31	hours	hour	NOUN
easat-4305	55	32	or	or	CCONJ
easat-4305	55	33	overnight	overnight	ADV
easat-4305	55	34	at	at	ADP
easat-4305	55	35	4	4	NUM
easat-4305	55	36	°	°	NOUN
easat-4305	55	37	c	c	NOUN
easat-4305	55	38	.	.	PUNCT
easat-4305	56	1	the	the	DET
easat-4305	56	2	antigen	antigen	NOUN
easat-4305	56	3	was	be	AUX
easat-4305	56	4	aspirated	aspirate	VERB
easat-4305	56	5	,	,	PUNCT
easat-4305	56	6	and	and	CCONJ
easat-4305	56	7	the	the	DET
easat-4305	56	8	wells	well	NOUN
easat-4305	56	9	were	be	AUX
easat-4305	56	10	washed	wash	VERB
easat-4305	56	11	three	three	NUM
easat-4305	56	12	times	time	NOUN
easat-4305	56	13	with	with	ADP
easat-4305	56	14	300	300	NUM
easat-4305	56	15	μl	μl	ADP
easat-4305	56	16	of	of	ADP
easat-4305	56	17	washing	washing	NOUN
easat-4305	56	18	buffer	buffer	NOUN
easat-4305	56	19	per	per	ADP
easat-4305	56	20	well	well	ADV
easat-4305	56	21	.	.	PUNCT
easat-4305	57	1	next	next	ADJ
easat-4305	57	2	,	,	PUNCT
easat-4305	57	3	200	200	NUM
easat-4305	57	4	μl	μl	ADP
easat-4305	57	5	of	of	ADP
easat-4305	57	6	blocking	block	VERB
easat-4305	57	7	buffer	buffer	NOUN
easat-4305	57	8	was	be	AUX
easat-4305	57	9	added	add	VERB
easat-4305	57	10	to	to	ADP
easat-4305	57	11	each	each	DET
easat-4305	57	12	well	well	ADV
easat-4305	57	13	and	and	CCONJ
easat-4305	57	14	incubated	incubate	VERB
easat-4305	57	15	at	at	ADP
easat-4305	57	16	37	37	NUM
easat-4305	57	17	°	°	ADP
easat-4305	57	18	c	c	NOUN
easat-4305	57	19	for	for	ADP
easat-4305	57	20	1	1	NUM
easat-4305	57	21	hour	hour	NOUN
easat-4305	57	22	.	.	PUNCT
easat-4305	58	1	the	the	DET
easat-4305	58	2	blocking	blocking	NOUN
easat-4305	58	3	buffer	buffer	NOUN
easat-4305	58	4	was	be	AUX
easat-4305	58	5	then	then	ADV
easat-4305	58	6	removed	remove	VERB
easat-4305	58	7	,	,	PUNCT
easat-4305	58	8	and	and	CCONJ
easat-4305	58	9	the	the	DET
easat-4305	58	10	wells	well	NOUN
easat-4305	58	11	were	be	AUX
easat-4305	58	12	washed	wash	VERB
easat-4305	58	13	three	three	NUM
easat-4305	58	14	times	time	NOUN
easat-4305	58	15	with	with	ADP
easat-4305	58	16	300	300	NUM
easat-4305	58	17	μl	μl	ADP
easat-4305	58	18	of	of	ADP
easat-4305	58	19	washing	washing	NOUN
easat-4305	58	20	buffer	buffer	NOUN
easat-4305	58	21	per	per	ADP
easat-4305	58	22	well	well	ADV
easat-4305	58	23	.	.	PUNCT
easat-4305	59	1	subsequently	subsequently	ADV
easat-4305	59	2	,	,	PUNCT
easat-4305	59	3	100	100	NUM
easat-4305	59	4	μl	μl	ADP
easat-4305	59	5	of	of	ADP
easat-4305	59	6	the	the	DET
easat-4305	59	7	specific	specific	ADJ
easat-4305	59	8	monoclonal	monoclonal	NOUN
easat-4305	59	9	antibody	antibody	NOUN
easat-4305	59	10	mab	mab	NOUN
easat-4305	59	11	-	-	PUNCT
easat-4305	59	12	txn	txn	NOUN
easat-4305	59	13	was	be	AUX
easat-4305	59	14	added	add	VERB
easat-4305	59	15	to	to	ADP
easat-4305	59	16	each	each	DET
easat-4305	59	17	well	well	ADV
easat-4305	59	18	and	and	CCONJ
easat-4305	59	19	incubated	incubate	VERB
easat-4305	59	20	at	at	ADP
easat-4305	59	21	37	37	NUM
easat-4305	59	22	°	°	ADP
easat-4305	59	23	c	c	NOUN
easat-4305	59	24	for	for	ADP
easat-4305	59	25	1	1	NUM
easat-4305	59	26	hour	hour	NOUN
easat-4305	59	27	.	.	PUNCT
easat-4305	60	1	after	after	ADP
easat-4305	60	2	incubation	incubation	NOUN
easat-4305	60	3	,	,	PUNCT
easat-4305	60	4	the	the	DET
easat-4305	60	5	antibody	antibody	NOUN
easat-4305	60	6	was	be	AUX
easat-4305	60	7	aspirated	aspirate	VERB
easat-4305	60	8	,	,	PUNCT
easat-4305	60	9	and	and	CCONJ
easat-4305	60	10	the	the	DET
easat-4305	60	11	wells	well	NOUN
easat-4305	60	12	were	be	AUX
easat-4305	60	13	washed	wash	VERB
easat-4305	60	14	three	three	NUM
easat-4305	60	15	times	time	NOUN
easat-4305	60	16	with	with	ADP
easat-4305	60	17	300	300	NUM
easat-4305	60	18	μl	μl	ADP
easat-4305	60	19	of	of	ADP
easat-4305	60	20	washing	washing	NOUN
easat-4305	60	21	buffer	buffer	NOUN
easat-4305	60	22	per	per	ADP
easat-4305	60	23	well	well	ADV
easat-4305	60	24	.	.	PUNCT
easat-4305	61	1	1012	1012	NUM
easat-4305	61	2	edelweiss	edelweiss	PROPN
easat-4305	61	3	applied	apply	VERB
easat-4305	61	4	science	science	NOUN
easat-4305	61	5	and	and	CCONJ
easat-4305	61	6	technology	technology	NOUN
easat-4305	61	7	issn	issn	PROPN
easat-4305	61	8	:	:	PUNCT
easat-4305	61	9	2576	2576	NUM
easat-4305	61	10	-	-	SYM
easat-4305	61	11	8484	8484	NUM
easat-4305	61	12	vol	vol	NOUN
easat-4305	61	13	.	.	PROPN
easat-4305	62	1	9	9	NUM
easat-4305	62	2	,	,	PUNCT
easat-4305	62	3	no	no	INTJ
easat-4305	62	4	.	.	NOUN
easat-4305	62	5	1	1	NUM
easat-4305	62	6	:	:	PUNCT
easat-4305	62	7	1010	1010	NUM
easat-4305	62	8	-	-	SYM
easat-4305	62	9	1018	1018	NUM
easat-4305	62	10	,	,	PUNCT
easat-4305	62	11	2025	2025	NUM
easat-4305	62	12	doi	doi	NOUN
easat-4305	62	13	:	:	PUNCT
easat-4305	62	14	10.55214/25768484.v9i1.4305	10.55214/25768484.v9i1.4305	NUM
easat-4305	62	15	©	©	PROPN
easat-4305	62	16	2025	2025	NUM
easat-4305	62	17	by	by	ADP
easat-4305	62	18	the	the	DET
easat-4305	62	19	authors	author	NOUN
easat-4305	62	20	;	;	PUNCT
easat-4305	62	21	licensee	licensee	PROPN
easat-4305	62	22	learning	learning	NOUN
easat-4305	62	23	gate	gate	NOUN
easat-4305	62	24	next	next	ADV
easat-4305	62	25	,	,	PUNCT
easat-4305	62	26	100	100	NUM
easat-4305	62	27	μl	μl	ADP
easat-4305	62	28	of	of	ADP
easat-4305	62	29	appropriately	appropriately	ADV
easat-4305	62	30	diluted	dilute	VERB
easat-4305	62	31	hrp	hrp	PROPN
easat-4305	62	32	-	-	PUNCT
easat-4305	62	33	conjugated	conjugate	VERB
easat-4305	62	34	secondary	secondary	ADJ
easat-4305	62	35	antibody	antibody	NOUN
easat-4305	62	36	was	be	AUX
easat-4305	62	37	added	add	VERB
easat-4305	62	38	to	to	ADP
easat-4305	62	39	each	each	DET
easat-4305	62	40	well	well	ADV
easat-4305	62	41	and	and	CCONJ
easat-4305	62	42	incubated	incubate	VERB
easat-4305	62	43	at	at	ADP
easat-4305	62	44	37	37	NUM
easat-4305	62	45	°	°	ADP
easat-4305	62	46	c	c	NOUN
easat-4305	62	47	for	for	ADP
easat-4305	62	48	1	1	NUM
easat-4305	62	49	hour	hour	NOUN
easat-4305	62	50	.	.	PUNCT
easat-4305	63	1	the	the	DET
easat-4305	63	2	secondary	secondary	ADJ
easat-4305	63	3	antibody	antibody	NOUN
easat-4305	63	4	was	be	AUX
easat-4305	63	5	then	then	ADV
easat-4305	63	6	aspirated	aspirate	VERB
easat-4305	63	7	,	,	PUNCT
easat-4305	63	8	and	and	CCONJ
easat-4305	63	9	the	the	DET
easat-4305	63	10	wells	well	NOUN
easat-4305	63	11	were	be	AUX
easat-4305	63	12	washed	wash	VERB
easat-4305	63	13	three	three	NUM
easat-4305	63	14	times	time	NOUN
easat-4305	63	15	with	with	ADP
easat-4305	63	16	300	300	NUM
easat-4305	63	17	μl	μl	ADP
easat-4305	63	18	of	of	ADP
easat-4305	63	19	washing	washing	NOUN
easat-4305	63	20	buffer	buffer	NOUN
easat-4305	63	21	per	per	ADP
easat-4305	63	22	well	well	ADV
easat-4305	63	23	.	.	PUNCT
easat-4305	64	1	next	next	ADJ
easat-4305	64	2	,	,	PUNCT
easat-4305	64	3	100	100	NUM
easat-4305	64	4	μl	μl	ADP
easat-4305	64	5	of	of	ADP
easat-4305	64	6	tmb	tmb	NOUN
easat-4305	64	7	substrate	substrate	NOUN
easat-4305	64	8	solution	solution	NOUN
easat-4305	64	9	was	be	AUX
easat-4305	64	10	added	add	VERB
easat-4305	64	11	to	to	ADP
easat-4305	64	12	each	each	PRON
easat-4305	64	13	well	well	ADV
easat-4305	64	14	,	,	PUNCT
easat-4305	64	15	and	and	CCONJ
easat-4305	64	16	the	the	DET
easat-4305	64	17	plate	plate	NOUN
easat-4305	64	18	was	be	AUX
easat-4305	64	19	incubated	incubate	VERB
easat-4305	64	20	in	in	ADP
easat-4305	64	21	the	the	DET
easat-4305	64	22	dark	dark	NOUN
easat-4305	64	23	for	for	ADP
easat-4305	64	24	30	30	NUM
easat-4305	64	25	minutes	minute	NOUN
easat-4305	64	26	.	.	PUNCT
easat-4305	65	1	the	the	DET
easat-4305	65	2	reaction	reaction	NOUN
easat-4305	65	3	was	be	AUX
easat-4305	65	4	stopped	stop	VERB
easat-4305	65	5	by	by	ADP
easat-4305	65	6	adding	add	VERB
easat-4305	65	7	100	100	NUM
easat-4305	65	8	μl	μl	ADP
easat-4305	65	9	of	of	ADP
easat-4305	65	10	1	1	NUM
easat-4305	65	11	m	m	NOUN
easat-4305	65	12	hcl	hcl	PROPN
easat-4305	65	13	to	to	ADP
easat-4305	65	14	each	each	DET
easat-4305	65	15	well	well	ADV
easat-4305	65	16	.	.	PUNCT
easat-4305	66	1	the	the	DET
easat-4305	66	2	results	result	NOUN
easat-4305	66	3	were	be	AUX
easat-4305	66	4	read	read	VERB
easat-4305	66	5	using	use	VERB
easat-4305	66	6	an	an	DET
easat-4305	66	7	elisa	elisa	NOUN
easat-4305	66	8	plate	plate	NOUN
easat-4305	66	9	reader	reader	NOUN
easat-4305	66	10	at	at	ADP
easat-4305	66	11	a	a	DET
easat-4305	66	12	wavelength	wavelength	NOUN
easat-4305	66	13	of	of	ADP
easat-4305	66	14	450	450	NUM
easat-4305	66	15	nm	nm	NOUN
easat-4305	66	16	.	.	PUNCT
easat-4305	67	1	the	the	DET
easat-4305	67	2	cutoff	cutoff	NOUN
easat-4305	67	3	value	value	NOUN
easat-4305	67	4	was	be	AUX
easat-4305	67	5	determined	determine	VERB
easat-4305	67	6	on	on	ADP
easat-4305	67	7	the	the	DET
easat-4305	67	8	basis	basis	NOUN
easat-4305	67	9	of	of	ADP
easat-4305	67	10	the	the	DET
easat-4305	67	11	od450	od450	ADJ
easat-4305	67	12	values	value	NOUN
easat-4305	67	13	of	of	ADP
easat-4305	67	14	15	15	NUM
easat-4305	67	15	serum	serum	NOUN
easat-4305	67	16	samples	sample	NOUN
easat-4305	67	17	from	from	ADP
easat-4305	67	18	healthy	healthy	ADJ
easat-4305	67	19	individuals	individual	NOUN
easat-4305	67	20	without	without	ADP
easat-4305	67	21	liver	liver	NOUN
easat-4305	67	22	-	-	PUNCT
easat-4305	67	23	related	relate	VERB
easat-4305	67	24	diseases	disease	NOUN
easat-4305	67	25	and	and	CCONJ
easat-4305	67	26	was	be	AUX
easat-4305	67	27	calculated	calculate	VERB
easat-4305	67	28	via	via	ADP
easat-4305	67	29	lardeux	lardeux	PROPN
easat-4305	67	30	’s	’s	PART
easat-4305	67	31	formula	formula	NOUN
easat-4305	68	1	[	[	X
easat-4305	68	2	6	6	NUM
easat-4305	68	3	]	]	PUNCT
easat-4305	68	4	.	.	PUNCT
easat-4305	69	1	cutoff	cutoff	NOUN
easat-4305	69	2	value	value	NOUN
easat-4305	69	3	=	=	PUNCT
easat-4305	70	1	x̅	x̅	PROPN
easat-4305	71	1	+	+	NUM
easat-4305	71	2	3.sd	3.sd	NUM
easat-4305	71	3	.	.	PUNCT
easat-4305	72	1	serum	serum	NOUN
easat-4305	72	2	samples	sample	NOUN
easat-4305	72	3	with	with	ADP
easat-4305	72	4	od450	od450	NOUN
easat-4305	72	5	nm	nm	DET
easat-4305	72	6	values	value	NOUN
easat-4305	72	7	exceeding	exceed	VERB
easat-4305	72	8	the	the	DET
easat-4305	72	9	determined	determined	ADJ
easat-4305	72	10	cutoff	cutoff	NOUN
easat-4305	72	11	were	be	AUX
easat-4305	72	12	considered	consider	VERB
easat-4305	72	13	positive	positive	ADJ
easat-4305	72	14	,	,	PUNCT
easat-4305	72	15	whereas	whereas	SCONJ
easat-4305	72	16	those	those	PRON
easat-4305	72	17	below	below	ADP
easat-4305	72	18	the	the	DET
easat-4305	72	19	cutoff	cutoff	NOUN
easat-4305	72	20	were	be	AUX
easat-4305	72	21	deemed	deem	VERB
easat-4305	72	22	negative	negative	ADJ
easat-4305	72	23	.	.	PUNCT
easat-4305	73	1	the	the	DET
easat-4305	73	2	sensitivity	sensitivity	NOUN
easat-4305	73	3	and	and	CCONJ
easat-4305	73	4	specificity	specificity	NOUN
easat-4305	73	5	of	of	ADP
easat-4305	73	6	the	the	DET
easat-4305	73	7	immunoassay	immunoassay	NOUN
easat-4305	73	8	for	for	ADP
easat-4305	73	9	detecting	detect	VERB
easat-4305	73	10	the	the	DET
easat-4305	73	11	txn	txn	NOUN
easat-4305	73	12	antigen	antigen	ADV
easat-4305	73	13	in	in	ADP
easat-4305	73	14	serum	serum	NOUN
easat-4305	73	15	samples	sample	NOUN
easat-4305	73	16	via	via	ADP
easat-4305	73	17	monoclonal	monoclonal	NOUN
easat-4305	73	18	antibodies	antibody	NOUN
easat-4305	73	19	were	be	AUX
easat-4305	73	20	evaluated	evaluate	VERB
easat-4305	73	21	on	on	ADP
easat-4305	73	22	the	the	DET
easat-4305	73	23	basis	basis	NOUN
easat-4305	73	24	of	of	ADP
easat-4305	73	25	the	the	DET
easat-4305	73	26	definitive	definitive	ADJ
easat-4305	73	27	diagnosis	diagnosis	NOUN
easat-4305	73	28	recorded	record	VERB
easat-4305	73	29	in	in	ADP
easat-4305	73	30	patient	patient	ADJ
easat-4305	73	31	medical	medical	ADJ
easat-4305	73	32	files	file	NOUN
easat-4305	73	33	.	.	PUNCT
easat-4305	74	1	calculations	calculation	NOUN
easat-4305	74	2	of	of	ADP
easat-4305	74	3	sensitivity	sensitivity	NOUN
easat-4305	74	4	,	,	PUNCT
easat-4305	74	5	specificity	specificity	NOUN
easat-4305	74	6	,	,	PUNCT
easat-4305	74	7	positive	positive	ADJ
easat-4305	74	8	predictive	predictive	ADJ
easat-4305	74	9	value	value	NOUN
easat-4305	74	10	(	(	PUNCT
easat-4305	74	11	ppv	ppv	NOUN
easat-4305	74	12	)	)	PUNCT
easat-4305	74	13	,	,	PUNCT
easat-4305	74	14	and	and	CCONJ
easat-4305	74	15	negative	negative	ADJ
easat-4305	74	16	predictive	predictive	ADJ
easat-4305	74	17	value	value	NOUN
easat-4305	74	18	(	(	PUNCT
easat-4305	74	19	npv	npv	NOUN
easat-4305	74	20	)	)	PUNCT
easat-4305	74	21	were	be	AUX
easat-4305	74	22	performed	perform	VERB
easat-4305	74	23	via	via	ADP
easat-4305	74	24	standard	standard	ADJ
easat-4305	74	25	diagnostic	diagnostic	ADJ
easat-4305	74	26	test	test	NOUN
easat-4305	74	27	formulas	formula	NOUN
easat-4305	74	28	.	.	PUNCT
easat-4305	75	1	study	study	NOUN
easat-4305	75	2	location	location	NOUN
easat-4305	75	3	and	and	CCONJ
easat-4305	75	4	duration	duration	NOUN
easat-4305	75	5	:	:	PUNCT
easat-4305	75	6	the	the	DET
easat-4305	75	7	study	study	NOUN
easat-4305	75	8	was	be	AUX
easat-4305	75	9	conducted	conduct	VERB
easat-4305	75	10	at	at	ADP
easat-4305	75	11	the	the	DET
easat-4305	75	12	microbial	microbial	ADJ
easat-4305	75	13	genomics	genomic	NOUN
easat-4305	75	14	laboratory	laboratory	NOUN
easat-4305	75	15	,	,	PUNCT
easat-4305	75	16	institute	institute	NOUN
easat-4305	75	17	of	of	ADP
easat-4305	75	18	genome	genome	NOUN
easat-4305	75	19	research	research	NOUN
easat-4305	75	20	,	,	PUNCT
easat-4305	75	21	vietnam	vietnam	PROPN
easat-4305	75	22	academy	academy	PROPN
easat-4305	75	23	of	of	ADP
easat-4305	75	24	science	science	NOUN
easat-4305	75	25	and	and	CCONJ
easat-4305	75	26	technology	technology	NOUN
easat-4305	75	27	.	.	PUNCT
easat-4305	76	1	serum	serum	NOUN
easat-4305	76	2	samples	sample	NOUN
easat-4305	76	3	were	be	AUX
easat-4305	76	4	collected	collect	VERB
easat-4305	76	5	from	from	ADP
easat-4305	76	6	the	the	DET
easat-4305	76	7	department	department	NOUN
easat-4305	76	8	of	of	ADP
easat-4305	76	9	hepatobiliary	hepatobiliary	ADJ
easat-4305	76	10	and	and	CCONJ
easat-4305	76	11	pancreatic	pancreatic	ADJ
easat-4305	76	12	medicine	medicine	NOUN
easat-4305	76	13	at	at	ADP
easat-4305	76	14	the	the	DET
easat-4305	76	15	108	108	NUM
easat-4305	76	16	military	military	ADJ
easat-4305	76	17	central	central	ADJ
easat-4305	76	18	hospital	hospital	NOUN
easat-4305	76	19	between	between	ADP
easat-4305	76	20	june	june	PROPN
easat-4305	76	21	2023	2023	NUM
easat-4305	76	22	and	and	CCONJ
easat-4305	76	23	june	june	PROPN
easat-4305	76	24	2024	2024	NUM
easat-4305	76	25	.	.	PUNCT
easat-4305	77	1	research	research	NOUN
easat-4305	77	2	ethics	ethic	NOUN
easat-4305	77	3	:	:	PUNCT
easat-4305	77	4	serum	serum	NOUN
easat-4305	77	5	samples	sample	NOUN
easat-4305	77	6	were	be	AUX
easat-4305	77	7	collected	collect	VERB
easat-4305	77	8	anonymously	anonymously	ADV
easat-4305	77	9	,	,	PUNCT
easat-4305	77	10	and	and	CCONJ
easat-4305	77	11	patient	patient	ADJ
easat-4305	77	12	information	information	NOUN
easat-4305	77	13	was	be	AUX
easat-4305	77	14	strictly	strictly	ADV
easat-4305	77	15	confidential	confidential	ADJ
easat-4305	77	16	,	,	PUNCT
easat-4305	77	17	adhering	adhere	VERB
easat-4305	77	18	to	to	ADP
easat-4305	77	19	international	international	ADJ
easat-4305	77	20	ethical	ethical	ADJ
easat-4305	77	21	guidelines	guideline	NOUN
easat-4305	77	22	.	.	PUNCT
easat-4305	78	1	all	all	DET
easat-4305	78	2	samples	sample	NOUN
easat-4305	78	3	were	be	AUX
easat-4305	78	4	exclusively	exclusively	ADV
easat-4305	78	5	used	use	VERB
easat-4305	78	6	for	for	ADP
easat-4305	78	7	academic	academic	ADJ
easat-4305	78	8	research	research	NOUN
easat-4305	78	9	purposes	purpose	NOUN
easat-4305	78	10	.	.	PUNCT
easat-4305	79	1	3	3	X
easat-4305	79	2	.	.	NOUN
easat-4305	79	3	results	result	VERB
easat-4305	79	4	3.1	3.1	NUM
easat-4305	79	5	.	.	PUNCT
easat-4305	80	1	characteristics	characteristic	NOUN
easat-4305	80	2	of	of	ADP
easat-4305	80	3	the	the	DET
easat-4305	80	4	study	study	NOUN
easat-4305	80	5	groups	group	NOUN
easat-4305	80	6	3.1.1	3.1.1	NUM
easat-4305	80	7	.	.	PUNCT
easat-4305	81	1	characteristics	characteristic	NOUN
easat-4305	81	2	of	of	ADP
easat-4305	81	3	the	the	DET
easat-4305	81	4	hcc	hcc	PROPN
easat-4305	81	5	group	group	NOUN
easat-4305	81	6	the	the	DET
easat-4305	81	7	majority	majority	NOUN
easat-4305	81	8	of	of	ADP
easat-4305	81	9	patients	patient	NOUN
easat-4305	81	10	with	with	ADP
easat-4305	81	11	hcc	hcc	PROPN
easat-4305	81	12	were	be	AUX
easat-4305	81	13	aged	age	VERB
easat-4305	81	14	≥60	≥60	NUM
easat-4305	81	15	years	year	NOUN
easat-4305	81	16	,	,	PUNCT
easat-4305	81	17	accounting	account	VERB
easat-4305	81	18	for	for	ADP
easat-4305	81	19	61.8	61.8	NUM
easat-4305	81	20	%	%	NOUN
easat-4305	81	21	of	of	ADP
easat-4305	81	22	the	the	DET
easat-4305	81	23	total	total	ADJ
easat-4305	81	24	patients	patient	NOUN
easat-4305	81	25	.	.	PUNCT
easat-4305	82	1	among	among	ADP
easat-4305	82	2	these	these	DET
easat-4305	82	3	patients	patient	NOUN
easat-4305	82	4	,	,	PUNCT
easat-4305	82	5	males	male	NOUN
easat-4305	82	6	predominated	predominate	VERB
easat-4305	82	7	,	,	PUNCT
easat-4305	82	8	with	with	ADP
easat-4305	82	9	approximately	approximately	ADV
easat-4305	82	10	seven	seven	NUM
easat-4305	82	11	times	time	NOUN
easat-4305	82	12	as	as	ADV
easat-4305	82	13	many	many	ADJ
easat-4305	82	14	males	male	NOUN
easat-4305	82	15	as	as	ADP
easat-4305	82	16	females	female	NOUN
easat-4305	82	17	in	in	ADP
easat-4305	82	18	the	the	DET
easat-4305	82	19	study	study	NOUN
easat-4305	82	20	group	group	NOUN
easat-4305	82	21	.	.	PUNCT
easat-4305	83	1	the	the	DET
easat-4305	83	2	most	most	ADV
easat-4305	83	3	common	common	ADJ
easat-4305	83	4	etiological	etiological	ADJ
easat-4305	83	5	factor	factor	NOUN
easat-4305	83	6	in	in	ADP
easat-4305	83	7	the	the	DET
easat-4305	83	8	development	development	NOUN
easat-4305	83	9	of	of	ADP
easat-4305	83	10	hcc	hcc	PROPN
easat-4305	83	11	was	be	AUX
easat-4305	83	12	hbv	hbv	NOUN
easat-4305	83	13	infection	infection	NOUN
easat-4305	83	14	,	,	PUNCT
easat-4305	83	15	which	which	PRON
easat-4305	83	16	was	be	AUX
easat-4305	83	17	present	present	ADJ
easat-4305	83	18	in	in	ADP
easat-4305	83	19	81	81	NUM
easat-4305	83	20	%	%	NOUN
easat-4305	83	21	of	of	ADP
easat-4305	83	22	the	the	DET
easat-4305	83	23	patients	patient	NOUN
easat-4305	83	24	.	.	PUNCT
easat-4305	84	1	coinfection	coinfection	NOUN
easat-4305	84	2	with	with	ADP
easat-4305	84	3	hcv	hcv	PROPN
easat-4305	84	4	was	be	AUX
easat-4305	84	5	observed	observe	VERB
easat-4305	84	6	in	in	ADP
easat-4305	84	7	a	a	DET
easat-4305	84	8	single	single	ADJ
easat-4305	84	9	patient	patient	NOUN
easat-4305	84	10	,	,	PUNCT
easat-4305	84	11	representing	represent	VERB
easat-4305	84	12	2.1	2.1	NUM
easat-4305	84	13	%	%	NOUN
easat-4305	84	14	of	of	ADP
easat-4305	84	15	the	the	DET
easat-4305	84	16	cohort	cohort	NOUN
easat-4305	84	17	.	.	PUNCT
easat-4305	85	1	alcohol	alcohol	NOUN
easat-4305	85	2	-	-	PUNCT
easat-4305	85	3	induced	induce	VERB
easat-4305	85	4	cirrhosis	cirrhosis	NOUN
easat-4305	85	5	was	be	AUX
easat-4305	85	6	also	also	ADV
easat-4305	85	7	a	a	DET
easat-4305	85	8	significant	significant	ADJ
easat-4305	85	9	contributing	contribute	VERB
easat-4305	85	10	factor	factor	NOUN
easat-4305	85	11	,	,	PUNCT
easat-4305	85	12	present	present	ADJ
easat-4305	85	13	in	in	ADP
easat-4305	85	14	6.3	6.3	NUM
easat-4305	85	15	%	%	NOUN
easat-4305	85	16	of	of	ADP
easat-4305	85	17	the	the	DET
easat-4305	85	18	patients	patient	NOUN
easat-4305	85	19	.	.	PUNCT
easat-4305	86	1	with	with	ADP
easat-4305	86	2	respect	respect	NOUN
easat-4305	86	3	to	to	ADP
easat-4305	86	4	the	the	DET
easat-4305	86	5	stage	stage	NOUN
easat-4305	86	6	of	of	ADP
easat-4305	86	7	diagnosis	diagnosis	NOUN
easat-4305	86	8	,	,	PUNCT
easat-4305	86	9	only	only	ADV
easat-4305	86	10	8	8	NUM
easat-4305	86	11	patients	patient	NOUN
easat-4305	86	12	(	(	PUNCT
easat-4305	86	13	17	17	NUM
easat-4305	86	14	%	%	NOUN
easat-4305	86	15	)	)	PUNCT
easat-4305	86	16	were	be	AUX
easat-4305	86	17	diagnosed	diagnose	VERB
easat-4305	86	18	at	at	ADP
easat-4305	86	19	an	an	DET
easat-4305	86	20	early	early	ADJ
easat-4305	86	21	stage	stage	NOUN
easat-4305	86	22	of	of	ADP
easat-4305	86	23	hcc	hcc	PROPN
easat-4305	86	24	,	,	PUNCT
easat-4305	86	25	whereas	whereas	SCONJ
easat-4305	86	26	the	the	DET
easat-4305	86	27	remaining	remain	VERB
easat-4305	86	28	39	39	NUM
easat-4305	86	29	patients	patient	NOUN
easat-4305	86	30	(	(	PUNCT
easat-4305	86	31	83	83	NUM
easat-4305	86	32	%	%	NOUN
easat-4305	86	33	)	)	PUNCT
easat-4305	86	34	were	be	AUX
easat-4305	86	35	diagnosed	diagnose	VERB
easat-4305	86	36	at	at	ADP
easat-4305	86	37	intermediate	intermediate	ADJ
easat-4305	86	38	,	,	PUNCT
easat-4305	86	39	advanced	advanced	ADJ
easat-4305	86	40	,	,	PUNCT
easat-4305	86	41	or	or	CCONJ
easat-4305	86	42	terminal	terminal	ADJ
easat-4305	86	43	stages	stage	NOUN
easat-4305	86	44	.	.	PUNCT
easat-4305	87	1	these	these	DET
easat-4305	87	2	later	later	ADJ
easat-4305	87	3	stages	stage	NOUN
easat-4305	87	4	were	be	AUX
easat-4305	87	5	collectively	collectively	ADV
easat-4305	87	6	categorized	categorize	VERB
easat-4305	87	7	as	as	ADP
easat-4305	87	8	late	late	ADJ
easat-4305	87	9	-	-	PUNCT
easat-4305	87	10	stage	stage	NOUN
easat-4305	87	11	hcc	hcc	PROPN
easat-4305	87	12	,	,	PUNCT
easat-4305	87	13	which	which	PRON
easat-4305	87	14	represented	represent	VERB
easat-4305	87	15	a	a	DET
easat-4305	87	16	fivefold	fivefold	ADJ
easat-4305	87	17	increase	increase	NOUN
easat-4305	87	18	in	in	ADP
easat-4305	87	19	comparison	comparison	NOUN
easat-4305	87	20	with	with	ADP
easat-4305	87	21	early	early	ADJ
easat-4305	87	22	-	-	PUNCT
easat-4305	87	23	stage	stage	NOUN
easat-4305	87	24	diagnoses	diagnosis	NOUN
easat-4305	87	25	.	.	PUNCT
easat-4305	88	1	the	the	DET
easat-4305	88	2	liver	liver	NOUN
easat-4305	88	3	disease	disease	NOUN
easat-4305	88	4	group	group	NOUN
easat-4305	88	5	,	,	PUNCT
easat-4305	88	6	consisting	consist	VERB
easat-4305	88	7	of	of	ADP
easat-4305	88	8	10	10	NUM
easat-4305	88	9	patients	patient	NOUN
easat-4305	88	10	,	,	PUNCT
easat-4305	88	11	included	include	VERB
easat-4305	88	12	individuals	individual	NOUN
easat-4305	88	13	aged	age	VERB
easat-4305	88	14	between	between	ADP
easat-4305	88	15	38	38	NUM
easat-4305	88	16	and	and	CCONJ
easat-4305	88	17	75	75	NUM
easat-4305	88	18	years	year	NOUN
easat-4305	88	19	who	who	PRON
easat-4305	88	20	were	be	AUX
easat-4305	88	21	diagnosed	diagnose	VERB
easat-4305	88	22	with	with	ADP
easat-4305	88	23	common	common	ADJ
easat-4305	88	24	liver	liver	NOUN
easat-4305	88	25	conditions	condition	NOUN
easat-4305	88	26	but	but	CCONJ
easat-4305	88	27	did	do	AUX
easat-4305	88	28	not	not	PART
easat-4305	88	29	have	have	VERB
easat-4305	88	30	hcc	hcc	PROPN
easat-4305	88	31	.	.	PUNCT
easat-4305	89	1	the	the	DET
easat-4305	89	2	nonliver	nonliver	ADJ
easat-4305	89	3	disease	disease	NOUN
easat-4305	89	4	group	group	NOUN
easat-4305	89	5	,	,	PUNCT
easat-4305	89	6	on	on	ADP
easat-4305	89	7	the	the	DET
easat-4305	89	8	other	other	ADJ
easat-4305	89	9	hand	hand	NOUN
easat-4305	89	10	,	,	PUNCT
easat-4305	89	11	comprised	comprise	VERB
easat-4305	89	12	15	15	NUM
easat-4305	89	13	individuals	individual	NOUN
easat-4305	89	14	aged	age	VERB
easat-4305	89	15	38	38	NUM
easat-4305	89	16	-	-	SYM
easat-4305	89	17	79	79	NUM
easat-4305	89	18	years	year	NOUN
easat-4305	89	19	who	who	PRON
easat-4305	89	20	were	be	AUX
easat-4305	89	21	free	free	ADJ
easat-4305	89	22	from	from	ADP
easat-4305	89	23	any	any	DET
easat-4305	89	24	liverrelated	liverrelate	VERB
easat-4305	89	25	conditions	condition	NOUN
easat-4305	89	26	(	(	PUNCT
easat-4305	89	27	table	table	NOUN
easat-4305	89	28	1	1	NUM
easat-4305	89	29	)	)	PUNCT
easat-4305	89	30	.	.	PUNCT
easat-4305	90	1	1013	1013	NUM
easat-4305	90	2	edelweiss	edelweiss	PROPN
easat-4305	90	3	applied	apply	VERB
easat-4305	90	4	science	science	NOUN
easat-4305	90	5	and	and	CCONJ
easat-4305	90	6	technology	technology	NOUN
easat-4305	90	7	issn	issn	PROPN
easat-4305	90	8	:	:	PUNCT
easat-4305	90	9	2576	2576	NUM
easat-4305	90	10	-	-	SYM
easat-4305	90	11	8484	8484	NUM
easat-4305	90	12	vol	vol	NOUN
easat-4305	90	13	.	.	PROPN
easat-4305	91	1	9	9	NUM
easat-4305	91	2	,	,	PUNCT
easat-4305	91	3	no	no	INTJ
easat-4305	91	4	.	.	NOUN
easat-4305	91	5	1	1	NUM
easat-4305	91	6	:	:	PUNCT
easat-4305	91	7	1010	1010	NUM
easat-4305	91	8	-	-	SYM
easat-4305	91	9	1018	1018	NUM
easat-4305	91	10	,	,	PUNCT
easat-4305	91	11	2025	2025	NUM
easat-4305	91	12	doi	doi	NOUN
easat-4305	91	13	:	:	PUNCT
easat-4305	91	14	10.55214/25768484.v9i1.4305	10.55214/25768484.v9i1.4305	NUM
easat-4305	91	15	©	©	PROPN
easat-4305	91	16	2025	2025	NUM
easat-4305	91	17	by	by	ADP
easat-4305	91	18	the	the	DET
easat-4305	91	19	authors	author	NOUN
easat-4305	91	20	;	;	PUNCT
easat-4305	91	21	licensee	licensee	PROPN
easat-4305	91	22	learning	learn	VERB
easat-4305	91	23	gate	gate	NOUN
easat-4305	91	24	table	table	NOUN
easat-4305	91	25	1	1	NUM
easat-4305	91	26	.	.	PUNCT
easat-4305	91	27	general	general	ADJ
easat-4305	91	28	characteristics	characteristic	NOUN
easat-4305	91	29	of	of	ADP
easat-4305	91	30	the	the	DET
easat-4305	91	31	hcc	hcc	PROPN
easat-4305	91	32	group	group	NOUN
easat-4305	91	33	.	.	PUNCT
easat-4305	92	1	characteristics	characteristic	NOUN
easat-4305	92	2	hepatocellular	hepatocellular	ADJ
easat-4305	92	3	carcinoma	carcinoma	NOUN
easat-4305	92	4	patients	patient	NOUN
easat-4305	92	5	(	(	PUNCT
easat-4305	92	6	n=47	n=47	PROPN
easat-4305	92	7	)	)	PUNCT
easat-4305	92	8	gender	gender	NOUN
easat-4305	92	9	male	male	NOUN
easat-4305	92	10	/	/	SYM
easat-4305	92	11	female	female	NOUN
easat-4305	92	12	41/6	41/6	DET
easat-4305	92	13	age	age	NOUN
easat-4305	92	14	<	<	X
easat-4305	92	15	45	45	NUM
easat-4305	92	16	5	5	NUM
easat-4305	92	17	14.7	14.7	NUM
easat-4305	92	18	%	%	NOUN
easat-4305	92	19	45	45	NUM
easat-4305	92	20	-	-	SYM
easat-4305	92	21	59	59	NUM
easat-4305	92	22	8	8	NUM
easat-4305	92	23	23.5	23.5	NUM
easat-4305	92	24	%	%	NOUN
easat-4305	92	25	≥	≥	NOUN
easat-4305	92	26	60	60	NUM
easat-4305	92	27	34	34	NUM
easat-4305	92	28	61.8	61.8	NUM
easat-4305	92	29	%	%	NOUN
easat-4305	92	30	total	total	NOUN
easat-4305	92	31	n	n	NOUN
easat-4305	92	32	=	=	SYM
easat-4305	92	33	47	47	NUM
easat-4305	92	34	100	100	NUM
easat-4305	92	35	%	%	NOUN
easat-4305	92	36	hbv	hbv	NOUN
easat-4305	92	37	38	38	NUM
easat-4305	92	38	81	81	NUM
easat-4305	92	39	%	%	NOUN
easat-4305	92	40	hcv	hcv	NOUN
easat-4305	92	41	5	5	NUM
easat-4305	92	42	10.6	10.6	NUM
easat-4305	92	43	%	%	NOUN
easat-4305	92	44	hbv	hbv	NOUN
easat-4305	92	45	and	and	CCONJ
easat-4305	92	46	hcv	hcv	VERB
easat-4305	92	47	co	co	NOUN
easat-4305	92	48	-	-	NOUN
easat-4305	92	49	infection	infection	ADJ
easat-4305	92	50	1	1	NUM
easat-4305	92	51	2.1	2.1	NUM
easat-4305	92	52	%	%	NOUN
easat-4305	92	53	alcohol	alcohol	NOUN
easat-4305	92	54	-	-	PUNCT
easat-4305	92	55	induced	induce	VERB
easat-4305	92	56	cirrhosis	cirrhosis	NOUN
easat-4305	92	57	3	3	NUM
easat-4305	92	58	6.3	6.3	NUM
easat-4305	92	59	%	%	NOUN
easat-4305	92	60	total	total	NOUN
easat-4305	92	61	n	n	NOUN
easat-4305	92	62	=	=	SYM
easat-4305	92	63	47	47	NUM
easat-4305	92	64	100	100	NUM
easat-4305	92	65	%	%	NOUN
easat-4305	92	66	stage	stage	NOUN
easat-4305	92	67	early	early	ADV
easat-4305	92	68	early	early	ADJ
easat-4305	92	69	8	8	NUM
easat-4305	92	70	17	17	NUM
easat-4305	92	71	%	%	NOUN
easat-4305	92	72	advanced	advanced	ADJ
easat-4305	92	73	intermediate	intermediate	ADJ
easat-4305	92	74	23	23	NUM
easat-4305	92	75	48.9	48.9	NUM
easat-4305	92	76	%	%	NOUN
easat-4305	92	77	advanced	advanced	ADJ
easat-4305	92	78	11	11	NUM
easat-4305	92	79	23.4	23.4	NUM
easat-4305	92	80	%	%	NOUN
easat-4305	92	81	terminal	terminal	NOUN
easat-4305	92	82	5	5	NUM
easat-4305	92	83	10.6	10.6	NUM
easat-4305	92	84	%	%	NOUN
easat-4305	92	85	total	total	NOUN
easat-4305	92	86	n	n	NOUN
easat-4305	92	87	=	=	SYM
easat-4305	92	88	47	47	NUM
easat-4305	92	89	100	100	NUM
easat-4305	92	90	%	%	NOUN
easat-4305	92	91	3.2	3.2	NUM
easat-4305	92	92	.	.	PUNCT
easat-4305	93	1	biochemical	biochemical	ADJ
easat-4305	93	2	markers	marker	NOUN
easat-4305	93	3	for	for	ADP
easat-4305	93	4	evaluating	evaluate	VERB
easat-4305	93	5	liver	liver	NOUN
easat-4305	93	6	function	function	NOUN
easat-4305	93	7	in	in	ADP
easat-4305	93	8	the	the	DET
easat-4305	93	9	study	study	NOUN
easat-4305	93	10	groups	group	NOUN
easat-4305	93	11	the	the	DET
easat-4305	93	12	biochemical	biochemical	ADJ
easat-4305	93	13	markers	marker	NOUN
easat-4305	93	14	used	use	VERB
easat-4305	93	15	to	to	PART
easat-4305	93	16	assess	assess	VERB
easat-4305	93	17	liver	liver	NOUN
easat-4305	93	18	function	function	NOUN
easat-4305	93	19	in	in	ADP
easat-4305	93	20	the	the	DET
easat-4305	93	21	study	study	NOUN
easat-4305	93	22	groups	group	NOUN
easat-4305	93	23	revealed	reveal	VERB
easat-4305	93	24	distinct	distinct	ADJ
easat-4305	93	25	patterns	pattern	NOUN
easat-4305	93	26	(	(	PUNCT
easat-4305	93	27	table	table	NOUN
easat-4305	93	28	2	2	NUM
easat-4305	93	29	)	)	PUNCT
easat-4305	93	30	.	.	PUNCT
easat-4305	94	1	in	in	ADP
easat-4305	94	2	terms	term	NOUN
easat-4305	94	3	of	of	ADP
easat-4305	94	4	ast	ast	NOUN
easat-4305	94	5	and	and	CCONJ
easat-4305	94	6	alt	alt	ADJ
easat-4305	94	7	,	,	PUNCT
easat-4305	94	8	the	the	DET
easat-4305	94	9	liver	liver	NOUN
easat-4305	94	10	disease	disease	NOUN
easat-4305	94	11	group	group	NOUN
easat-4305	94	12	without	without	ADP
easat-4305	94	13	malignancy	malignancy	NOUN
easat-4305	94	14	presented	present	VERB
easat-4305	94	15	the	the	DET
easat-4305	94	16	highest	high	ADJ
easat-4305	94	17	values	value	NOUN
easat-4305	94	18	for	for	ADP
easat-4305	94	19	both	both	DET
easat-4305	94	20	markers	marker	NOUN
easat-4305	94	21	,	,	PUNCT
easat-4305	94	22	indicating	indicate	VERB
easat-4305	94	23	the	the	DET
easat-4305	94	24	most	most	ADV
easat-4305	94	25	severe	severe	ADJ
easat-4305	94	26	liver	liver	NOUN
easat-4305	94	27	cell	cell	NOUN
easat-4305	94	28	damage	damage	NOUN
easat-4305	94	29	.	.	PUNCT
easat-4305	95	1	the	the	DET
easat-4305	95	2	large	large	ADJ
easat-4305	95	3	standard	standard	ADJ
easat-4305	95	4	deviation	deviation	NOUN
easat-4305	95	5	in	in	ADP
easat-4305	95	6	this	this	DET
easat-4305	95	7	group	group	NOUN
easat-4305	95	8	suggests	suggest	VERB
easat-4305	95	9	significant	significant	ADJ
easat-4305	95	10	variability	variability	NOUN
easat-4305	95	11	in	in	ADP
easat-4305	95	12	the	the	DET
easat-4305	95	13	degree	degree	NOUN
easat-4305	95	14	of	of	ADP
easat-4305	95	15	liver	liver	NOUN
easat-4305	95	16	injury	injury	NOUN
easat-4305	95	17	.	.	PUNCT
easat-4305	96	1	moreover	moreover	ADV
easat-4305	96	2	,	,	PUNCT
easat-4305	96	3	the	the	DET
easat-4305	96	4	ast	ast	NOUN
easat-4305	96	5	and	and	CCONJ
easat-4305	96	6	alt	alt	VERB
easat-4305	96	7	values	value	NOUN
easat-4305	96	8	in	in	ADP
easat-4305	96	9	the	the	DET
easat-4305	96	10	hcc	hcc	PROPN
easat-4305	96	11	group	group	NOUN
easat-4305	96	12	were	be	AUX
easat-4305	96	13	greater	great	ADJ
easat-4305	96	14	than	than	ADP
easat-4305	96	15	those	those	PRON
easat-4305	96	16	in	in	ADP
easat-4305	96	17	the	the	DET
easat-4305	96	18	healthy	healthy	ADJ
easat-4305	96	19	group	group	NOUN
easat-4305	96	20	,	,	PUNCT
easat-4305	96	21	although	although	SCONJ
easat-4305	96	22	they	they	PRON
easat-4305	96	23	were	be	AUX
easat-4305	96	24	lower	low	ADJ
easat-4305	96	25	than	than	ADP
easat-4305	96	26	those	those	PRON
easat-4305	96	27	observed	observe	VERB
easat-4305	96	28	in	in	ADP
easat-4305	96	29	the	the	DET
easat-4305	96	30	liver	liver	NOUN
easat-4305	96	31	disease	disease	NOUN
easat-4305	96	32	group	group	NOUN
easat-4305	96	33	without	without	ADP
easat-4305	96	34	malignancy	malignancy	NOUN
easat-4305	96	35	.	.	PUNCT
easat-4305	97	1	the	the	DET
easat-4305	97	2	nonliver	nonliver	ADJ
easat-4305	97	3	disease	disease	NOUN
easat-4305	97	4	group	group	NOUN
easat-4305	97	5	,	,	PUNCT
easat-4305	97	6	on	on	ADP
easat-4305	97	7	the	the	DET
easat-4305	97	8	other	other	ADJ
easat-4305	97	9	hand	hand	NOUN
easat-4305	97	10	,	,	PUNCT
easat-4305	97	11	presented	present	VERB
easat-4305	97	12	the	the	DET
easat-4305	97	13	lowest	low	ADJ
easat-4305	97	14	and	and	CCONJ
easat-4305	97	15	most	most	ADV
easat-4305	97	16	stable	stable	ADJ
easat-4305	97	17	levels	level	NOUN
easat-4305	97	18	of	of	ADP
easat-4305	97	19	ast	ast	NOUN
easat-4305	97	20	and	and	CCONJ
easat-4305	97	21	alt	alt	ADJ
easat-4305	97	22	,	,	PUNCT
easat-4305	97	23	which	which	PRON
easat-4305	97	24	is	be	AUX
easat-4305	97	25	consistent	consistent	ADJ
easat-4305	97	26	with	with	ADP
easat-4305	97	27	the	the	DET
easat-4305	97	28	absence	absence	NOUN
easat-4305	97	29	of	of	ADP
easat-4305	97	30	liver	liver	NOUN
easat-4305	97	31	damage	damage	NOUN
easat-4305	97	32	.	.	PUNCT
easat-4305	98	1	table	table	NOUN
easat-4305	98	2	2	2	NUM
easat-4305	98	3	.	.	PUNCT
easat-4305	98	4	biochemical	biochemical	ADJ
easat-4305	98	5	markers	marker	NOUN
easat-4305	98	6	evaluating	evaluate	VERB
easat-4305	98	7	liver	liver	NOUN
easat-4305	98	8	function	function	NOUN
easat-4305	98	9	.	.	PUNCT
easat-4305	99	1	group	group	NOUN
easat-4305	99	2	of	of	ADP
easat-4305	99	3	patients	patient	NOUN
easat-4305	99	4	with	with	ADP
easat-4305	99	5	hepatocellular	hepatocellular	ADJ
easat-4305	99	6	carcinoma	carcinoma	NOUN
easat-4305	99	7	(	(	PUNCT
easat-4305	99	8	n=47	n=47	PROPN
easat-4305	99	9	)	)	PUNCT
easat-4305	99	10	group	group	NOUN
easat-4305	99	11	with	with	ADP
easat-4305	99	12	liver	liver	NOUN
easat-4305	99	13	disease	disease	NOUN
easat-4305	99	14	but	but	CCONJ
easat-4305	99	15	not	not	PART
easat-4305	99	16	malignant	malignant	ADJ
easat-4305	99	17	(	(	PUNCT
easat-4305	99	18	n=10	n=10	NOUN
easat-4305	99	19	)	)	PUNCT
easat-4305	99	20	group	group	NOUN
easat-4305	99	21	without	without	ADP
easat-4305	99	22	liver	liver	NOUN
easat-4305	99	23	disease	disease	NOUN
easat-4305	99	24	(	(	PUNCT
easat-4305	99	25	n=15	n=15	SYM
easat-4305	99	26	)	)	PUNCT
easat-4305	99	27	p	p	ADJ
easat-4305	99	28	-	-	PUNCT
easat-4305	99	29	value	value	NOUN
easat-4305	99	30	ast	ast	NOUN
easat-4305	99	31	(	(	PUNCT
easat-4305	99	32	u	u	NOUN
easat-4305	99	33	/	/	SYM
easat-4305	99	34	l	l	NOUN
easat-4305	99	35	)	)	PUNCT
easat-4305	99	36	73.01	73.01	NUM
easat-4305	99	37	±	±	NUM
easat-4305	99	38	47.09	47.09	NUM
easat-4305	99	39	190.93	190.93	NUM
easat-4305	99	40	±	±	NUM
easat-4305	99	41	319.34	319.34	NUM
easat-4305	99	42	40.92	40.92	NUM
easat-4305	99	43	±	±	NUM
easat-4305	99	44	27.31	27.31	NUM
easat-4305	99	45	<	<	X
easat-4305	99	46	0.001	0.001	NUM
easat-4305	99	47	alt	alt	NOUN
easat-4305	99	48	(	(	PUNCT
easat-4305	99	49	u	u	NOUN
easat-4305	99	50	/	/	SYM
easat-4305	99	51	l	l	NOUN
easat-4305	99	52	)	)	PUNCT
easat-4305	99	53	59.06	59.06	NUM
easat-4305	99	54	±	±	NUM
easat-4305	99	55	36.97	36.97	NUM
easat-4305	99	56	312.2	312.2	NUM
easat-4305	99	57	±	±	NOUN
easat-4305	99	58	760.11	760.11	NUM
easat-4305	99	59	69.86	69.86	NUM
easat-4305	99	60	±	±	NOUN
easat-4305	99	61	91.47	91.47	NUM
easat-4305	99	62	<	<	X
easat-4305	99	63	0.001	0.001	NUM
easat-4305	99	64	total	total	ADJ
easat-4305	99	65	bilirubin	bilirubin	NOUN
easat-4305	99	66	(	(	PUNCT
easat-4305	99	67	µmol	µmol	PROPN
easat-4305	99	68	/	/	SYM
easat-4305	99	69	l	l	NOUN
easat-4305	99	70	)	)	PUNCT
easat-4305	99	71	15.94	15.94	NUM
easat-4305	99	72	±	±	NUM
easat-4305	99	73	7.47	7.47	NUM
easat-4305	99	74	92.15	92.15	NUM
easat-4305	99	75	±	±	NUM
easat-4305	99	76	96.31	96.31	NUM
easat-4305	99	77	22.32	22.32	NUM
easat-4305	99	78	±	±	NUM
easat-4305	99	79	20.03	20.03	NUM
easat-4305	99	80	<	<	X
easat-4305	99	81	0.001	0.001	NUM
easat-4305	99	82	albumin	albumin	NOUN
easat-4305	99	83	(	(	PUNCT
easat-4305	99	84	g	g	NOUN
easat-4305	99	85	/	/	SYM
easat-4305	99	86	l	l	NOUN
easat-4305	99	87	)	)	PUNCT
easat-4305	99	88	39.40	39.40	NUM
easat-4305	99	89	±	±	NUM
easat-4305	99	90	4.66	4.66	NUM
easat-4305	99	91	29.88	29.88	NUM
easat-4305	99	92	±	±	NUM
easat-4305	99	93	4.77	4.77	NUM
easat-4305	99	94	39.6	39.6	NUM
easat-4305	99	95	±	±	NUM
easat-4305	99	96	2.5	2.5	NUM
easat-4305	99	97	<	<	X
easat-4305	99	98	0.001	0.001	NUM
easat-4305	99	99	pt	pt	PROPN
easat-4305	99	100	-	-	PUNCT
easat-4305	99	101	inr	inr	NOUN
easat-4305	99	102	1.08	1.08	NUM
easat-4305	99	103	±	±	NUM
easat-4305	99	104	0.14	0.14	NUM
easat-4305	99	105	1.25	1.25	NUM
easat-4305	99	106	±	±	NOUN
easat-4305	99	107	0.24	0.24	NUM
easat-4305	99	108	0.997	0.997	NUM
easat-4305	99	109	±	±	NUM
easat-4305	99	110	0.092	0.092	NUM
easat-4305	99	111	<	<	X
easat-4305	99	112	0.001	0.001	NUM
easat-4305	99	113	for	for	ADP
easat-4305	99	114	total	total	ADJ
easat-4305	99	115	bilirubin	bilirubin	NOUN
easat-4305	99	116	,	,	PUNCT
easat-4305	99	117	the	the	DET
easat-4305	99	118	liver	liver	NOUN
easat-4305	99	119	disease	disease	NOUN
easat-4305	99	120	group	group	NOUN
easat-4305	99	121	without	without	ADP
easat-4305	99	122	malignancy	malignancy	NOUN
easat-4305	99	123	also	also	ADV
easat-4305	99	124	had	have	VERB
easat-4305	99	125	the	the	DET
easat-4305	99	126	highest	high	ADJ
easat-4305	99	127	average	average	ADJ
easat-4305	99	128	value	value	NOUN
easat-4305	99	129	,	,	PUNCT
easat-4305	99	130	reflecting	reflect	VERB
easat-4305	99	131	clear	clear	ADJ
easat-4305	99	132	metabolic	metabolic	NOUN
easat-4305	99	133	disturbances	disturbance	NOUN
easat-4305	99	134	and	and	CCONJ
easat-4305	99	135	bile	bile	NOUN
easat-4305	99	136	obstruction	obstruction	NOUN
easat-4305	99	137	.	.	PUNCT
easat-4305	100	1	the	the	DET
easat-4305	100	2	hcc	hcc	PROPN
easat-4305	100	3	group	group	NOUN
easat-4305	100	4	presented	present	VERB
easat-4305	100	5	increased	increase	VERB
easat-4305	100	6	bilirubin	bilirubin	NOUN
easat-4305	100	7	levels	level	NOUN
easat-4305	100	8	,	,	PUNCT
easat-4305	100	9	but	but	CCONJ
easat-4305	100	10	these	these	DET
easat-4305	100	11	values	value	NOUN
easat-4305	100	12	were	be	AUX
easat-4305	100	13	still	still	ADV
easat-4305	100	14	lower	low	ADJ
easat-4305	100	15	than	than	ADP
easat-4305	100	16	those	those	PRON
easat-4305	100	17	in	in	ADP
easat-4305	100	18	the	the	DET
easat-4305	100	19	liver	liver	NOUN
easat-4305	100	20	disease	disease	NOUN
easat-4305	100	21	group	group	NOUN
easat-4305	100	22	without	without	ADP
easat-4305	100	23	malignancy	malignancy	NOUN
easat-4305	100	24	.	.	PUNCT
easat-4305	101	1	in	in	ADP
easat-4305	101	2	contrast	contrast	NOUN
easat-4305	101	3	,	,	PUNCT
easat-4305	101	4	the	the	DET
easat-4305	101	5	nonliver	nonliver	ADJ
easat-4305	101	6	disease	disease	NOUN
easat-4305	101	7	group	group	NOUN
easat-4305	101	8	maintained	maintain	VERB
easat-4305	101	9	low	low	ADJ
easat-4305	101	10	bilirubin	bilirubin	NOUN
easat-4305	101	11	levels	level	NOUN
easat-4305	101	12	within	within	ADP
easat-4305	101	13	the	the	DET
easat-4305	101	14	normal	normal	ADJ
easat-4305	101	15	range	range	NOUN
easat-4305	101	16	,	,	PUNCT
easat-4305	101	17	indicating	indicate	VERB
easat-4305	101	18	healthy	healthy	ADJ
easat-4305	101	19	liver	liver	NOUN
easat-4305	101	20	function	function	NOUN
easat-4305	101	21	.	.	PUNCT
easat-4305	102	1	the	the	DET
easat-4305	102	2	lowest	low	ADJ
easat-4305	102	3	level	level	NOUN
easat-4305	102	4	of	of	ADP
easat-4305	102	5	albumin	albumin	NOUN
easat-4305	102	6	was	be	AUX
easat-4305	102	7	detected	detect	VERB
easat-4305	102	8	in	in	ADP
easat-4305	102	9	the	the	DET
easat-4305	102	10	liver	liver	NOUN
easat-4305	102	11	disease	disease	NOUN
easat-4305	102	12	group	group	NOUN
easat-4305	102	13	without	without	ADP
easat-4305	102	14	malignancy	malignancy	NOUN
easat-4305	102	15	,	,	PUNCT
easat-4305	102	16	which	which	PRON
easat-4305	102	17	is	be	AUX
easat-4305	102	18	indicative	indicative	ADJ
easat-4305	102	19	of	of	ADP
easat-4305	102	20	impaired	impaired	ADJ
easat-4305	102	21	liver	liver	NOUN
easat-4305	102	22	protein	protein	NOUN
easat-4305	102	23	synthesis	synthesis	NOUN
easat-4305	102	24	.	.	PUNCT
easat-4305	103	1	the	the	DET
easat-4305	103	2	hcc	hcc	PROPN
easat-4305	103	3	group	group	NOUN
easat-4305	103	4	presented	present	VERB
easat-4305	103	5	albumin	albumin	ADJ
easat-4305	103	6	levels	level	NOUN
easat-4305	103	7	comparable	comparable	ADJ
easat-4305	103	8	to	to	ADP
easat-4305	103	9	those	those	PRON
easat-4305	103	10	of	of	ADP
easat-4305	103	11	the	the	DET
easat-4305	103	12	nonliver	nonliver	ADJ
easat-4305	103	13	disease	disease	NOUN
easat-4305	103	14	group	group	NOUN
easat-4305	103	15	,	,	PUNCT
easat-4305	103	16	suggesting	suggest	VERB
easat-4305	103	17	that	that	SCONJ
easat-4305	103	18	liver	liver	NOUN
easat-4305	103	19	synthetic	synthetic	ADJ
easat-4305	103	20	function	function	NOUN
easat-4305	103	21	was	be	AUX
easat-4305	103	22	not	not	PART
easat-4305	103	23	severely	severely	ADV
easat-4305	103	24	compromised	compromise	VERB
easat-4305	103	25	in	in	ADP
easat-4305	103	26	these	these	DET
easat-4305	103	27	patients	patient	NOUN
easat-4305	103	28	.	.	PUNCT
easat-4305	104	1	finally	finally	ADV
easat-4305	104	2	,	,	PUNCT
easat-4305	104	3	for	for	ADP
easat-4305	104	4	pt	pt	NOUN
easat-4305	104	5	-	-	PUNCT
easat-4305	104	6	inr	inr	NOUN
easat-4305	104	7	,	,	PUNCT
easat-4305	104	8	the	the	DET
easat-4305	104	9	liver	liver	NOUN
easat-4305	104	10	disease	disease	NOUN
easat-4305	104	11	group	group	NOUN
easat-4305	104	12	without	without	ADP
easat-4305	104	13	malignancy	malignancy	NOUN
easat-4305	104	14	presented	present	VERB
easat-4305	104	15	the	the	DET
easat-4305	104	16	highest	high	ADJ
easat-4305	104	17	values	value	NOUN
easat-4305	104	18	,	,	PUNCT
easat-4305	104	19	reflecting	reflect	VERB
easat-4305	104	20	severe	severe	ADJ
easat-4305	104	21	coagulopathy	coagulopathy	ADJ
easat-4305	104	22	.	.	PUNCT
easat-4305	105	1	compared	compare	VERB
easat-4305	105	2	with	with	ADP
easat-4305	105	3	the	the	DET
easat-4305	105	4	healthy	healthy	ADJ
easat-4305	105	5	group	group	NOUN
easat-4305	105	6	,	,	PUNCT
easat-4305	105	7	the	the	DET
easat-4305	105	8	hcc	hcc	PROPN
easat-4305	105	9	group	group	NOUN
easat-4305	105	10	presented	present	VERB
easat-4305	105	11	a	a	DET
easat-4305	105	12	slight	slight	ADJ
easat-4305	105	13	increase	increase	NOUN
easat-4305	105	14	in	in	ADP
easat-4305	105	15	the	the	DET
easat-4305	105	16	pt	pt	PROPN
easat-4305	105	17	-	-	PUNCT
easat-4305	105	18	inr	inr	NOUN
easat-4305	105	19	,	,	PUNCT
easat-4305	105	20	but	but	CCONJ
easat-4305	105	21	these	these	DET
easat-4305	105	22	levels	level	NOUN
easat-4305	105	23	were	be	AUX
easat-4305	105	24	still	still	ADV
easat-4305	105	25	within	within	ADP
easat-4305	105	26	a	a	DET
easat-4305	105	27	manageable	manageable	ADJ
easat-4305	105	28	range	range	NOUN
easat-4305	105	29	.	.	PUNCT
easat-4305	106	1	the	the	DET
easat-4305	106	2	nonliver	nonliver	ADJ
easat-4305	106	3	disease	disease	NOUN
easat-4305	106	4	group	group	NOUN
easat-4305	106	5	displayed	display	VERB
easat-4305	106	6	stable	stable	ADJ
easat-4305	106	7	pt	pt	PROPN
easat-4305	106	8	-	-	PUNCT
easat-4305	106	9	inr	inr	NOUN
easat-4305	106	10	values	value	NOUN
easat-4305	106	11	,	,	PUNCT
easat-4305	106	12	all	all	PRON
easat-4305	106	13	within	within	ADP
easat-4305	106	14	the	the	DET
easat-4305	106	15	normal	normal	ADJ
easat-4305	106	16	limits	limit	NOUN
easat-4305	106	17	,	,	PUNCT
easat-4305	106	18	indicating	indicate	VERB
easat-4305	106	19	no	no	DET
easat-4305	106	20	coagulopathy	coagulopathy	ADJ
easat-4305	106	21	.	.	PUNCT
easat-4305	107	1	1014	1014	NUM
easat-4305	107	2	edelweiss	edelweiss	PROPN
easat-4305	107	3	applied	apply	VERB
easat-4305	107	4	science	science	NOUN
easat-4305	107	5	and	and	CCONJ
easat-4305	107	6	technology	technology	NOUN
easat-4305	107	7	issn	issn	PROPN
easat-4305	107	8	:	:	PUNCT
easat-4305	107	9	2576	2576	NUM
easat-4305	107	10	-	-	SYM
easat-4305	107	11	8484	8484	NUM
easat-4305	107	12	vol	vol	NOUN
easat-4305	107	13	.	.	PROPN
easat-4305	108	1	9	9	NUM
easat-4305	108	2	,	,	PUNCT
easat-4305	108	3	no	no	INTJ
easat-4305	108	4	.	.	NOUN
easat-4305	108	5	1	1	NUM
easat-4305	108	6	:	:	PUNCT
easat-4305	108	7	1010	1010	NUM
easat-4305	108	8	-	-	SYM
easat-4305	108	9	1018	1018	NUM
easat-4305	108	10	,	,	PUNCT
easat-4305	108	11	2025	2025	NUM
easat-4305	108	12	doi	doi	NOUN
easat-4305	108	13	:	:	PUNCT
easat-4305	108	14	10.55214/25768484.v9i1.4305	10.55214/25768484.v9i1.4305	NUM
easat-4305	108	15	©	©	PROPN
easat-4305	108	16	2025	2025	NUM
easat-4305	108	17	by	by	ADP
easat-4305	108	18	the	the	DET
easat-4305	108	19	authors	author	NOUN
easat-4305	108	20	;	;	PUNCT
easat-4305	108	21	licensee	licensee	PROPN
easat-4305	108	22	learning	learning	NOUN
easat-4305	108	23	gate	gate	NOUN
easat-4305	108	24	these	these	DET
easat-4305	108	25	findings	finding	NOUN
easat-4305	108	26	highlight	highlight	VERB
easat-4305	108	27	the	the	DET
easat-4305	108	28	differences	difference	NOUN
easat-4305	108	29	in	in	ADP
easat-4305	108	30	liver	liver	NOUN
easat-4305	108	31	function	function	NOUN
easat-4305	108	32	across	across	ADP
easat-4305	108	33	the	the	DET
easat-4305	108	34	study	study	NOUN
easat-4305	108	35	groups	group	NOUN
easat-4305	108	36	,	,	PUNCT
easat-4305	108	37	with	with	ADP
easat-4305	108	38	the	the	DET
easat-4305	108	39	liver	liver	NOUN
easat-4305	108	40	disease	disease	NOUN
easat-4305	108	41	group	group	NOUN
easat-4305	108	42	without	without	ADP
easat-4305	108	43	malignancy	malignancy	NOUN
easat-4305	108	44	exhibiting	exhibit	VERB
easat-4305	108	45	the	the	DET
easat-4305	108	46	most	most	ADV
easat-4305	108	47	severe	severe	ADJ
easat-4305	108	48	disturbances	disturbance	NOUN
easat-4305	108	49	,	,	PUNCT
easat-4305	108	50	whereas	whereas	SCONJ
easat-4305	108	51	the	the	DET
easat-4305	108	52	hcc	hcc	PROPN
easat-4305	108	53	and	and	CCONJ
easat-4305	108	54	nonliver	nonliver	ADV
easat-4305	108	55	disease	disease	NOUN
easat-4305	108	56	groups	group	NOUN
easat-4305	108	57	presented	present	VERB
easat-4305	108	58	more	more	ADV
easat-4305	108	59	moderate	moderate	ADJ
easat-4305	108	60	or	or	CCONJ
easat-4305	108	61	stable	stable	ADJ
easat-4305	108	62	liver	liver	NOUN
easat-4305	108	63	function	function	NOUN
easat-4305	108	64	.	.	PUNCT
easat-4305	109	1	3.3	3.3	NUM
easat-4305	109	2	.	.	PUNCT
easat-4305	109	3	optimization	optimization	NOUN
easat-4305	109	4	of	of	ADP
easat-4305	109	5	conditions	condition	NOUN
easat-4305	109	6	for	for	ADP
easat-4305	109	7	indirect	indirect	ADJ
easat-4305	109	8	elisa	elisa	NOUN
easat-4305	109	9	immunoassay	immunoassay	NOUN
easat-4305	109	10	to	to	PART
easat-4305	109	11	optimize	optimize	VERB
easat-4305	109	12	the	the	DET
easat-4305	109	13	concentrations	concentration	NOUN
easat-4305	109	14	of	of	ADP
easat-4305	109	15	the	the	DET
easat-4305	109	16	recombinant	recombinant	ADJ
easat-4305	109	17	antigen	antigen	NOUN
easat-4305	109	18	and	and	CCONJ
easat-4305	109	19	monoclonal	monoclonal	NOUN
easat-4305	109	20	antibody	antibody	NOUN
easat-4305	109	21	,	,	PUNCT
easat-4305	109	22	it	it	PRON
easat-4305	109	23	is	be	AUX
easat-4305	109	24	essential	essential	ADJ
easat-4305	109	25	to	to	PART
easat-4305	109	26	provide	provide	VERB
easat-4305	109	27	an	an	DET
easat-4305	109	28	adequate	adequate	ADJ
easat-4305	109	29	amount	amount	NOUN
easat-4305	109	30	of	of	ADP
easat-4305	109	31	monoclonal	monoclonal	NOUN
easat-4305	109	32	antibody	antibody	NOUN
easat-4305	109	33	to	to	PART
easat-4305	109	34	detect	detect	VERB
easat-4305	109	35	the	the	DET
easat-4305	109	36	antigen	antigen	NOUN
easat-4305	109	37	,	,	PUNCT
easat-4305	109	38	ensuring	ensure	VERB
easat-4305	109	39	that	that	SCONJ
easat-4305	109	40	neither	neither	DET
easat-4305	109	41	component	component	NOUN
easat-4305	109	42	is	be	AUX
easat-4305	109	43	in	in	ADP
easat-4305	109	44	excess	excess	ADJ
easat-4305	109	45	,	,	PUNCT
easat-4305	109	46	as	as	SCONJ
easat-4305	109	47	this	this	PRON
easat-4305	109	48	could	could	AUX
easat-4305	109	49	result	result	VERB
easat-4305	109	50	in	in	ADP
easat-4305	109	51	a	a	DET
easat-4305	109	52	nonspecific	nonspecific	ADJ
easat-4305	109	53	background	background	NOUN
easat-4305	109	54	threshold	threshold	NOUN
easat-4305	109	55	.	.	PUNCT
easat-4305	110	1	the	the	DET
easat-4305	110	2	optimal	optimal	ADJ
easat-4305	110	3	concentration	concentration	NOUN
easat-4305	110	4	of	of	ADP
easat-4305	110	5	the	the	DET
easat-4305	110	6	monoclonal	monoclonal	NOUN
easat-4305	110	7	antibody	antibody	NOUN
easat-4305	110	8	mab	mab	NOUN
easat-4305	110	9	-	-	PUNCT
easat-4305	110	10	txn	txn	NOUN
easat-4305	110	11	was	be	AUX
easat-4305	110	12	achieved	achieve	VERB
easat-4305	110	13	by	by	ADP
easat-4305	110	14	diluting	dilute	VERB
easat-4305	110	15	it	it	PRON
easat-4305	110	16	1:128	1:128	NUM
easat-4305	110	17	,	,	PUNCT
easat-4305	110	18	resulting	result	VERB
easat-4305	110	19	in	in	ADP
easat-4305	110	20	a	a	DET
easat-4305	110	21	final	final	ADJ
easat-4305	110	22	concentration	concentration	NOUN
easat-4305	110	23	of	of	ADP
easat-4305	110	24	9.10	9.10	NUM
easat-4305	110	25	-	-	SYM
easat-4305	110	26	3	3	NUM
easat-4305	110	27	mg	mg	PROPN
easat-4305	110	28	/	/	SYM
easat-4305	110	29	ml	ml	PROPN
easat-4305	110	30	(	(	PUNCT
easat-4305	110	31	table	table	NOUN
easat-4305	110	32	3	3	NUM
easat-4305	110	33	)	)	PUNCT
easat-4305	110	34	.	.	PUNCT
easat-4305	111	1	for	for	ADP
easat-4305	111	2	the	the	DET
easat-4305	111	3	recombinant	recombinant	ADJ
easat-4305	111	4	antigen	antigen	ADJ
easat-4305	111	5	rag	rag	NOUN
easat-4305	111	6	-	-	PUNCT
easat-4305	111	7	txn	txn	NOUN
easat-4305	111	8	,	,	PUNCT
easat-4305	111	9	which	which	PRON
easat-4305	111	10	was	be	AUX
easat-4305	111	11	used	use	VERB
easat-4305	111	12	as	as	ADP
easat-4305	111	13	the	the	DET
easat-4305	111	14	positive	positive	ADJ
easat-4305	111	15	control	control	NOUN
easat-4305	111	16	,	,	PUNCT
easat-4305	111	17	the	the	DET
easat-4305	111	18	optimal	optimal	ADJ
easat-4305	111	19	dilution	dilution	NOUN
easat-4305	111	20	was	be	AUX
easat-4305	111	21	1:8	1:8	NUM
easat-4305	111	22	,	,	PUNCT
easat-4305	111	23	resulting	result	VERB
easat-4305	111	24	in	in	ADP
easat-4305	111	25	a	a	DET
easat-4305	111	26	final	final	ADJ
easat-4305	111	27	concentration	concentration	NOUN
easat-4305	111	28	of	of	ADP
easat-4305	111	29	10	10	NUM
easat-4305	111	30	-	-	SYM
easat-4305	111	31	1	1	NUM
easat-4305	111	32	mg	mg	NUM
easat-4305	111	33	/	/	SYM
easat-4305	111	34	ml	ml	PROPN
easat-4305	111	35	(	(	PUNCT
easat-4305	111	36	table	table	NOUN
easat-4305	111	37	3	3	NUM
easat-4305	111	38	)	)	PUNCT
easat-4305	111	39	.	.	PUNCT
easat-4305	112	1	the	the	DET
easat-4305	112	2	most	most	ADV
easat-4305	112	3	suitable	suitable	ADJ
easat-4305	112	4	dilution	dilution	NOUN
easat-4305	112	5	for	for	ADP
easat-4305	112	6	the	the	DET
easat-4305	112	7	conjugated	conjugated	ADJ
easat-4305	112	8	antibody	antibody	NOUN
easat-4305	112	9	was	be	AUX
easat-4305	112	10	1:15,000	1:15,000	NUM
easat-4305	112	11	,	,	PUNCT
easat-4305	112	12	as	as	SCONJ
easat-4305	112	13	demonstrated	demonstrate	VERB
easat-4305	112	14	in	in	ADP
easat-4305	112	15	figure	figure	NOUN
easat-4305	112	16	1	1	NUM
easat-4305	112	17	.	.	PUNCT
easat-4305	112	18	figure	figure	NOUN
easat-4305	112	19	1	1	NUM
easat-4305	112	20	.	.	PUNCT
easat-4305	112	21	optimization	optimization	NOUN
easat-4305	112	22	of	of	ADP
easat-4305	112	23	the	the	DET
easat-4305	112	24	dilution	dilution	NOUN
easat-4305	112	25	concentration	concentration	NOUN
easat-4305	112	26	of	of	ADP
easat-4305	112	27	the	the	DET
easat-4305	112	28	conjugated	conjugated	ADJ
easat-4305	112	29	antibody	antibody	NOUN
easat-4305	112	30	.	.	PUNCT
easat-4305	113	1	table	table	NOUN
easat-4305	113	2	3	3	NUM
easat-4305	113	3	.	.	PUNCT
easat-4305	113	4	elisa	elisa	NOUN
easat-4305	113	5	results	result	NOUN
easat-4305	113	6	for	for	ADP
easat-4305	113	7	assessing	assess	VERB
easat-4305	113	8	the	the	DET
easat-4305	113	9	concentrations	concentration	NOUN
easat-4305	113	10	of	of	ADP
easat-4305	113	11	the	the	DET
easat-4305	113	12	recombinant	recombinant	ADJ
easat-4305	113	13	antigen	antigen	NOUN
easat-4305	113	14	and	and	CCONJ
easat-4305	113	15	monoclonal	monoclonal	NOUN
easat-4305	113	16	antibody	antibody	NOUN
easat-4305	113	17	.	.	PUNCT
easat-4305	114	1	dilution	dilution	NOUN
easat-4305	114	2	ratio	ratio	NOUN
easat-4305	114	3	rag	rag	NOUN
easat-4305	114	4	od	od	PROPN
easat-4305	114	5	nm	nm	PROPN
easat-4305	114	6	1:2	1:2	NUM
easat-4305	114	7	1:4	1:4	NUM
easat-4305	114	8	1:8	1:8	NUM
easat-4305	114	9	1:16	1:16	NUM
easat-4305	114	10	1:32	1:32	PROPN
easat-4305	114	11	1:64	1:64	NUM
easat-4305	114	12	0	0	NUM
easat-4305	114	13	mab	mab	VERB
easat-4305	114	14	1:8	1:8	NUM
easat-4305	114	15	1.275	1.275	NUM
easat-4305	114	16	1.169	1.169	NUM
easat-4305	114	17	1.018	1.018	NUM
easat-4305	114	18	1.143	1.143	NUM
easat-4305	114	19	0.981	0.981	NUM
easat-4305	114	20	0.782	0.782	NUM
easat-4305	114	21	0.124	0.124	NUM
easat-4305	114	22	450	450	NUM
easat-4305	114	23	1:16	1:16	NUM
easat-4305	114	24	1.099	1.099	NUM
easat-4305	114	25	1.198	1.198	NUM
easat-4305	114	26	1.248	1.248	NUM
easat-4305	114	27	1.301	1.301	NUM
easat-4305	114	28	1.200	1.200	NUM
easat-4305	114	29	0.893	0.893	NUM
easat-4305	114	30	0.109	0.109	NUM
easat-4305	114	31	450	450	NUM
easat-4305	114	32	1:32	1:32	NUM
easat-4305	114	33	1.490	1.490	NUM
easat-4305	114	34	1.344	1.344	NUM
easat-4305	114	35	1.198	1.198	NUM
easat-4305	114	36	1.296	1.296	NUM
easat-4305	114	37	1.209	1.209	NUM
easat-4305	114	38	0.955	0.955	NUM
easat-4305	114	39	0.113	0.113	NUM
easat-4305	114	40	450	450	NUM
easat-4305	114	41	1:64	1:64	NUM
easat-4305	114	42	1.508	1.508	NUM
easat-4305	114	43	1.492	1.492	NUM
easat-4305	114	44	1.611	1.611	NUM
easat-4305	114	45	1.451	1.451	NUM
easat-4305	114	46	1.375	1.375	NUM
easat-4305	114	47	1.034	1.034	NUM
easat-4305	114	48	0.120	0.120	NUM
easat-4305	114	49	450	450	NUM
easat-4305	114	50	1:128	1:128	NUM
easat-4305	114	51	1.899	1.899	NUM
easat-4305	114	52	1.961	1.961	NUM
easat-4305	114	53	1.975	1.975	NUM
easat-4305	114	54	1.503	1.503	NUM
easat-4305	114	55	1.115	1.115	NUM
easat-4305	114	56	1.012	1.012	NUM
easat-4305	114	57	0.189	0.189	NUM
easat-4305	114	58	450	450	NUM
easat-4305	114	59	1:256	1:256	NUM
easat-4305	114	60	1.602	1.602	NUM
easat-4305	114	61	1.768	1.768	NUM
easat-4305	114	62	0.979	0.979	NUM
easat-4305	114	63	0.997	0.997	NUM
easat-4305	114	64	0.887	0.887	NUM
easat-4305	114	65	1.150	1.150	NUM
easat-4305	114	66	0.022	0.022	NUM
easat-4305	114	67	450	450	NUM
easat-4305	114	68	1:512	1:512	NUM
easat-4305	114	69	1.532	1.532	NUM
easat-4305	114	70	1.806	1.806	NUM
easat-4305	114	71	0.928	0.928	NUM
easat-4305	114	72	0.910	0.910	NUM
easat-4305	114	73	0.825	0.825	NUM
easat-4305	114	74	0.766	0.766	NUM
easat-4305	114	75	0.176	0.176	NUM
easat-4305	114	76	450	450	NUM
easat-4305	114	77	0	0	NUM
easat-4305	114	78	0.164	0.164	NUM
easat-4305	114	79	0.182	0.182	NUM
easat-4305	114	80	0.210	0.210	NUM
easat-4305	114	81	0.127	0.127	NUM
easat-4305	114	82	0.110	0.110	NUM
easat-4305	114	83	0.099	0.099	NUM
easat-4305	114	84	0.083	0.083	NUM
easat-4305	114	85	450	450	NUM
easat-4305	114	86	3.4	3.4	NUM
easat-4305	114	87	.	.	PUNCT
easat-4305	114	88	evaluation	evaluation	NOUN
easat-4305	114	89	of	of	ADP
easat-4305	114	90	the	the	DET
easat-4305	114	91	sensitivity	sensitivity	NOUN
easat-4305	114	92	and	and	CCONJ
easat-4305	114	93	specificity	specificity	NOUN
easat-4305	114	94	of	of	ADP
easat-4305	114	95	the	the	DET
easat-4305	114	96	test	test	NOUN
easat-4305	114	97	the	the	DET
easat-4305	114	98	indirect	indirect	ADJ
easat-4305	114	99	elisa	elisa	NOUN
easat-4305	114	100	test	test	NOUN
easat-4305	114	101	using	use	VERB
easat-4305	114	102	the	the	DET
easat-4305	114	103	monoclonal	monoclonal	NOUN
easat-4305	114	104	antibody	antibody	NOUN
easat-4305	114	105	mab	mab	NOUN
easat-4305	114	106	-	-	PUNCT
easat-4305	114	107	txn	txn	NOUN
easat-4305	114	108	demonstrated	demonstrate	VERB
easat-4305	114	109	a	a	DET
easat-4305	114	110	sensitivity	sensitivity	NOUN
easat-4305	114	111	of	of	ADP
easat-4305	114	112	95.74	95.74	NUM
easat-4305	114	113	%	%	NOUN
easat-4305	114	114	,	,	PUNCT
easat-4305	114	115	specificity	specificity	NOUN
easat-4305	114	116	of	of	ADP
easat-4305	114	117	84.00	84.00	NUM
easat-4305	114	118	%	%	NOUN
easat-4305	114	119	,	,	PUNCT
easat-4305	114	120	positive	positive	ADJ
easat-4305	114	121	predictive	predictive	ADJ
easat-4305	114	122	value	value	NOUN
easat-4305	114	123	(	(	PUNCT
easat-4305	114	124	ppv	ppv	NOUN
easat-4305	114	125	)	)	PUNCT
easat-4305	114	126	of	of	ADP
easat-4305	114	127	91.83	91.83	NUM
easat-4305	114	128	%	%	NOUN
easat-4305	114	129	,	,	PUNCT
easat-4305	114	130	and	and	CCONJ
easat-4305	114	131	negative	negative	ADJ
easat-4305	114	132	predictive	predictive	ADJ
easat-4305	114	133	value	value	NOUN
easat-4305	114	134	(	(	PUNCT
easat-4305	114	135	npv	npv	NOUN
easat-4305	114	136	)	)	PUNCT
easat-4305	114	137	of	of	ADP
easat-4305	114	138	91.30	91.30	NUM
easat-4305	114	139	%	%	NOUN
easat-4305	114	140	(	(	PUNCT
easat-4305	114	141	table	table	NOUN
easat-4305	114	142	4	4	NUM
easat-4305	114	143	)	)	PUNCT
easat-4305	114	144	.	.	PUNCT
easat-4305	115	1	1015	1015	NUM
easat-4305	115	2	edelweiss	edelweiss	PROPN
easat-4305	115	3	applied	apply	VERB
easat-4305	115	4	science	science	NOUN
easat-4305	115	5	and	and	CCONJ
easat-4305	115	6	technology	technology	NOUN
easat-4305	115	7	issn	issn	PROPN
easat-4305	115	8	:	:	PUNCT
easat-4305	115	9	2576	2576	NUM
easat-4305	115	10	-	-	SYM
easat-4305	115	11	8484	8484	NUM
easat-4305	115	12	vol	vol	NOUN
easat-4305	115	13	.	.	PROPN
easat-4305	116	1	9	9	NUM
easat-4305	116	2	,	,	PUNCT
easat-4305	116	3	no	no	INTJ
easat-4305	116	4	.	.	NOUN
easat-4305	116	5	1	1	NUM
easat-4305	116	6	:	:	PUNCT
easat-4305	116	7	1010	1010	NUM
easat-4305	116	8	-	-	SYM
easat-4305	116	9	1018	1018	NUM
easat-4305	116	10	,	,	PUNCT
easat-4305	116	11	2025	2025	NUM
easat-4305	116	12	doi	doi	NOUN
easat-4305	116	13	:	:	PUNCT
easat-4305	116	14	10.55214/25768484.v9i1.4305	10.55214/25768484.v9i1.4305	NUM
easat-4305	116	15	©	©	PROPN
easat-4305	116	16	2025	2025	NUM
easat-4305	116	17	by	by	ADP
easat-4305	116	18	the	the	DET
easat-4305	116	19	authors	author	NOUN
easat-4305	116	20	;	;	PUNCT
easat-4305	116	21	licensee	licensee	PROPN
easat-4305	116	22	learning	learn	VERB
easat-4305	116	23	gate	gate	NOUN
easat-4305	116	24	table	table	NOUN
easat-4305	116	25	4	4	NUM
easat-4305	116	26	.	.	PUNCT
easat-4305	117	1	the	the	DET
easat-4305	117	2	sensitivity	sensitivity	NOUN
easat-4305	117	3	,	,	PUNCT
easat-4305	117	4	specificity	specificity	NOUN
easat-4305	117	5	,	,	PUNCT
easat-4305	117	6	positive	positive	ADJ
easat-4305	117	7	predictive	predictive	ADJ
easat-4305	117	8	value	value	NOUN
easat-4305	117	9	(	(	PUNCT
easat-4305	117	10	ppv	ppv	NOUN
easat-4305	117	11	)	)	PUNCT
easat-4305	117	12	,	,	PUNCT
easat-4305	117	13	and	and	CCONJ
easat-4305	117	14	negative	negative	ADJ
easat-4305	117	15	predictive	predictive	ADJ
easat-4305	117	16	value	value	NOUN
easat-4305	117	17	(	(	PUNCT
easat-4305	117	18	npv	npv	NOUN
easat-4305	117	19	)	)	PUNCT
easat-4305	117	20	were	be	AUX
easat-4305	117	21	evaluated	evaluate	VERB
easat-4305	117	22	when	when	SCONJ
easat-4305	117	23	the	the	DET
easat-4305	117	24	monoclonal	monoclonal	NOUN
easat-4305	117	25	antibody	antibody	NOUN
easat-4305	117	26	txn	txn	NOUN
easat-4305	117	27	was	be	AUX
easat-4305	117	28	used	use	VERB
easat-4305	117	29	for	for	ADP
easat-4305	117	30	predicting	predict	VERB
easat-4305	117	31	hcc	hcc	PROPN
easat-4305	117	32	.	.	PUNCT
easat-4305	118	1	elisa	elisa	PROPN
easat-4305	118	2	txn	txn	PROPN
easat-4305	118	3	confirmed	confirm	VERB
easat-4305	118	4	diagnosis	diagnosis	NOUN
easat-4305	118	5	of	of	ADP
easat-4305	118	6	hcc	hcc	PROPN
easat-4305	118	7	total	total	NOUN
easat-4305	118	8	(	(	PUNCT
easat-4305	118	9	+	+	NOUN
easat-4305	118	10	)	)	PUNCT
easat-4305	118	11	(	(	PUNCT
easat-4305	118	12	–	–	PUNCT
easat-4305	118	13	)	)	PUNCT
easat-4305	118	14	(	(	PUNCT
easat-4305	118	15	+	+	NOUN
easat-4305	118	16	)	)	PUNCT
easat-4305	118	17	45	45	NUM
easat-4305	118	18	4	4	NUM
easat-4305	118	19	elisa	elisa	X
easat-4305	118	20	(	(	PUNCT
easat-4305	118	21	+	+	NOUN
easat-4305	118	22	)	)	PUNCT
easat-4305	118	23	=	=	SYM
easat-4305	118	24	49	49	NUM
easat-4305	118	25	(	(	PUNCT
easat-4305	118	26	–	–	PUNCT
easat-4305	118	27	)	)	PUNCT
easat-4305	118	28	2	2	NUM
easat-4305	118	29	21	21	NUM
easat-4305	118	30	elisa	elisa	X
easat-4305	118	31	(	(	PUNCT
easat-4305	118	32	–	–	PUNCT
easat-4305	118	33	)	)	PUNCT
easat-4305	118	34	=	=	SYM
easat-4305	119	1	23	23	NUM
easat-4305	119	2	total	total	NOUN
easat-4305	119	3	47	47	NUM
easat-4305	119	4	25	25	NUM
easat-4305	119	5	72	72	NUM
easat-4305	119	6	se	se	X
easat-4305	119	7	(	(	PUNCT
easat-4305	119	8	%	%	INTJ
easat-4305	119	9	)	)	PUNCT
easat-4305	119	10	95.74	95.74	NUM
easat-4305	119	11	sp	sp	ADP
easat-4305	119	12	(	(	PUNCT
easat-4305	119	13	%	%	INTJ
easat-4305	119	14	)	)	PUNCT
easat-4305	119	15	84.00	84.00	NUM
easat-4305	119	16	npv	npv	NOUN
easat-4305	119	17	(	(	PUNCT
easat-4305	119	18	%	%	INTJ
easat-4305	119	19	)	)	PUNCT
easat-4305	119	20	91.30	91.30	NUM
easat-4305	119	21	ppv	ppv	NOUN
easat-4305	119	22	(	(	PUNCT
easat-4305	119	23	%	%	INTJ
easat-4305	119	24	)	)	PUNCT
easat-4305	119	25	91.83	91.83	NUM
easat-4305	119	26	%	%	NOUN
easat-4305	119	27	according	accord	VERB
easat-4305	119	28	to	to	ADP
easat-4305	119	29	the	the	DET
easat-4305	119	30	results	result	NOUN
easat-4305	119	31	of	of	ADP
easat-4305	119	32	the	the	DET
easat-4305	119	33	indirect	indirect	ADJ
easat-4305	119	34	elisa	elisa	NOUN
easat-4305	119	35	test	test	NOUN
easat-4305	119	36	,	,	PUNCT
easat-4305	119	37	the	the	DET
easat-4305	119	38	optical	optical	ADJ
easat-4305	119	39	density	density	NOUN
easat-4305	119	40	(	(	PUNCT
easat-4305	119	41	od	od	NOUN
easat-4305	119	42	)	)	PUNCT
easat-4305	119	43	values	value	NOUN
easat-4305	119	44	of	of	ADP
easat-4305	119	45	the	the	DET
easat-4305	119	46	earlystage	earlystage	NOUN
easat-4305	119	47	hcc	hcc	PROPN
easat-4305	119	48	patient	patient	NOUN
easat-4305	119	49	samples	sample	NOUN
easat-4305	119	50	were	be	AUX
easat-4305	119	51	very	very	ADV
easat-4305	119	52	close	close	ADJ
easat-4305	119	53	to	to	ADP
easat-4305	119	54	the	the	DET
easat-4305	119	55	cutoff	cutoff	NOUN
easat-4305	119	56	threshold	threshold	NOUN
easat-4305	119	57	.	.	PUNCT
easat-4305	120	1	six	six	NUM
easat-4305	120	2	patients	patient	NOUN
easat-4305	120	3	tested	test	VERB
easat-4305	120	4	positive	positive	ADJ
easat-4305	120	5	for	for	ADP
easat-4305	120	6	txn	txn	NOUN
easat-4305	120	7	,	,	PUNCT
easat-4305	120	8	while	while	SCONJ
easat-4305	120	9	two	two	NUM
easat-4305	120	10	did	do	AUX
easat-4305	120	11	not	not	PART
easat-4305	120	12	show	show	VERB
easat-4305	120	13	any	any	DET
easat-4305	120	14	detectable	detectable	ADJ
easat-4305	120	15	txn	txn	NOUN
easat-4305	120	16	antigen	antigen	PROPN
easat-4305	120	17	.	.	PUNCT
easat-4305	121	1	among	among	ADP
easat-4305	121	2	the	the	DET
easat-4305	121	3	samples	sample	NOUN
easat-4305	121	4	at	at	ADP
easat-4305	121	5	high	high	ADJ
easat-4305	121	6	risk	risk	NOUN
easat-4305	121	7	of	of	ADP
easat-4305	121	8	developing	develop	VERB
easat-4305	121	9	hcc	hcc	PROPN
easat-4305	121	10	,	,	PUNCT
easat-4305	121	11	the	the	DET
easat-4305	121	12	majority	majority	NOUN
easat-4305	121	13	fell	fall	VERB
easat-4305	121	14	below	below	ADP
easat-4305	121	15	the	the	DET
easat-4305	121	16	cutoff	cutoff	NOUN
easat-4305	121	17	threshold	threshold	NOUN
easat-4305	121	18	,	,	PUNCT
easat-4305	121	19	with	with	ADP
easat-4305	121	20	4	4	NUM
easat-4305	121	21	patients	patient	NOUN
easat-4305	121	22	testing	test	VERB
easat-4305	121	23	positive	positive	ADJ
easat-4305	121	24	for	for	ADP
easat-4305	121	25	txn	txn	NOUN
easat-4305	121	26	and	and	CCONJ
easat-4305	121	27	6	6	NUM
easat-4305	121	28	testing	testing	NOUN
easat-4305	121	29	negative	negative	ADJ
easat-4305	121	30	.	.	PUNCT
easat-4305	122	1	in	in	ADP
easat-4305	122	2	contrast	contrast	NOUN
easat-4305	122	3	,	,	PUNCT
easat-4305	122	4	the	the	DET
easat-4305	122	5	39	39	NUM
easat-4305	122	6	late	late	ADJ
easat-4305	122	7	-	-	PUNCT
easat-4305	122	8	stage	stage	NOUN
easat-4305	122	9	hcc	hcc	PROPN
easat-4305	122	10	patients	patient	NOUN
easat-4305	122	11	presented	present	VERB
easat-4305	122	12	significantly	significantly	ADV
easat-4305	122	13	higher	high	ADJ
easat-4305	122	14	od	od	PROPN
easat-4305	122	15	values	value	NOUN
easat-4305	122	16	,	,	PUNCT
easat-4305	122	17	well	well	ADV
easat-4305	122	18	above	above	ADP
easat-4305	122	19	the	the	DET
easat-4305	122	20	threshold	threshold	NOUN
easat-4305	122	21	,	,	PUNCT
easat-4305	122	22	with	with	ADP
easat-4305	122	23	all	all	DET
easat-4305	122	24	39	39	NUM
easat-4305	122	25	patients	patient	NOUN
easat-4305	122	26	testing	test	VERB
easat-4305	122	27	positive	positive	ADJ
easat-4305	122	28	for	for	ADP
easat-4305	122	29	the	the	DET
easat-4305	122	30	txn	txn	NOUN
easat-4305	122	31	antigen	antigen	ADV
easat-4305	122	32	in	in	ADP
easat-4305	122	33	their	their	PRON
easat-4305	122	34	serum	serum	NOUN
easat-4305	122	35	(	(	PUNCT
easat-4305	122	36	figure	figure	NOUN
easat-4305	122	37	2	2	NUM
easat-4305	122	38	)	)	PUNCT
easat-4305	122	39	.	.	PUNCT
easat-4305	123	1	figure	figure	NOUN
easat-4305	123	2	2	2	NUM
easat-4305	123	3	.	.	PUNCT
easat-4305	123	4	elisa	elisa	NOUN
easat-4305	123	5	results	result	NOUN
easat-4305	123	6	for	for	ADP
easat-4305	123	7	identifying	identify	VERB
easat-4305	123	8	positive	positive	ADJ
easat-4305	123	9	and	and	CCONJ
easat-4305	123	10	negative	negative	ADJ
easat-4305	123	11	samples	sample	NOUN
easat-4305	123	12	in	in	ADP
easat-4305	123	13	the	the	DET
easat-4305	123	14	three	three	NUM
easat-4305	123	15	study	study	NOUN
easat-4305	123	16	groups	group	NOUN
easat-4305	123	17	and	and	CCONJ
easat-4305	123	18	the	the	DET
easat-4305	123	19	cutoff	cutoff	NOUN
easat-4305	123	20	value	value	NOUN
easat-4305	123	21	for	for	ADP
easat-4305	123	22	healthy	healthy	ADJ
easat-4305	123	23	human	human	ADJ
easat-4305	123	24	serum	serum	NOUN
easat-4305	123	25	samples	sample	NOUN
easat-4305	123	26	without	without	ADP
easat-4305	123	27	liver	liver	NOUN
easat-4305	123	28	disease	disease	NOUN
easat-4305	123	29	.	.	PUNCT
easat-4305	124	1	group	group	PROPN
easat-4305	124	2	a	a	PRON
easat-4305	124	3	:	:	SYM
easat-4305	124	4	8	8	NUM
easat-4305	124	5	samples	sample	NOUN
easat-4305	124	6	from	from	ADP
easat-4305	124	7	early	early	ADJ
easat-4305	124	8	-	-	PUNCT
easat-4305	124	9	stage	stage	NOUN
easat-4305	124	10	hcc	hcc	NOUN
easat-4305	124	11	patients	patient	NOUN
easat-4305	124	12	;	;	PUNCT
easat-4305	124	13	group	group	NOUN
easat-4305	124	14	b	b	NOUN
easat-4305	124	15	:	:	PUNCT
easat-4305	124	16	39	39	NUM
easat-4305	124	17	samples	sample	NOUN
easat-4305	124	18	from	from	ADP
easat-4305	124	19	late	late	ADJ
easat-4305	124	20	-	-	PUNCT
easat-4305	124	21	stage	stage	NOUN
easat-4305	124	22	hcc	hcc	NOUN
easat-4305	124	23	patients	patient	NOUN
easat-4305	124	24	;	;	PUNCT
easat-4305	124	25	group	group	NOUN
easat-4305	124	26	c	c	NOUN
easat-4305	124	27	:	:	PUNCT
easat-4305	124	28	10	10	NUM
easat-4305	124	29	samples	sample	NOUN
easat-4305	124	30	at	at	ADP
easat-4305	124	31	high	high	ADJ
easat-4305	124	32	risk	risk	NOUN
easat-4305	124	33	of	of	ADP
easat-4305	124	34	hcc	hcc	PROPN
easat-4305	124	35	.	.	PROPN
easat-4305	125	1	4	4	NUM
easat-4305	125	2	.	.	X
easat-4305	125	3	discussion	discussion	NOUN
easat-4305	125	4	4.1	4.1	NUM
easat-4305	125	5	.	.	PUNCT
easat-4305	126	1	general	general	ADJ
easat-4305	126	2	characteristics	characteristic	NOUN
easat-4305	126	3	of	of	ADP
easat-4305	126	4	the	the	DET
easat-4305	126	5	study	study	NOUN
easat-4305	126	6	group	group	NOUN
easat-4305	126	7	hepatocellular	hepatocellular	ADJ
easat-4305	126	8	carcinoma	carcinoma	NOUN
easat-4305	126	9	primarily	primarily	ADV
easat-4305	126	10	affects	affect	VERB
easat-4305	126	11	men	man	NOUN
easat-4305	126	12	and	and	CCONJ
easat-4305	126	13	older	old	ADJ
easat-4305	126	14	adults	adult	NOUN
easat-4305	126	15	,	,	PUNCT
easat-4305	126	16	with	with	ADP
easat-4305	126	17	the	the	DET
easat-4305	126	18	risk	risk	NOUN
easat-4305	126	19	increasing	increase	VERB
easat-4305	126	20	over	over	ADP
easat-4305	126	21	time	time	NOUN
easat-4305	126	22	due	due	ADP
easat-4305	126	23	to	to	ADP
easat-4305	126	24	factors	factor	NOUN
easat-4305	126	25	such	such	ADJ
easat-4305	126	26	as	as	ADP
easat-4305	126	27	hbv	hbv	NOUN
easat-4305	126	28	/	/	SYM
easat-4305	126	29	hcv	hcv	NOUN
easat-4305	126	30	infections	infection	NOUN
easat-4305	126	31	and	and	CCONJ
easat-4305	126	32	cirrhosis	cirrhosis	NOUN
easat-4305	126	33	.	.	PUNCT
easat-4305	127	1	our	our	PRON
easat-4305	127	2	study	study	NOUN
easat-4305	127	3	confirms	confirm	VERB
easat-4305	127	4	that	that	SCONJ
easat-4305	127	5	the	the	DET
easat-4305	127	6	incidence	incidence	NOUN
easat-4305	127	7	of	of	ADP
easat-4305	127	8	hcc	hcc	PROPN
easat-4305	127	9	is	be	AUX
easat-4305	127	10	strongly	strongly	ADV
easat-4305	127	11	associated	associate	VERB
easat-4305	127	12	with	with	ADP
easat-4305	127	13	these	these	DET
easat-4305	127	14	demographic	demographic	ADJ
easat-4305	127	15	and	and	CCONJ
easat-4305	127	16	clinical	clinical	ADJ
easat-4305	127	17	factors	factor	NOUN
easat-4305	127	18	,	,	PUNCT
easat-4305	127	19	highlighting	highlight	VERB
easat-4305	127	20	the	the	DET
easat-4305	127	21	importance	importance	NOUN
easat-4305	127	22	of	of	ADP
easat-4305	127	23	addressing	address	VERB
easat-4305	127	24	these	these	DET
easat-4305	127	25	risks	risk	NOUN
easat-4305	127	26	in	in	ADP
easat-4305	127	27	prevention	prevention	NOUN
easat-4305	127	28	strategies	strategy	NOUN
easat-4305	127	29	.	.	PUNCT
easat-4305	128	1	1016	1016	NUM
easat-4305	128	2	edelweiss	edelweiss	PROPN
easat-4305	128	3	applied	apply	VERB
easat-4305	128	4	science	science	NOUN
easat-4305	128	5	and	and	CCONJ
easat-4305	128	6	technology	technology	NOUN
easat-4305	128	7	issn	issn	PROPN
easat-4305	128	8	:	:	PUNCT
easat-4305	128	9	2576	2576	NUM
easat-4305	128	10	-	-	SYM
easat-4305	128	11	8484	8484	NUM
easat-4305	128	12	vol	vol	NOUN
easat-4305	128	13	.	.	PROPN
easat-4305	129	1	9	9	NUM
easat-4305	129	2	,	,	PUNCT
easat-4305	129	3	no	no	INTJ
easat-4305	129	4	.	.	NOUN
easat-4305	129	5	1	1	NUM
easat-4305	129	6	:	:	PUNCT
easat-4305	129	7	1010	1010	NUM
easat-4305	129	8	-	-	SYM
easat-4305	129	9	1018	1018	NUM
easat-4305	129	10	,	,	PUNCT
easat-4305	129	11	2025	2025	NUM
easat-4305	129	12	doi	doi	NOUN
easat-4305	129	13	:	:	PUNCT
easat-4305	129	14	10.55214/25768484.v9i1.4305	10.55214/25768484.v9i1.4305	NUM
easat-4305	129	15	©	©	PROPN
easat-4305	129	16	2025	2025	NUM
easat-4305	129	17	by	by	ADP
easat-4305	129	18	the	the	DET
easat-4305	129	19	authors	author	NOUN
easat-4305	129	20	;	;	PUNCT
easat-4305	129	21	licensee	licensee	PROPN
easat-4305	129	22	learning	learning	NOUN
easat-4305	129	23	gate	gate	NOUN
easat-4305	129	24	among	among	ADP
easat-4305	129	25	the	the	DET
easat-4305	129	26	risk	risk	NOUN
easat-4305	129	27	factors	factor	NOUN
easat-4305	129	28	,	,	PUNCT
easat-4305	129	29	hbv	hbv	NOUN
easat-4305	129	30	infection	infection	NOUN
easat-4305	129	31	was	be	AUX
easat-4305	129	32	the	the	DET
easat-4305	129	33	most	most	ADV
easat-4305	129	34	prevalent	prevalent	ADJ
easat-4305	129	35	in	in	ADP
easat-4305	129	36	the	the	DET
easat-4305	129	37	study	study	NOUN
easat-4305	129	38	population	population	NOUN
easat-4305	129	39	,	,	PUNCT
easat-4305	129	40	which	which	PRON
easat-4305	129	41	underscores	underscore	VERB
easat-4305	129	42	the	the	DET
easat-4305	129	43	critical	critical	ADJ
easat-4305	129	44	role	role	NOUN
easat-4305	129	45	of	of	ADP
easat-4305	129	46	hbv	hbv	NOUN
easat-4305	129	47	vaccination	vaccination	NOUN
easat-4305	129	48	and	and	CCONJ
easat-4305	129	49	treatment	treatment	NOUN
easat-4305	129	50	in	in	ADP
easat-4305	129	51	reducing	reduce	VERB
easat-4305	129	52	the	the	DET
easat-4305	129	53	risk	risk	NOUN
easat-4305	129	54	of	of	ADP
easat-4305	129	55	hcc	hcc	PROPN
easat-4305	129	56	.	.	PUNCT
easat-4305	130	1	effective	effective	ADJ
easat-4305	130	2	management	management	NOUN
easat-4305	130	3	of	of	ADP
easat-4305	130	4	hbv	hbv	NOUN
easat-4305	130	5	could	could	AUX
easat-4305	130	6	significantly	significantly	ADV
easat-4305	130	7	lower	lower	VERB
easat-4305	130	8	the	the	DET
easat-4305	130	9	burden	burden	NOUN
easat-4305	130	10	of	of	ADP
easat-4305	130	11	liver	liver	NOUN
easat-4305	130	12	cancer	cancer	NOUN
easat-4305	130	13	,	,	PUNCT
easat-4305	130	14	particularly	particularly	ADV
easat-4305	130	15	in	in	ADP
easat-4305	130	16	regions	region	NOUN
easat-4305	130	17	with	with	ADP
easat-4305	130	18	high	high	ADJ
easat-4305	130	19	prevalence	prevalence	NOUN
easat-4305	130	20	rates	rate	NOUN
easat-4305	130	21	of	of	ADP
easat-4305	130	22	this	this	DET
easat-4305	130	23	viral	viral	ADJ
easat-4305	130	24	infection	infection	NOUN
easat-4305	130	25	.	.	PUNCT
easat-4305	131	1	the	the	DET
easat-4305	131	2	majority	majority	NOUN
easat-4305	131	3	of	of	ADP
easat-4305	131	4	patients	patient	NOUN
easat-4305	131	5	in	in	ADP
easat-4305	131	6	this	this	DET
easat-4305	131	7	study	study	NOUN
easat-4305	131	8	were	be	AUX
easat-4305	131	9	diagnosed	diagnose	VERB
easat-4305	131	10	at	at	ADP
easat-4305	131	11	an	an	DET
easat-4305	131	12	advanced	advanced	ADJ
easat-4305	131	13	stage	stage	NOUN
easat-4305	131	14	of	of	ADP
easat-4305	131	15	hcc	hcc	PROPN
easat-4305	131	16	,	,	PUNCT
easat-4305	131	17	which	which	PRON
easat-4305	131	18	limits	limit	VERB
easat-4305	131	19	the	the	DET
easat-4305	131	20	effectiveness	effectiveness	NOUN
easat-4305	131	21	of	of	ADP
easat-4305	131	22	treatment	treatment	NOUN
easat-4305	131	23	and	and	CCONJ
easat-4305	131	24	worsens	worsen	VERB
easat-4305	131	25	the	the	DET
easat-4305	131	26	prognosis	prognosis	NOUN
easat-4305	131	27	.	.	PUNCT
easat-4305	132	1	this	this	DET
easat-4305	132	2	finding	finding	NOUN
easat-4305	132	3	emphasizes	emphasize	VERB
easat-4305	132	4	the	the	DET
easat-4305	132	5	need	need	NOUN
easat-4305	132	6	for	for	ADP
easat-4305	132	7	earlier	early	ADJ
easat-4305	132	8	detection	detection	NOUN
easat-4305	132	9	and	and	CCONJ
easat-4305	132	10	monitoring	monitoring	NOUN
easat-4305	132	11	of	of	ADP
easat-4305	132	12	individuals	individual	NOUN
easat-4305	132	13	at	at	ADP
easat-4305	132	14	high	high	ADJ
easat-4305	132	15	risk	risk	NOUN
easat-4305	132	16	,	,	PUNCT
easat-4305	132	17	as	as	SCONJ
easat-4305	132	18	early	early	ADJ
easat-4305	132	19	intervention	intervention	NOUN
easat-4305	132	20	could	could	AUX
easat-4305	132	21	significantly	significantly	ADV
easat-4305	132	22	improve	improve	VERB
easat-4305	132	23	treatment	treatment	NOUN
easat-4305	132	24	outcomes	outcome	NOUN
easat-4305	132	25	and	and	CCONJ
easat-4305	132	26	survival	survival	NOUN
easat-4305	132	27	rates	rate	NOUN
easat-4305	132	28	.	.	PUNCT
easat-4305	133	1	in	in	ADP
easat-4305	133	2	terms	term	NOUN
easat-4305	133	3	of	of	ADP
easat-4305	133	4	liver	liver	NOUN
easat-4305	133	5	pathology	pathology	NOUN
easat-4305	133	6	,	,	PUNCT
easat-4305	133	7	the	the	DET
easat-4305	133	8	nonmalignant	nonmalignant	ADJ
easat-4305	133	9	liver	liver	NOUN
easat-4305	133	10	disease	disease	NOUN
easat-4305	133	11	group	group	NOUN
easat-4305	133	12	presented	present	VERB
easat-4305	133	13	the	the	DET
easat-4305	133	14	most	most	ADV
easat-4305	133	15	severe	severe	ADJ
easat-4305	133	16	liver	liver	NOUN
easat-4305	133	17	damage	damage	NOUN
easat-4305	133	18	,	,	PUNCT
easat-4305	133	19	reflected	reflect	VERB
easat-4305	133	20	by	by	ADP
easat-4305	133	21	elevated	elevated	ADJ
easat-4305	133	22	ast	ast	NOUN
easat-4305	133	23	,	,	PUNCT
easat-4305	133	24	alt	alt	ADJ
easat-4305	133	25	,	,	PUNCT
easat-4305	133	26	and	and	CCONJ
easat-4305	133	27	bilirubin	bilirubin	NOUN
easat-4305	133	28	levels	level	NOUN
easat-4305	133	29	,	,	PUNCT
easat-4305	133	30	as	as	ADV
easat-4305	133	31	well	well	ADV
easat-4305	133	32	as	as	ADP
easat-4305	133	33	reduced	reduce	VERB
easat-4305	133	34	albumin	albumin	NOUN
easat-4305	133	35	and	and	CCONJ
easat-4305	133	36	pt	pt	PROPN
easat-4305	133	37	-	-	PUNCT
easat-4305	133	38	inr	inr	NOUN
easat-4305	133	39	values	value	NOUN
easat-4305	133	40	.	.	PUNCT
easat-4305	134	1	these	these	DET
easat-4305	134	2	results	result	NOUN
easat-4305	134	3	suggest	suggest	VERB
easat-4305	134	4	that	that	SCONJ
easat-4305	134	5	nonmalignant	nonmalignant	ADJ
easat-4305	134	6	conditions	condition	NOUN
easat-4305	134	7	such	such	ADJ
easat-4305	134	8	as	as	ADP
easat-4305	134	9	cirrhosis	cirrhosis	NOUN
easat-4305	134	10	and	and	CCONJ
easat-4305	134	11	severe	severe	ADJ
easat-4305	134	12	hepatitis	hepatitis	NOUN
easat-4305	134	13	can	can	AUX
easat-4305	134	14	cause	cause	VERB
easat-4305	134	15	substantial	substantial	ADJ
easat-4305	134	16	liver	liver	NOUN
easat-4305	134	17	dysfunction	dysfunction	NOUN
easat-4305	134	18	,	,	PUNCT
easat-4305	134	19	which	which	PRON
easat-4305	134	20	is	be	AUX
easat-4305	134	21	potentially	potentially	ADV
easat-4305	134	22	even	even	ADV
easat-4305	134	23	more	more	ADV
easat-4305	134	24	severe	severe	ADJ
easat-4305	134	25	than	than	ADP
easat-4305	134	26	liver	liver	NOUN
easat-4305	134	27	cancer	cancer	NOUN
easat-4305	134	28	at	at	ADP
easat-4305	134	29	certain	certain	ADJ
easat-4305	134	30	stages	stage	NOUN
easat-4305	134	31	.	.	PUNCT
easat-4305	135	1	in	in	ADP
easat-4305	135	2	contrast	contrast	NOUN
easat-4305	135	3	,	,	PUNCT
easat-4305	135	4	the	the	DET
easat-4305	135	5	hcc	hcc	PROPN
easat-4305	135	6	group	group	NOUN
easat-4305	135	7	exhibited	exhibit	VERB
easat-4305	135	8	moderate	moderate	ADJ
easat-4305	135	9	liver	liver	NOUN
easat-4305	135	10	damage	damage	NOUN
easat-4305	135	11	,	,	PUNCT
easat-4305	135	12	indicating	indicate	VERB
easat-4305	135	13	that	that	SCONJ
easat-4305	135	14	although	although	SCONJ
easat-4305	135	15	liver	liver	NOUN
easat-4305	135	16	function	function	NOUN
easat-4305	135	17	was	be	AUX
easat-4305	135	18	impaired	impair	VERB
easat-4305	135	19	,	,	PUNCT
easat-4305	135	20	the	the	DET
easat-4305	135	21	damage	damage	NOUN
easat-4305	135	22	was	be	AUX
easat-4305	135	23	not	not	PART
easat-4305	135	24	as	as	ADV
easat-4305	135	25	severe	severe	ADJ
easat-4305	135	26	as	as	SCONJ
easat-4305	135	27	that	that	PRON
easat-4305	135	28	observed	observe	VERB
easat-4305	135	29	in	in	ADP
easat-4305	135	30	late	late	ADJ
easat-4305	135	31	-	-	PUNCT
easat-4305	135	32	stage	stage	NOUN
easat-4305	135	33	cirrhosis	cirrhosis	NOUN
easat-4305	135	34	or	or	CCONJ
easat-4305	135	35	other	other	ADJ
easat-4305	135	36	advanced	advanced	ADJ
easat-4305	135	37	liver	liver	NOUN
easat-4305	135	38	diseases	disease	NOUN
easat-4305	135	39	.	.	PUNCT
easat-4305	136	1	this	this	PRON
easat-4305	136	2	aligns	align	VERB
easat-4305	136	3	with	with	ADP
easat-4305	136	4	the	the	DET
easat-4305	136	5	characteristics	characteristic	NOUN
easat-4305	136	6	of	of	ADP
easat-4305	136	7	liver	liver	NOUN
easat-4305	136	8	cancer	cancer	NOUN
easat-4305	136	9	in	in	ADP
easat-4305	136	10	its	its	PRON
easat-4305	136	11	intermediate	intermediate	ADJ
easat-4305	136	12	stage	stage	NOUN
easat-4305	136	13	,	,	PUNCT
easat-4305	136	14	where	where	SCONJ
easat-4305	136	15	liver	liver	NOUN
easat-4305	136	16	function	function	NOUN
easat-4305	136	17	may	may	AUX
easat-4305	136	18	still	still	ADV
easat-4305	136	19	be	be	AUX
easat-4305	136	20	somewhat	somewhat	ADV
easat-4305	136	21	preserved	preserve	VERB
easat-4305	136	22	but	but	CCONJ
easat-4305	136	23	begins	begin	VERB
easat-4305	136	24	to	to	PART
easat-4305	136	25	show	show	VERB
easat-4305	136	26	signs	sign	NOUN
easat-4305	136	27	of	of	ADP
easat-4305	136	28	significant	significant	ADJ
easat-4305	136	29	impairment	impairment	NOUN
easat-4305	136	30	.	.	PUNCT
easat-4305	137	1	finally	finally	ADV
easat-4305	137	2	,	,	PUNCT
easat-4305	137	3	the	the	DET
easat-4305	137	4	group	group	NOUN
easat-4305	137	5	without	without	ADP
easat-4305	137	6	liver	liver	NOUN
easat-4305	137	7	pathology	pathology	NOUN
easat-4305	137	8	maintained	maintain	VERB
easat-4305	137	9	normal	normal	ADJ
easat-4305	137	10	liver	liver	NOUN
easat-4305	137	11	function	function	NOUN
easat-4305	137	12	indicators	indicator	NOUN
easat-4305	137	13	,	,	PUNCT
easat-4305	137	14	reflecting	reflect	VERB
easat-4305	137	15	the	the	DET
easat-4305	137	16	absence	absence	NOUN
easat-4305	137	17	of	of	ADP
easat-4305	137	18	any	any	DET
easat-4305	137	19	liver	liver	NOUN
easat-4305	137	20	damage	damage	NOUN
easat-4305	137	21	.	.	PUNCT
easat-4305	138	1	these	these	DET
easat-4305	138	2	findings	finding	NOUN
easat-4305	138	3	highlight	highlight	VERB
easat-4305	138	4	the	the	DET
easat-4305	138	5	potential	potential	NOUN
easat-4305	138	6	for	for	ADP
easat-4305	138	7	early	early	ADJ
easat-4305	138	8	diagnosis	diagnosis	NOUN
easat-4305	138	9	and	and	CCONJ
easat-4305	138	10	intervention	intervention	NOUN
easat-4305	138	11	to	to	PART
easat-4305	138	12	prevent	prevent	VERB
easat-4305	138	13	the	the	DET
easat-4305	138	14	progression	progression	NOUN
easat-4305	138	15	of	of	ADP
easat-4305	138	16	liver	liver	NOUN
easat-4305	138	17	diseases	disease	NOUN
easat-4305	138	18	,	,	PUNCT
easat-4305	138	19	including	include	VERB
easat-4305	138	20	hcc	hcc	PROPN
easat-4305	138	21	.	.	PROPN
easat-4305	138	22	4.2	4.2	NUM
easat-4305	138	23	.	.	PUNCT
easat-4305	139	1	optimization	optimization	NOUN
easat-4305	139	2	of	of	ADP
easat-4305	139	3	conditions	condition	NOUN
easat-4305	139	4	for	for	ADP
easat-4305	139	5	indirect	indirect	ADJ
easat-4305	139	6	elisa	elisa	NOUN
easat-4305	139	7	das	das	PROPN
easat-4305	139	8	and	and	CCONJ
easat-4305	139	9	white	white	ADJ
easat-4305	140	1	[	[	X
easat-4305	140	2	7	7	X
easat-4305	140	3	]	]	PUNCT
easat-4305	140	4	used	use	VERB
easat-4305	140	5	a	a	DET
easat-4305	140	6	sandwich	sandwich	NOUN
easat-4305	140	7	elisa	elisa	NOUN
easat-4305	140	8	method	method	NOUN
easat-4305	140	9	with	with	ADP
easat-4305	140	10	polyclonal	polyclonal	ADJ
easat-4305	140	11	goat	goat	PROPN
easat-4305	140	12	antibodies	antibodie	VERB
easat-4305	140	13	that	that	PRON
easat-4305	140	14	reacted	react	VERB
easat-4305	140	15	with	with	ADP
easat-4305	140	16	human	human	ADJ
easat-4305	140	17	thioredoxin	thioredoxin	PROPN
easat-4305	140	18	and	and	CCONJ
easat-4305	140	19	were	be	AUX
easat-4305	140	20	labeled	label	VERB
easat-4305	140	21	with	with	ADP
easat-4305	140	22	digoxigenin	digoxigenin	NOUN
easat-4305	140	23	.	.	PUNCT
easat-4305	141	1	this	this	DET
easat-4305	141	2	method	method	NOUN
easat-4305	141	3	was	be	AUX
easat-4305	141	4	optimized	optimize	VERB
easat-4305	141	5	for	for	ADP
easat-4305	141	6	antibody	antibody	NOUN
easat-4305	141	7	concentration	concentration	NOUN
easat-4305	141	8	,	,	PUNCT
easat-4305	141	9	blocking	block	VERB
easat-4305	141	10	solution	solution	NOUN
easat-4305	141	11	,	,	PUNCT
easat-4305	141	12	plate	plate	NOUN
easat-4305	141	13	type	type	NOUN
easat-4305	141	14	,	,	PUNCT
easat-4305	141	15	incubation	incubation	NOUN
easat-4305	141	16	time	time	NOUN
easat-4305	141	17	,	,	PUNCT
easat-4305	141	18	and	and	CCONJ
easat-4305	141	19	reaction	reaction	NOUN
easat-4305	141	20	volume	volume	NOUN
easat-4305	141	21	[	[	X
easat-4305	141	22	7	7	NUM
easat-4305	141	23	]	]	PUNCT
easat-4305	141	24	.	.	PUNCT
easat-4305	142	1	the	the	DET
easat-4305	142	2	results	result	NOUN
easat-4305	142	3	revealed	reveal	VERB
easat-4305	142	4	that	that	SCONJ
easat-4305	142	5	thioredoxin	thioredoxin	PROPN
easat-4305	142	6	could	could	AUX
easat-4305	142	7	be	be	AUX
easat-4305	142	8	detected	detect	VERB
easat-4305	142	9	at	at	ADP
easat-4305	142	10	a	a	DET
easat-4305	142	11	minimum	minimum	ADJ
easat-4305	142	12	concentration	concentration	NOUN
easat-4305	142	13	of	of	ADP
easat-4305	142	14	15	15	NUM
easat-4305	142	15	pg	pg	NOUN
easat-4305	142	16	/	/	SYM
easat-4305	142	17	ml	ml	X
easat-4305	142	18	in	in	ADP
easat-4305	142	19	serum	serum	NOUN
easat-4305	142	20	samples	sample	NOUN
easat-4305	143	1	[	[	X
easat-4305	143	2	7	7	NUM
easat-4305	143	3	]	]	PUNCT
easat-4305	143	4	.	.	PUNCT
easat-4305	144	1	in	in	ADP
easat-4305	144	2	the	the	DET
easat-4305	144	3	study	study	NOUN
easat-4305	144	4	by	by	ADP
easat-4305	144	5	lee	lee	PROPN
easat-4305	144	6	,	,	PUNCT
easat-4305	144	7	et	et	PROPN
easat-4305	144	8	al	al	PROPN
easat-4305	144	9	.	.	PUNCT
easat-4305	145	1	[	[	X
easat-4305	145	2	8	8	NUM
easat-4305	145	3	]	]	PUNCT
easat-4305	145	4	using	use	VERB
easat-4305	145	5	hehpa	hehpa	NOUN
easat-4305	145	6	nanoparticles	nanoparticle	NOUN
easat-4305	145	7	,	,	PUNCT
easat-4305	145	8	a	a	DET
easat-4305	145	9	direct	direct	ADJ
easat-4305	145	10	sandwich	sandwich	NOUN
easat-4305	145	11	elisa	elisa	NOUN
easat-4305	145	12	method	method	NOUN
easat-4305	145	13	was	be	AUX
easat-4305	145	14	able	able	ADJ
easat-4305	145	15	to	to	PART
easat-4305	145	16	measure	measure	VERB
easat-4305	145	17	txn-1	txn-1	ADP
easat-4305	145	18	in	in	ADP
easat-4305	145	19	the	the	DET
easat-4305	145	20	range	range	NOUN
easat-4305	145	21	from	from	ADP
easat-4305	145	22	10	10	NUM
easat-4305	145	23	femtomolar	femtomolar	ADJ
easat-4305	145	24	(	(	PUNCT
easat-4305	145	25	fm	fm	NOUN
easat-4305	145	26	)	)	PUNCT
easat-4305	145	27	to	to	ADP
easat-4305	145	28	100	100	NUM
easat-4305	145	29	picomolar	picomolar	NOUN
easat-4305	145	30	(	(	PUNCT
easat-4305	145	31	pm	pm	NOUN
easat-4305	145	32	)	)	PUNCT
easat-4305	145	33	,	,	PUNCT
easat-4305	145	34	which	which	PRON
easat-4305	145	35	was	be	AUX
easat-4305	145	36	significantly	significantly	ADV
easat-4305	145	37	more	more	ADV
easat-4305	145	38	sensitive	sensitive	ADJ
easat-4305	145	39	than	than	ADP
easat-4305	145	40	the	the	DET
easat-4305	145	41	use	use	NOUN
easat-4305	145	42	of	of	ADP
easat-4305	145	43	only	only	ADJ
easat-4305	145	44	monoclonal	monoclonal	NOUN
easat-4305	145	45	antibodies	antibody	NOUN
easat-4305	145	46	for	for	ADP
easat-4305	145	47	detection	detection	NOUN
easat-4305	145	48	[	[	X
easat-4305	145	49	8	8	NUM
easat-4305	145	50	]	]	PUNCT
easat-4305	145	51	.	.	PUNCT
easat-4305	146	1	therefore	therefore	ADV
easat-4305	146	2	,	,	PUNCT
easat-4305	146	3	further	further	ADJ
easat-4305	146	4	studies	study	NOUN
easat-4305	146	5	are	be	AUX
easat-4305	146	6	needed	need	VERB
easat-4305	146	7	to	to	PART
easat-4305	146	8	assess	assess	VERB
easat-4305	146	9	the	the	DET
easat-4305	146	10	accuracy	accuracy	NOUN
easat-4305	146	11	of	of	ADP
easat-4305	146	12	the	the	DET
easat-4305	146	13	monoclonal	monoclonal	NOUN
easat-4305	146	14	antibody	antibody	NOUN
easat-4305	146	15	developed	develop	VERB
easat-4305	146	16	to	to	PART
easat-4305	146	17	evaluate	evaluate	VERB
easat-4305	146	18	the	the	DET
easat-4305	146	19	detection	detection	NOUN
easat-4305	146	20	threshold	threshold	NOUN
easat-4305	146	21	of	of	ADP
easat-4305	146	22	txn	txn	PROPN
easat-4305	146	23	.	.	PUNCT
easat-4305	147	1	4.3	4.3	NUM
easat-4305	147	2	.	.	PUNCT
easat-4305	147	3	evaluation	evaluation	NOUN
easat-4305	147	4	of	of	ADP
easat-4305	147	5	the	the	DET
easat-4305	147	6	sensitivity	sensitivity	NOUN
easat-4305	147	7	and	and	CCONJ
easat-4305	147	8	specificity	specificity	NOUN
easat-4305	147	9	of	of	ADP
easat-4305	147	10	the	the	DET
easat-4305	147	11	test	test	NOUN
easat-4305	147	12	in	in	ADP
easat-4305	147	13	this	this	DET
easat-4305	147	14	study	study	NOUN
easat-4305	147	15	,	,	PUNCT
easat-4305	147	16	the	the	DET
easat-4305	147	17	indirect	indirect	ADJ
easat-4305	147	18	elisa	elisa	NOUN
easat-4305	147	19	test	test	NOUN
easat-4305	147	20	using	use	VERB
easat-4305	147	21	the	the	DET
easat-4305	147	22	monoclonal	monoclonal	NOUN
easat-4305	147	23	antibody	antibody	NOUN
easat-4305	147	24	mab	mab	NOUN
easat-4305	147	25	-	-	PUNCT
easat-4305	147	26	txn	txn	NOUN
easat-4305	147	27	had	have	VERB
easat-4305	147	28	a	a	DET
easat-4305	147	29	sensitivity	sensitivity	NOUN
easat-4305	147	30	of	of	ADP
easat-4305	147	31	95.74	95.74	NUM
easat-4305	147	32	%	%	NOUN
easat-4305	147	33	,	,	PUNCT
easat-4305	147	34	specificity	specificity	NOUN
easat-4305	147	35	of	of	ADP
easat-4305	147	36	84.00	84.00	NUM
easat-4305	147	37	%	%	NOUN
easat-4305	147	38	,	,	PUNCT
easat-4305	147	39	positive	positive	ADJ
easat-4305	147	40	predictive	predictive	ADJ
easat-4305	147	41	value	value	NOUN
easat-4305	147	42	(	(	PUNCT
easat-4305	147	43	ppv	ppv	NOUN
easat-4305	147	44	)	)	PUNCT
easat-4305	147	45	of	of	ADP
easat-4305	147	46	91.83	91.83	NUM
easat-4305	147	47	%	%	NOUN
easat-4305	147	48	,	,	PUNCT
easat-4305	147	49	and	and	CCONJ
easat-4305	147	50	negative	negative	ADJ
easat-4305	147	51	predictive	predictive	ADJ
easat-4305	147	52	value	value	NOUN
easat-4305	147	53	(	(	PUNCT
easat-4305	147	54	npv	npv	NOUN
easat-4305	147	55	)	)	PUNCT
easat-4305	147	56	of	of	ADP
easat-4305	147	57	91.30	91.30	NUM
easat-4305	147	58	%	%	NOUN
easat-4305	147	59	.	.	PUNCT
easat-4305	148	1	currently	currently	ADV
easat-4305	148	2	,	,	PUNCT
easat-4305	148	3	txn	txn	PROPN
easat-4305	148	4	is	be	AUX
easat-4305	148	5	emerging	emerge	VERB
easat-4305	148	6	as	as	ADP
easat-4305	148	7	a	a	DET
easat-4305	148	8	promising	promising	ADJ
easat-4305	148	9	biomarker	biomarker	NOUN
easat-4305	148	10	for	for	ADP
easat-4305	148	11	hcc	hcc	PROPN
easat-4305	148	12	diagnosis	diagnosis	NOUN
easat-4305	148	13	,	,	PUNCT
easat-4305	148	14	with	with	ADP
easat-4305	148	15	significantly	significantly	ADV
easat-4305	148	16	higher	high	ADJ
easat-4305	148	17	txn	txn	PROPN
easat-4305	148	18	concentrations	concentration	NOUN
easat-4305	148	19	in	in	ADP
easat-4305	148	20	the	the	DET
easat-4305	148	21	serum	serum	NOUN
easat-4305	148	22	of	of	ADP
easat-4305	148	23	hcc	hcc	PROPN
easat-4305	148	24	patients	patient	NOUN
easat-4305	148	25	than	than	ADP
easat-4305	148	26	in	in	ADP
easat-4305	148	27	that	that	PRON
easat-4305	148	28	of	of	ADP
easat-4305	148	29	cirrhosis	cirrhosis	NOUN
easat-4305	148	30	patients	patient	NOUN
easat-4305	148	31	and	and	CCONJ
easat-4305	148	32	those	those	PRON
easat-4305	148	33	at	at	ADP
easat-4305	148	34	high	high	ADJ
easat-4305	148	35	risk	risk	NOUN
easat-4305	148	36	for	for	ADP
easat-4305	148	37	hcc	hcc	PROPN
easat-4305	148	38	.	.	PUNCT
easat-4305	149	1	according	accord	VERB
easat-4305	149	2	to	to	ADP
easat-4305	149	3	abdelwahab	abdelwahab	PROPN
easat-4305	149	4	et	et	PROPN
easat-4305	149	5	al	al	PROPN
easat-4305	149	6	.	.	PROPN
easat-4305	149	7	,	,	PUNCT
easat-4305	149	8	at	at	ADP
easat-4305	149	9	a	a	DET
easat-4305	149	10	threshold	threshold	NOUN
easat-4305	149	11	of	of	ADP
easat-4305	149	12	20.5	20.5	NUM
easat-4305	149	13	ng	ng	NOUN
easat-4305	149	14	/	/	SYM
easat-4305	149	15	ml	ml	PROPN
easat-4305	149	16	,	,	PUNCT
easat-4305	149	17	txn	txn	PROPN
easat-4305	149	18	achieved	achieve	VERB
easat-4305	149	19	a	a	DET
easat-4305	149	20	sensitivity	sensitivity	NOUN
easat-4305	149	21	of	of	ADP
easat-4305	149	22	78.7	78.7	NUM
easat-4305	149	23	%	%	NOUN
easat-4305	149	24	and	and	CCONJ
easat-4305	149	25	specificity	specificity	NOUN
easat-4305	149	26	of	of	ADP
easat-4305	149	27	87.8	87.8	NUM
easat-4305	149	28	%	%	NOUN
easat-4305	149	29	,	,	PUNCT
easat-4305	149	30	outperforming	outperform	VERB
easat-4305	149	31	afp	afp	NOUN
easat-4305	149	32	at	at	ADP
easat-4305	149	33	the	the	DET
easat-4305	149	34	same	same	ADJ
easat-4305	149	35	threshold	threshold	NOUN
easat-4305	149	36	,	,	PUNCT
easat-4305	149	37	with	with	ADP
easat-4305	149	38	an	an	DET
easat-4305	149	39	auc	auc	NOUN
easat-4305	149	40	of	of	ADP
easat-4305	149	41	0.906	0.906	NUM
easat-4305	149	42	compared	compare	VERB
easat-4305	149	43	with	with	ADP
easat-4305	149	44	0.840	0.840	NUM
easat-4305	149	45	[	[	X
easat-4305	149	46	9	9	NUM
easat-4305	149	47	]	]	PUNCT
easat-4305	149	48	.	.	PUNCT
easat-4305	150	1	in	in	ADP
easat-4305	150	2	another	another	DET
easat-4305	150	3	study	study	NOUN
easat-4305	150	4	by	by	ADP
easat-4305	150	5	lee	lee	PROPN
easat-4305	150	6	,	,	PUNCT
easat-4305	150	7	et	et	PROPN
easat-4305	150	8	al	al	PROPN
easat-4305	150	9	.	.	PUNCT
easat-4305	151	1	[	[	X
easat-4305	151	2	8	8	X
easat-4305	151	3	]	]	PUNCT
easat-4305	151	4	which	which	PRON
easat-4305	151	5	was	be	AUX
easat-4305	151	6	conducted	conduct	VERB
easat-4305	151	7	on	on	ADP
easat-4305	151	8	25	25	NUM
easat-4305	151	9	hcc	hcc	PROPN
easat-4305	151	10	patients	patient	NOUN
easat-4305	151	11	,	,	PUNCT
easat-4305	151	12	the	the	DET
easat-4305	151	13	expected	expect	VERB
easat-4305	151	14	optimal	optimal	ADJ
easat-4305	151	15	threshold	threshold	NOUN
easat-4305	151	16	for	for	ADP
easat-4305	151	17	txn	txn	PROPN
easat-4305	151	18	was	be	AUX
easat-4305	151	19	determined	determine	VERB
easat-4305	151	20	to	to	PART
easat-4305	151	21	be	be	AUX
easat-4305	151	22	20.5	20.5	NUM
easat-4305	151	23	ng	ng	NOUN
easat-4305	151	24	/	/	SYM
easat-4305	151	25	ml	ml	PROPN
easat-4305	151	26	,	,	PUNCT
easat-4305	151	27	with	with	ADP
easat-4305	151	28	an	an	DET
easat-4305	151	29	auc	auc	NOUN
easat-4305	151	30	of	of	ADP
easat-4305	151	31	0.946	0.946	NUM
easat-4305	151	32	(	(	PUNCT
easat-4305	151	33	95	95	NUM
easat-4305	151	34	%	%	NOUN
easat-4305	151	35	confidence	confidence	NOUN
easat-4305	151	36	interval	interval	NOUN
easat-4305	151	37	:	:	PUNCT
easat-4305	151	38	0.923–0.969	0.923–0.969	NOUN
easat-4305	151	39	)	)	PUNCT
easat-4305	151	40	.	.	PUNCT
easat-4305	152	1	notably	notably	ADV
easat-4305	152	2	,	,	PUNCT
easat-4305	152	3	the	the	DET
easat-4305	152	4	percentage	percentage	NOUN
easat-4305	152	5	of	of	ADP
easat-4305	152	6	very	very	ADV
easat-4305	152	7	early	early	ADJ
easat-4305	152	8	-	-	PUNCT
easat-4305	152	9	stage	stage	NOUN
easat-4305	152	10	hcc	hcc	NOUN
easat-4305	152	11	patients	patient	NOUN
easat-4305	152	12	who	who	PRON
easat-4305	152	13	tested	test	VERB
easat-4305	152	14	positive	positive	ADJ
easat-4305	152	15	for	for	ADP
easat-4305	152	16	thioredoxin	thioredoxin	PROPN
easat-4305	152	17	was	be	AUX
easat-4305	152	18	significantly	significantly	ADV
easat-4305	152	19	greater	great	ADJ
easat-4305	152	20	than	than	ADP
easat-4305	152	21	that	that	PRON
easat-4305	152	22	who	who	PRON
easat-4305	152	23	tested	test	VERB
easat-4305	152	24	positive	positive	ADJ
easat-4305	152	25	for	for	ADP
easat-4305	152	26	afp	afp	PROPN
easat-4305	152	27	(	(	PUNCT
easat-4305	152	28	73.7	73.7	NUM
easat-4305	152	29	%	%	NOUN
easat-4305	152	30	vs.	vs.	ADP
easat-4305	152	31	31.6	31.6	NUM
easat-4305	152	32	%	%	NOUN
easat-4305	152	33	;	;	PUNCT
easat-4305	152	34	p	p	X
easat-4305	152	35	<	<	X
easat-4305	152	36	0.0001	0.0001	NUM
easat-4305	152	37	)	)	PUNCT
easat-4305	153	1	[	[	X
easat-4305	153	2	10	10	NUM
easat-4305	153	3	]	]	PUNCT
easat-4305	153	4	.	.	PUNCT
easat-4305	154	1	a	a	DET
easat-4305	154	2	further	further	ADJ
easat-4305	154	3	study	study	NOUN
easat-4305	154	4	by	by	ADP
easat-4305	154	5	sheta	sheta	PROPN
easat-4305	154	6	,	,	PUNCT
easat-4305	154	7	et	et	PROPN
easat-4305	154	8	al	al	PROPN
easat-4305	154	9	.	.	PUNCT
easat-4305	155	1	[	[	X
easat-4305	155	2	11	11	NUM
easat-4305	155	3	]	]	PUNCT
easat-4305	155	4	comparing	compare	VERB
easat-4305	155	5	the	the	DET
easat-4305	155	6	sensitivity	sensitivity	NOUN
easat-4305	155	7	of	of	ADP
easat-4305	155	8	txn	txn	NOUN
easat-4305	155	9	and	and	CCONJ
easat-4305	155	10	afp	afp	PROPN
easat-4305	155	11	in	in	ADP
easat-4305	155	12	hcc	hcc	PROPN
easat-4305	155	13	patients	patient	NOUN
easat-4305	155	14	with	with	ADP
easat-4305	155	15	cirrhosis	cirrhosis	NOUN
easat-4305	155	16	revealed	reveal	VERB
easat-4305	155	17	that	that	SCONJ
easat-4305	155	18	at	at	ADP
easat-4305	155	19	a	a	DET
easat-4305	155	20	threshold	threshold	NOUN
easat-4305	155	21	of	of	ADP
easat-4305	155	22	23.28	23.28	NUM
easat-4305	155	23	ng	ng	NOUN
easat-4305	155	24	/	/	SYM
easat-4305	155	25	ml	ml	PROPN
easat-4305	155	26	,	,	PUNCT
easat-4305	155	27	txn	txn	PROPN
easat-4305	155	28	achieved	achieve	VERB
easat-4305	155	29	a	a	DET
easat-4305	155	30	sensitivity	sensitivity	NOUN
easat-4305	155	31	of	of	ADP
easat-4305	155	32	85.4	85.4	NUM
easat-4305	155	33	%	%	NOUN
easat-4305	155	34	,	,	PUNCT
easat-4305	155	35	specificity	specificity	NOUN
easat-4305	155	36	of	of	ADP
easat-4305	155	37	89.6	89.6	NUM
easat-4305	155	38	%	%	NOUN
easat-4305	155	39	,	,	PUNCT
easat-4305	155	40	ppv	ppv	NOUN
easat-4305	155	41	of	of	ADP
easat-4305	155	42	89.1	89.1	NUM
easat-4305	155	43	%	%	NOUN
easat-4305	155	44	,	,	PUNCT
easat-4305	155	45	npv	npv	NOUN
easat-4305	155	46	of	of	ADP
easat-4305	155	47	86	86	NUM
easat-4305	155	48	%	%	NOUN
easat-4305	155	49	,	,	PUNCT
easat-4305	155	50	and	and	CCONJ
easat-4305	155	51	an	an	DET
easat-4305	155	52	auc	auc	NOUN
easat-4305	155	53	of	of	ADP
easat-4305	155	54	0.841	0.841	NUM
easat-4305	155	55	.	.	PUNCT
easat-4305	156	1	in	in	ADP
easat-4305	156	2	combination	combination	NOUN
easat-4305	156	3	with	with	ADP
easat-4305	156	4	afp	afp	PROPN
easat-4305	156	5	,	,	PUNCT
easat-4305	156	6	the	the	DET
easat-4305	156	7	sensitivity	sensitivity	NOUN
easat-4305	156	8	reached	reach	VERB
easat-4305	156	9	93.8	93.8	NUM
easat-4305	156	10	%	%	NOUN
easat-4305	156	11	,	,	PUNCT
easat-4305	156	12	the	the	DET
easat-4305	156	13	specificity	specificity	NOUN
easat-4305	156	14	reached	reach	VERB
easat-4305	156	15	97.9	97.9	NUM
easat-4305	156	16	%	%	NOUN
easat-4305	156	17	,	,	PUNCT
easat-4305	156	18	and	and	CCONJ
easat-4305	156	19	the	the	DET
easat-4305	156	20	auc	auc	NOUN
easat-4305	156	21	reached	reach	VERB
easat-4305	156	22	0.99	0.99	NUM
easat-4305	156	23	,	,	PUNCT
easat-4305	156	24	demonstrating	demonstrate	VERB
easat-4305	156	25	superior	superior	ADJ
easat-4305	156	26	diagnostic	diagnostic	ADJ
easat-4305	156	27	ability	ability	NOUN
easat-4305	156	28	to	to	PART
easat-4305	156	29	differentiate	differentiate	VERB
easat-4305	156	30	hcc	hcc	PROPN
easat-4305	156	31	from	from	ADP
easat-4305	156	32	simple	simple	ADJ
easat-4305	156	33	cirrhosis	cirrhosis	NOUN
easat-4305	156	34	[	[	X
easat-4305	156	35	11	11	NUM
easat-4305	156	36	]	]	PUNCT
easat-4305	156	37	.	.	PUNCT
easat-4305	157	1	in	in	ADP
easat-4305	157	2	our	our	PRON
easat-4305	157	3	study	study	NOUN
easat-4305	157	4	,	,	PUNCT
easat-4305	157	5	monoclonal	monoclonal	NOUN
easat-4305	157	6	antibodies	antibody	NOUN
easat-4305	157	7	effectively	effectively	ADV
easat-4305	157	8	detected	detect	VERB
easat-4305	157	9	txn	txn	NOUN
easat-4305	157	10	antigens	antigen	NOUN
easat-4305	157	11	in	in	ADP
easat-4305	157	12	late	late	ADJ
easat-4305	157	13	-	-	PUNCT
easat-4305	157	14	stage	stage	NOUN
easat-4305	157	15	hcc	hcc	PROPN
easat-4305	157	16	patient	patient	NOUN
easat-4305	157	17	samples	sample	NOUN
easat-4305	157	18	,	,	PUNCT
easat-4305	157	19	but	but	CCONJ
easat-4305	157	20	there	there	PRON
easat-4305	157	21	was	be	VERB
easat-4305	157	22	still	still	ADV
easat-4305	157	23	some	some	DET
easat-4305	157	24	ambiguity	ambiguity	NOUN
easat-4305	157	25	in	in	ADP
easat-4305	157	26	early	early	ADJ
easat-4305	157	27	-	-	PUNCT
easat-4305	157	28	stage	stage	NOUN
easat-4305	157	29	hcc	hcc	NOUN
easat-4305	157	30	and	and	CCONJ
easat-4305	157	31	high	high	ADJ
easat-4305	157	32	-	-	PUNCT
easat-4305	157	33	risk	risk	NOUN
easat-4305	157	34	cases	case	NOUN
easat-4305	157	35	.	.	PUNCT
easat-4305	158	1	nevertheless	nevertheless	ADV
easat-4305	158	2	,	,	PUNCT
easat-4305	158	3	the	the	DET
easat-4305	158	4	1017	1017	NUM
easat-4305	158	5	edelweiss	edelweiss	PROPN
easat-4305	158	6	applied	apply	VERB
easat-4305	158	7	science	science	NOUN
easat-4305	158	8	and	and	CCONJ
easat-4305	158	9	technology	technology	NOUN
easat-4305	158	10	issn	issn	PROPN
easat-4305	158	11	:	:	PUNCT
easat-4305	158	12	2576	2576	NUM
easat-4305	158	13	-	-	SYM
easat-4305	158	14	8484	8484	NUM
easat-4305	158	15	vol	vol	NOUN
easat-4305	158	16	.	.	PROPN
easat-4305	159	1	9	9	NUM
easat-4305	159	2	,	,	PUNCT
easat-4305	159	3	no	no	INTJ
easat-4305	159	4	.	.	NOUN
easat-4305	159	5	1	1	NUM
easat-4305	159	6	:	:	PUNCT
easat-4305	159	7	1010	1010	NUM
easat-4305	159	8	-	-	SYM
easat-4305	159	9	1018	1018	NUM
easat-4305	159	10	,	,	PUNCT
easat-4305	159	11	2025	2025	NUM
easat-4305	159	12	doi	doi	NOUN
easat-4305	159	13	:	:	PUNCT
easat-4305	159	14	10.55214/25768484.v9i1.4305	10.55214/25768484.v9i1.4305	NUM
easat-4305	159	15	©	©	PROPN
easat-4305	159	16	2025	2025	NUM
easat-4305	159	17	by	by	ADP
easat-4305	159	18	the	the	DET
easat-4305	159	19	authors	author	NOUN
easat-4305	159	20	;	;	PUNCT
easat-4305	159	21	licensee	licensee	PROPN
easat-4305	159	22	learning	learning	NOUN
easat-4305	159	23	gate	gate	PROPN
easat-4305	159	24	potential	potential	NOUN
easat-4305	159	25	of	of	ADP
easat-4305	159	26	txn	txn	NOUN
easat-4305	159	27	to	to	PART
easat-4305	159	28	complement	complement	VERB
easat-4305	159	29	afp	afp	NOUN
easat-4305	159	30	in	in	ADP
easat-4305	159	31	detecting	detect	VERB
easat-4305	159	32	and	and	CCONJ
easat-4305	159	33	distinguishing	distinguish	VERB
easat-4305	159	34	hcc	hcc	PROPN
easat-4305	159	35	is	be	AUX
easat-4305	159	36	well	well	ADV
easat-4305	159	37	known	know	VERB
easat-4305	159	38	for	for	ADP
easat-4305	159	39	assessing	assess	VERB
easat-4305	159	40	disease	disease	NOUN
easat-4305	159	41	status	status	NOUN
easat-4305	159	42	.	.	PUNCT
easat-4305	160	1	further	further	ADJ
easat-4305	160	2	studies	study	NOUN
easat-4305	160	3	with	with	ADP
easat-4305	160	4	larger	large	ADJ
easat-4305	160	5	sample	sample	NOUN
easat-4305	160	6	sizes	size	NOUN
easat-4305	160	7	are	be	AUX
easat-4305	160	8	needed	need	VERB
easat-4305	160	9	to	to	PART
easat-4305	160	10	refine	refine	VERB
easat-4305	160	11	these	these	DET
easat-4305	160	12	findings	finding	NOUN
easat-4305	160	13	.	.	PUNCT
easat-4305	161	1	5	5	X
easat-4305	161	2	.	.	X
easat-4305	161	3	conclusion	conclusion	VERB
easat-4305	161	4	the	the	DET
easat-4305	161	5	results	result	NOUN
easat-4305	161	6	of	of	ADP
easat-4305	161	7	this	this	DET
easat-4305	161	8	study	study	NOUN
easat-4305	161	9	demonstrate	demonstrate	VERB
easat-4305	161	10	that	that	SCONJ
easat-4305	161	11	the	the	DET
easat-4305	161	12	indirect	indirect	ADJ
easat-4305	161	13	elisa	elisa	PROPN
easat-4305	161	14	test	test	NOUN
easat-4305	161	15	developed	develop	VERB
easat-4305	161	16	using	use	VERB
easat-4305	161	17	the	the	DET
easat-4305	161	18	monoclonal	monoclonal	NOUN
easat-4305	161	19	antibody	antibody	NOUN
easat-4305	161	20	mab	mab	NOUN
easat-4305	161	21	-	-	PUNCT
easat-4305	161	22	txn	txn	NOUN
easat-4305	161	23	has	have	VERB
easat-4305	161	24	significant	significant	ADJ
easat-4305	161	25	application	application	NOUN
easat-4305	161	26	value	value	NOUN
easat-4305	161	27	in	in	ADP
easat-4305	161	28	detecting	detect	VERB
easat-4305	161	29	the	the	DET
easat-4305	161	30	txn	txn	NOUN
easat-4305	161	31	antigen	antigen	ADV
easat-4305	161	32	in	in	ADP
easat-4305	161	33	serum	serum	NOUN
easat-4305	161	34	.	.	PUNCT
easat-4305	162	1	funding	funding	NOUN
easat-4305	162	2	:	:	PUNCT
easat-4305	162	3	this	this	DET
easat-4305	162	4	research	research	NOUN
easat-4305	162	5	is	be	AUX
easat-4305	162	6	supported	support	VERB
easat-4305	162	7	by	by	ADP
easat-4305	162	8	scientific	scientific	ADJ
easat-4305	162	9	and	and	CCONJ
easat-4305	162	10	technological	technological	ADJ
easat-4305	162	11	tasks	task	NOUN
easat-4305	162	12	according	accord	VERB
easat-4305	162	13	to	to	ADP
easat-4305	162	14	the	the	DET
easat-4305	162	15	protocol	protocol	NOUN
easat-4305	162	16	of	of	ADP
easat-4305	162	17	the	the	DET
easat-4305	162	18	vietnam	vietnam	PROPN
easat-4305	162	19	ministry	ministry	PROPN
easat-4305	162	20	of	of	ADP
easat-4305	162	21	science	science	NOUN
easat-4305	162	22	and	and	CCONJ
easat-4305	162	23	technology	technology	NOUN
easat-4305	162	24	(	(	PUNCT
easat-4305	162	25	grant	grant	PROPN
easat-4305	162	26	number	number	NOUN
easat-4305	162	27	:	:	PUNCT
easat-4305	162	28	nđt.102	nđt.102	NOUN
easat-4305	162	29	-	-	PUNCT
easat-4305	162	30	ger/21	ger/21	NOUN
easat-4305	162	31	)	)	PUNCT
easat-4305	162	32	.	.	PUNCT
easat-4305	163	1	institutional	institutional	ADJ
easat-4305	163	2	review	review	PROPN
easat-4305	163	3	board	board	NOUN
easat-4305	163	4	statement	statement	NOUN
easat-4305	163	5	:	:	PUNCT
easat-4305	163	6	the	the	DET
easat-4305	163	7	ethical	ethical	ADJ
easat-4305	163	8	committee	committee	NOUN
easat-4305	163	9	of	of	ADP
easat-4305	163	10	the	the	DET
easat-4305	163	11	vietnam	vietnam	PROPN
easat-4305	163	12	academy	academy	PROPN
easat-4305	163	13	of	of	ADP
easat-4305	163	14	science	science	NOUN
easat-4305	163	15	and	and	CCONJ
easat-4305	163	16	technology	technology	NOUN
easat-4305	163	17	;	;	PUNCT
easat-4305	163	18	institute	institute	NOUN
easat-4305	163	19	of	of	ADP
easat-4305	163	20	genome	genome	NOUN
easat-4305	163	21	research	research	NOUN
easat-4305	163	22	,	,	PUNCT
easat-4305	163	23	vietnam	vietnam	PROPN
easat-4305	163	24	,	,	PUNCT
easat-4305	163	25	on	on	ADP
easat-4305	163	26	12	12	NUM
easat-4305	163	27	october	october	PROPN
easat-4305	163	28	2020	2020	NUM
easat-4305	163	29	(	(	PUNCT
easat-4305	163	30	ref	ref	NOUN
easat-4305	163	31	.	.	PUNCT
easat-4305	164	1	no	no	INTJ
easat-4305	164	2	.	.	PUNCT
easat-4305	165	1	:	:	PUNCT
easat-4305	165	2	06	06	NUM
easat-4305	165	3	-	-	SYM
easat-4305	165	4	2020	2020	NUM
easat-4305	165	5	/	/	SYM
easat-4305	165	6	nchghddd	nchghddd	NOUN
easat-4305	165	7	)	)	PUNCT
easat-4305	165	8	.	.	PUNCT
easat-4305	166	1	transparency	transparency	NOUN
easat-4305	166	2	:	:	PUNCT
easat-4305	166	3	the	the	DET
easat-4305	166	4	authors	author	NOUN
easat-4305	166	5	state	state	VERB
easat-4305	166	6	that	that	SCONJ
easat-4305	166	7	the	the	DET
easat-4305	166	8	manuscript	manuscript	NOUN
easat-4305	166	9	is	be	AUX
easat-4305	166	10	honest	honest	ADJ
easat-4305	166	11	,	,	PUNCT
easat-4305	166	12	truthful	truthful	ADJ
easat-4305	166	13	,	,	PUNCT
easat-4305	166	14	and	and	CCONJ
easat-4305	166	15	transparent	transparent	ADJ
easat-4305	166	16	,	,	PUNCT
easat-4305	166	17	that	that	SCONJ
easat-4305	166	18	no	no	DET
easat-4305	166	19	key	key	ADJ
easat-4305	166	20	aspects	aspect	NOUN
easat-4305	166	21	of	of	ADP
easat-4305	166	22	the	the	DET
easat-4305	166	23	investigation	investigation	NOUN
easat-4305	166	24	have	have	AUX
easat-4305	166	25	been	be	AUX
easat-4305	166	26	omitted	omit	VERB
easat-4305	166	27	,	,	PUNCT
easat-4305	166	28	and	and	CCONJ
easat-4305	166	29	that	that	SCONJ
easat-4305	166	30	any	any	DET
easat-4305	166	31	differences	difference	NOUN
easat-4305	166	32	from	from	ADP
easat-4305	166	33	the	the	DET
easat-4305	166	34	study	study	NOUN
easat-4305	166	35	as	as	SCONJ
easat-4305	166	36	planned	plan	VERB
easat-4305	166	37	have	have	AUX
easat-4305	166	38	been	be	AUX
easat-4305	166	39	clarified	clarify	VERB
easat-4305	166	40	.	.	PUNCT
easat-4305	167	1	this	this	DET
easat-4305	167	2	study	study	NOUN
easat-4305	167	3	followed	follow	VERB
easat-4305	167	4	all	all	PRON
easat-4305	167	5	writing	write	VERB
easat-4305	167	6	ethics	ethic	NOUN
easat-4305	167	7	.	.	PUNCT
easat-4305	168	1	competing	compete	VERB
easat-4305	168	2	interests	interest	NOUN
easat-4305	168	3	:	:	PUNCT
easat-4305	168	4	the	the	DET
easat-4305	168	5	authors	author	NOUN
easat-4305	168	6	declare	declare	VERB
easat-4305	168	7	that	that	SCONJ
easat-4305	168	8	they	they	PRON
easat-4305	168	9	have	have	VERB
easat-4305	168	10	no	no	DET
easat-4305	168	11	competing	compete	VERB
easat-4305	168	12	interests	interest	NOUN
easat-4305	168	13	.	.	PUNCT
easat-4305	169	1	authors	author	NOUN
easat-4305	169	2	’	'	PUNCT
easat-4305	169	3	contributions	contribution	NOUN
easat-4305	169	4	:	:	PUNCT
easat-4305	169	5	all	all	DET
easat-4305	169	6	the	the	DET
easat-4305	169	7	authors	author	NOUN
easat-4305	169	8	contributed	contribute	VERB
easat-4305	169	9	equally	equally	ADV
easat-4305	169	10	to	to	ADP
easat-4305	169	11	the	the	DET
easat-4305	169	12	conception	conception	NOUN
easat-4305	169	13	and	and	CCONJ
easat-4305	169	14	design	design	NOUN
easat-4305	169	15	of	of	ADP
easat-4305	169	16	the	the	DET
easat-4305	169	17	study	study	NOUN
easat-4305	169	18	.	.	PUNCT
easat-4305	170	1	all	all	DET
easat-4305	170	2	the	the	DET
easat-4305	170	3	authors	author	NOUN
easat-4305	170	4	have	have	AUX
easat-4305	170	5	read	read	VERB
easat-4305	170	6	and	and	CCONJ
easat-4305	170	7	agreed	agree	VERB
easat-4305	170	8	to	to	ADP
easat-4305	170	9	the	the	DET
easat-4305	170	10	published	publish	VERB
easat-4305	170	11	version	version	NOUN
easat-4305	170	12	of	of	ADP
easat-4305	170	13	the	the	DET
easat-4305	170	14	manuscript	manuscript	NOUN
easat-4305	170	15	.	.	PUNCT
easat-4305	171	1	copyright	copyright	NOUN
easat-4305	171	2	:	:	PUNCT
easat-4305	171	3	©	©	PROPN
easat-4305	171	4	2025	2025	NUM
easat-4305	171	5	by	by	ADP
easat-4305	171	6	the	the	DET
easat-4305	171	7	authors	author	NOUN
easat-4305	171	8	.	.	PUNCT
easat-4305	172	1	this	this	DET
easat-4305	172	2	open	open	ADJ
easat-4305	172	3	-	-	PUNCT
easat-4305	172	4	access	access	NOUN
easat-4305	172	5	article	article	NOUN
easat-4305	172	6	is	be	AUX
easat-4305	172	7	distributed	distribute	VERB
easat-4305	172	8	under	under	ADP
easat-4305	172	9	the	the	DET
easat-4305	172	10	terms	term	NOUN
easat-4305	172	11	and	and	CCONJ
easat-4305	172	12	conditions	condition	NOUN
easat-4305	172	13	of	of	ADP
easat-4305	172	14	the	the	DET
easat-4305	172	15	creative	creative	ADJ
easat-4305	172	16	commons	common	NOUN
easat-4305	172	17	attribution	attribution	NOUN
easat-4305	172	18	(	(	PUNCT
easat-4305	172	19	cc	cc	NOUN
easat-4305	172	20	by	by	ADP
easat-4305	172	21	)	)	PUNCT
easat-4305	172	22	license	license	NOUN
easat-4305	172	23	(	(	PUNCT
easat-4305	172	24	https://creativecommons.org/licenses/by/4.0/	https://creativecommons.org/licenses/by/4.0/	PROPN
easat-4305	172	25	)	)	PUNCT
easat-4305	172	26	.	.	PUNCT
easat-4305	173	1	references	reference	NOUN
easat-4305	173	2	[	[	X
easat-4305	173	3	1	1	NUM
easat-4305	173	4	]	]	X
easat-4305	173	5	d.	d.	PROPN
easat-4305	173	6	kim	kim	PROPN
easat-4305	173	7	,	,	PUNCT
easat-4305	173	8	"	"	PUNCT
easat-4305	173	9	changing	change	VERB
easat-4305	173	10	etiology	etiology	NOUN
easat-4305	173	11	and	and	CCONJ
easat-4305	173	12	epidemiology	epidemiology	NOUN
easat-4305	173	13	of	of	ADP
easat-4305	173	14	hepatocellular	hepatocellular	ADJ
easat-4305	173	15	carcinoma	carcinoma	NOUN
easat-4305	173	16	:	:	PUNCT
easat-4305	173	17	asia	asia	PROPN
easat-4305	173	18	and	and	CCONJ
easat-4305	173	19	worldwide	worldwide	ADV
easat-4305	173	20	,	,	PUNCT
easat-4305	173	21	"	"	PUNCT
easat-4305	173	22	journal	journal	NOUN
easat-4305	173	23	of	of	ADP
easat-4305	173	24	liver	liver	NOUN
easat-4305	173	25	cancer	cancer	NOUN
easat-4305	173	26	,	,	PUNCT
easat-4305	173	27	vol	vol	NOUN
easat-4305	173	28	.	.	PROPN
easat-4305	173	29	24	24	NUM
easat-4305	173	30	,	,	PUNCT
easat-4305	173	31	no	no	INTJ
easat-4305	173	32	.	.	NOUN
easat-4305	173	33	1	1	NUM
easat-4305	173	34	,	,	PUNCT
easat-4305	173	35	pp	pp	ADJ
easat-4305	173	36	.	.	PUNCT
easat-4305	174	1	62	62	NUM
easat-4305	174	2	-	-	SYM
easat-4305	174	3	70	70	NUM
easat-4305	174	4	,	,	PUNCT
easat-4305	174	5	2024	2024	NUM
easat-4305	174	6	.	.	PUNCT
easat-4305	175	1	https://doi.org/10.17998/jlc.2024.03.13	https://doi.org/10.17998/jlc.2024.03.13	PRON
easat-4305	175	2	[	[	X
easat-4305	175	3	2	2	X
easat-4305	175	4	]	]	PUNCT
easat-4305	176	1	j.	j.	PROPN
easat-4305	176	2	h.	h.	PROPN
easat-4305	176	3	oh	oh	INTJ
easat-4305	176	4	and	and	CCONJ
easat-4305	176	5	d.	d.	PROPN
easat-4305	176	6	w.	w.	PROPN
easat-4305	176	7	jun	jun	PROPN
easat-4305	176	8	,	,	PUNCT
easat-4305	176	9	"	"	PUNCT
easat-4305	176	10	the	the	DET
easat-4305	176	11	latest	late	ADJ
easat-4305	176	12	global	global	ADJ
easat-4305	176	13	burden	burden	NOUN
easat-4305	176	14	of	of	ADP
easat-4305	176	15	liver	liver	NOUN
easat-4305	176	16	cancer	cancer	NOUN
easat-4305	176	17	:	:	PUNCT
easat-4305	176	18	a	a	DET
easat-4305	176	19	past	past	NOUN
easat-4305	176	20	and	and	CCONJ
easat-4305	176	21	present	present	ADJ
easat-4305	176	22	threat	threat	NOUN
easat-4305	176	23	,	,	PUNCT
easat-4305	176	24	"	"	PUNCT
easat-4305	176	25	clinical	clinical	ADJ
easat-4305	176	26	and	and	CCONJ
easat-4305	176	27	molecular	molecular	ADJ
easat-4305	176	28	hepatology	hepatology	NOUN
easat-4305	176	29	,	,	PUNCT
easat-4305	176	30	vol	vol	NOUN
easat-4305	176	31	.	.	PROPN
easat-4305	176	32	29	29	NUM
easat-4305	176	33	,	,	PUNCT
easat-4305	176	34	no	no	INTJ
easat-4305	176	35	.	.	NOUN
easat-4305	176	36	2	2	NUM
easat-4305	176	37	,	,	PUNCT
easat-4305	176	38	p.	p.	NOUN
easat-4305	176	39	355	355	NUM
easat-4305	176	40	,	,	PUNCT
easat-4305	176	41	2023	2023	NUM
easat-4305	176	42	.	.	PUNCT
easat-4305	177	1	https://doi.org/10.3350/cmh.2023.0070	https://doi.org/10.3350/cmh.2023.0070	PROPN
easat-4305	178	1	[	[	X
easat-4305	178	2	3	3	X
easat-4305	178	3	]	]	X
easat-4305	178	4	e.	e.	PROPN
easat-4305	178	5	chartampilas	chartampilas	PROPN
easat-4305	178	6	,	,	PUNCT
easat-4305	178	7	v.	v.	ADP
easat-4305	178	8	rafailidis	rafailidis	NOUN
easat-4305	178	9	,	,	PUNCT
easat-4305	178	10	v.	v.	PROPN
easat-4305	178	11	georgopoulou	georgopoulou	PROPN
easat-4305	178	12	,	,	PUNCT
easat-4305	178	13	g.	g.	PROPN
easat-4305	178	14	kalarakis	kalarakis	PROPN
easat-4305	178	15	,	,	PUNCT
easat-4305	178	16	a.	a.	NOUN
easat-4305	178	17	hatzidakis	hatzidakis	PROPN
easat-4305	178	18	,	,	PUNCT
easat-4305	178	19	and	and	CCONJ
easat-4305	178	20	p.	p.	PROPN
easat-4305	178	21	prassopoulos	prassopoulo	NOUN
easat-4305	178	22	,	,	PUNCT
easat-4305	178	23	"	"	PUNCT
easat-4305	178	24	current	current	ADJ
easat-4305	178	25	imaging	imaging	NOUN
easat-4305	178	26	diagnosis	diagnosis	NOUN
easat-4305	178	27	of	of	ADP
easat-4305	178	28	hepatocellular	hepatocellular	ADJ
easat-4305	178	29	carcinoma	carcinoma	NOUN
easat-4305	178	30	,	,	PUNCT
easat-4305	178	31	"	"	PUNCT
easat-4305	178	32	cancers	cancer	NOUN
easat-4305	178	33	,	,	PUNCT
easat-4305	178	34	vol	vol	NOUN
easat-4305	178	35	.	.	PROPN
easat-4305	179	1	14	14	NUM
easat-4305	179	2	,	,	PUNCT
easat-4305	179	3	no	no	INTJ
easat-4305	179	4	.	.	NOUN
easat-4305	179	5	16	16	NUM
easat-4305	179	6	,	,	PUNCT
easat-4305	179	7	p.	p.	NOUN
easat-4305	179	8	3997	3997	NUM
easat-4305	179	9	,	,	PUNCT
easat-4305	179	10	2022	2022	NUM
easat-4305	179	11	.	.	PUNCT
easat-4305	180	1	https://doi.org/10.3390/cancers14163997	https://doi.org/10.3390/cancers14163997	NOUN
easat-4305	181	1	[	[	X
easat-4305	181	2	4	4	NUM
easat-4305	181	3	]	]	PUNCT
easat-4305	181	4	k.	k.	PROPN
easat-4305	182	1	g.	g.	PROPN
easat-4305	182	2	núñez	núñez	PROPN
easat-4305	182	3	et	et	PROPN
easat-4305	182	4	al	al	PROPN
easat-4305	182	5	.	.	PROPN
easat-4305	182	6	,	,	PUNCT
easat-4305	182	7	"	"	PUNCT
easat-4305	182	8	baseline	baseline	VERB
easat-4305	182	9	alpha	alpha	NOUN
easat-4305	182	10	-	-	PUNCT
easat-4305	182	11	fetoprotein	fetoprotein	ADJ
easat-4305	182	12	,	,	PUNCT
easat-4305	182	13	alpha	alpha	NOUN
easat-4305	182	14	-	-	PUNCT
easat-4305	182	15	fetoprotein	fetoprotein	NOUN
easat-4305	182	16	-	-	PUNCT
easat-4305	182	17	l3	l3	NOUN
easat-4305	182	18	,	,	PUNCT
easat-4305	182	19	and	and	CCONJ
easat-4305	182	20	des	des	PROPN
easat-4305	182	21	-	-	ADJ
easat-4305	182	22	gamma	gamma	NOUN
easat-4305	182	23	-	-	PUNCT
easat-4305	182	24	carboxy	carboxy	ADJ
easat-4305	182	25	prothrombin	prothrombin	NOUN
easat-4305	182	26	biomarker	biomarker	NOUN
easat-4305	182	27	status	status	NOUN
easat-4305	182	28	in	in	ADP
easat-4305	182	29	bridge	bridge	NOUN
easat-4305	182	30	to	to	PART
easat-4305	182	31	liver	liver	VERB
easat-4305	182	32	transplant	transplant	NOUN
easat-4305	182	33	outcomes	outcome	NOUN
easat-4305	182	34	for	for	ADP
easat-4305	182	35	hepatocellular	hepatocellular	ADJ
easat-4305	182	36	carcinoma	carcinoma	NOUN
easat-4305	182	37	,	,	PUNCT
easat-4305	182	38	"	"	PUNCT
easat-4305	182	39	cancers	cancer	NOUN
easat-4305	182	40	,	,	PUNCT
easat-4305	182	41	vol	vol	NOUN
easat-4305	182	42	.	.	PROPN
easat-4305	182	43	13	13	NUM
easat-4305	182	44	,	,	PUNCT
easat-4305	182	45	no	no	INTJ
easat-4305	182	46	.	.	NOUN
easat-4305	182	47	19	19	NUM
easat-4305	182	48	,	,	PUNCT
easat-4305	182	49	p.	p.	NOUN
easat-4305	182	50	4765	4765	NUM
easat-4305	182	51	,	,	PUNCT
easat-4305	182	52	2021	2021	NUM
easat-4305	182	53	.	.	PUNCT
easat-4305	183	1	https://doi.org/10.3390/cancers13194765	https://doi.org/10.3390/cancers13194765	PROPN
easat-4305	184	1	[	[	X
easat-4305	184	2	5	5	NUM
easat-4305	184	3	]	]	X
easat-4305	184	4	n.	n.	PROPN
easat-4305	184	5	d.	d.	PROPN
easat-4305	184	6	parikh	parikh	PROPN
easat-4305	184	7	,	,	PUNCT
easat-4305	184	8	a.	a.	PROPN
easat-4305	184	9	s.	s.	PROPN
easat-4305	184	10	mehta	mehta	PROPN
easat-4305	184	11	,	,	PUNCT
easat-4305	184	12	a.	a.	NOUN
easat-4305	184	13	g.	g.	PROPN
easat-4305	184	14	singal	singal	PROPN
easat-4305	184	15	,	,	PUNCT
easat-4305	184	16	t.	t.	NOUN
easat-4305	184	17	block	block	NOUN
easat-4305	184	18	,	,	PUNCT
easat-4305	184	19	j.	j.	PROPN
easat-4305	184	20	a.	a.	PROPN
easat-4305	184	21	marrero	marrero	PROPN
easat-4305	184	22	,	,	PUNCT
easat-4305	184	23	and	and	CCONJ
easat-4305	184	24	a.	a.	PROPN
easat-4305	184	25	s.	s.	PROPN
easat-4305	184	26	lok	lok	PROPN
easat-4305	184	27	,	,	PUNCT
easat-4305	184	28	"	"	PUNCT
easat-4305	184	29	biomarkers	biomarker	NOUN
easat-4305	184	30	for	for	ADP
easat-4305	184	31	the	the	DET
easat-4305	184	32	early	early	ADJ
easat-4305	184	33	detection	detection	NOUN
easat-4305	184	34	of	of	ADP
easat-4305	184	35	hepatocellular	hepatocellular	ADJ
easat-4305	184	36	carcinoma	carcinoma	NOUN
easat-4305	184	37	,	,	PUNCT
easat-4305	184	38	"	"	PUNCT
easat-4305	184	39	cancer	cancer	NOUN
easat-4305	184	40	epidemiology	epidemiology	NOUN
easat-4305	184	41	,	,	PUNCT
easat-4305	184	42	biomarkers	biomarker	NOUN
easat-4305	184	43	&	&	CCONJ
easat-4305	184	44	prevention	prevention	NOUN
easat-4305	184	45	,	,	PUNCT
easat-4305	184	46	vol	vol	NOUN
easat-4305	184	47	.	.	PROPN
easat-4305	184	48	29	29	NUM
easat-4305	184	49	,	,	PUNCT
easat-4305	184	50	no	no	INTJ
easat-4305	184	51	.	.	NOUN
easat-4305	184	52	12	12	NUM
easat-4305	184	53	,	,	PUNCT
easat-4305	184	54	pp	pp	ADJ
easat-4305	184	55	.	.	PUNCT
easat-4305	185	1	2495	2495	NUM
easat-4305	185	2	-	-	SYM
easat-4305	185	3	2503	2503	NUM
easat-4305	185	4	,	,	PUNCT
easat-4305	185	5	2020	2020	NUM
easat-4305	185	6	.	.	PUNCT
easat-4305	186	1	https://doi.org/10.69622/26763760	https://doi.org/10.69622/26763760	X
easat-4305	187	1	[	[	X
easat-4305	187	2	6	6	X
easat-4305	187	3	]	]	PUNCT
easat-4305	187	4	f.	f.	PROPN
easat-4305	187	5	lardeux	lardeux	PROPN
easat-4305	187	6	,	,	PUNCT
easat-4305	187	7	g.	g.	PROPN
easat-4305	187	8	torrico	torrico	PROPN
easat-4305	187	9	,	,	PUNCT
easat-4305	187	10	and	and	CCONJ
easat-4305	187	11	c.	c.	PROPN
easat-4305	187	12	aliaga	aliaga	PROPN
easat-4305	187	13	,	,	PUNCT
easat-4305	187	14	"	"	PUNCT
easat-4305	187	15	calculation	calculation	NOUN
easat-4305	187	16	of	of	ADP
easat-4305	187	17	the	the	DET
easat-4305	187	18	elisa	elisa	NOUN
easat-4305	187	19	’s	’s	PART
easat-4305	187	20	cut	cut	NOUN
easat-4305	187	21	-	-	PUNCT
easat-4305	187	22	off	off	NOUN
easat-4305	187	23	based	base	VERB
easat-4305	187	24	on	on	ADP
easat-4305	187	25	the	the	DET
easat-4305	187	26	change	change	NOUN
easat-4305	187	27	-	-	PUNCT
easat-4305	187	28	point	point	NOUN
easat-4305	187	29	analysis	analysis	NOUN
easat-4305	187	30	method	method	NOUN
easat-4305	187	31	for	for	ADP
easat-4305	187	32	detection	detection	NOUN
easat-4305	187	33	of	of	ADP
easat-4305	187	34	trypanosoma	trypanosoma	PROPN
easat-4305	187	35	cruzi	cruzi	PROPN
easat-4305	187	36	infection	infection	NOUN
easat-4305	187	37	in	in	ADP
easat-4305	187	38	bolivian	bolivian	ADJ
easat-4305	187	39	dogs	dog	NOUN
easat-4305	187	40	in	in	ADP
easat-4305	187	41	the	the	DET
easat-4305	187	42	absence	absence	NOUN
easat-4305	187	43	of	of	ADP
easat-4305	187	44	controls	control	NOUN
easat-4305	187	45	,	,	PUNCT
easat-4305	187	46	"	"	PUNCT
easat-4305	187	47	memórias	memórias	PROPN
easat-4305	187	48	do	do	VERB
easat-4305	187	49	instituto	instituto	PROPN
easat-4305	187	50	oswaldo	oswaldo	PROPN
easat-4305	187	51	cruz	cruz	PROPN
easat-4305	187	52	,	,	PUNCT
easat-4305	187	53	vol	vol	NOUN
easat-4305	187	54	.	.	NOUN
easat-4305	187	55	111	111	NUM
easat-4305	187	56	,	,	PUNCT
easat-4305	187	57	no	no	INTJ
easat-4305	187	58	.	.	NOUN
easat-4305	187	59	08	08	NUM
easat-4305	187	60	,	,	PUNCT
easat-4305	187	61	pp	pp	ADJ
easat-4305	187	62	.	.	PUNCT
easat-4305	187	63	501	501	NUM
easat-4305	187	64	-	-	SYM
easat-4305	187	65	504	504	NUM
easat-4305	187	66	,	,	PUNCT
easat-4305	187	67	2016	2016	NUM
easat-4305	187	68	.	.	PUNCT
easat-4305	188	1	https://doi.org/10.1590/0074-02760160119	https://doi.org/10.1590/0074-02760160119	PRON
easat-4305	188	2	[	[	X
easat-4305	188	3	7	7	NUM
easat-4305	188	4	]	]	PUNCT
easat-4305	188	5	k.	k.	PROPN
easat-4305	188	6	c.	c.	PROPN
easat-4305	188	7	das	das	PROPN
easat-4305	188	8	and	and	CCONJ
easat-4305	188	9	c.	c.	PROPN
easat-4305	188	10	w.	w.	PROPN
easat-4305	188	11	white	white	PROPN
easat-4305	188	12	,	,	PUNCT
easat-4305	188	13	"	"	PUNCT
easat-4305	188	14	detection	detection	NOUN
easat-4305	188	15	of	of	ADP
easat-4305	188	16	thioredoxin	thioredoxin	PROPN
easat-4305	188	17	in	in	ADP
easat-4305	188	18	human	human	ADJ
easat-4305	188	19	serum	serum	NOUN
easat-4305	188	20	and	and	CCONJ
easat-4305	188	21	biological	biological	ADJ
easat-4305	188	22	samples	sample	NOUN
easat-4305	188	23	using	use	VERB
easat-4305	188	24	a	a	DET
easat-4305	188	25	sensitive	sensitive	ADJ
easat-4305	188	26	sandwich	sandwich	NOUN
easat-4305	188	27	elisa	elisa	NOUN
easat-4305	188	28	with	with	ADP
easat-4305	188	29	digoxigenin	digoxigenin	NOUN
easat-4305	188	30	-	-	PUNCT
easat-4305	188	31	labeled	label	VERB
easat-4305	188	32	antibody	antibody	NOUN
easat-4305	188	33	,	,	PUNCT
easat-4305	188	34	"	"	PUNCT
easat-4305	188	35	journal	journal	NOUN
easat-4305	188	36	of	of	ADP
easat-4305	188	37	immunological	immunological	ADJ
easat-4305	188	38	methods	method	NOUN
easat-4305	188	39	,	,	PUNCT
easat-4305	188	40	vol	vol	NOUN
easat-4305	188	41	.	.	PROPN
easat-4305	189	1	211	211	NUM
easat-4305	189	2	,	,	PUNCT
easat-4305	189	3	no	no	INTJ
easat-4305	189	4	.	.	NOUN
easat-4305	189	5	1	1	NUM
easat-4305	189	6	-	-	SYM
easat-4305	189	7	2	2	NUM
easat-4305	189	8	,	,	PUNCT
easat-4305	189	9	pp	pp	ADJ
easat-4305	189	10	.	.	PUNCT
easat-4305	190	1	9	9	NUM
easat-4305	190	2	-	-	SYM
easat-4305	190	3	20	20	NUM
easat-4305	190	4	,	,	PUNCT
easat-4305	190	5	1998	1998	NUM
easat-4305	190	6	.	.	PUNCT
easat-4305	191	1	https://doi.org/10.1016/s0022-1759(97)00163-4	https://doi.org/10.1016/s0022-1759(97)00163-4	NOUN
easat-4305	192	1	[	[	X
easat-4305	192	2	8	8	NUM
easat-4305	192	3	]	]	PUNCT
easat-4305	192	4	m.-j	m.-j	PROPN
easat-4305	192	5	.	.	PUNCT
easat-4305	193	1	lee	lee	PROPN
easat-4305	193	2	,	,	PUNCT
easat-4305	193	3	e.-s	e.-s	PROPN
easat-4305	193	4	.	.	PUNCT
easat-4305	194	1	lee	lee	PROPN
easat-4305	194	2	,	,	PUNCT
easat-4305	194	3	t.-h	t.-h	PROPN
easat-4305	194	4	.	.	PUNCT
easat-4305	195	1	kim	kim	PROPN
easat-4305	195	2	,	,	PUNCT
easat-4305	195	3	j.-w	j.-w	PROPN
easat-4305	195	4	.	.	PUNCT
easat-4305	196	1	jeon	jeon	PROPN
easat-4305	196	2	,	,	PUNCT
easat-4305	196	3	y.	y.	PROPN
easat-4305	196	4	kim	kim	PROPN
easat-4305	196	5	,	,	PUNCT
easat-4305	196	6	and	and	CCONJ
easat-4305	196	7	b.-k	b.-k	PROPN
easat-4305	196	8	.	.	PUNCT
easat-4305	197	1	oh	oh	INTJ
easat-4305	197	2	,	,	PUNCT
easat-4305	197	3	"	"	PUNCT
easat-4305	197	4	detection	detection	NOUN
easat-4305	197	5	of	of	ADP
easat-4305	197	6	thioredoxin-1	thioredoxin-1	NUM
easat-4305	197	7	using	use	VERB
easat-4305	197	8	ultra	ultra	ADJ
easat-4305	197	9	-	-	ADJ
easat-4305	197	10	sensitive	sensitive	ADJ
easat-4305	197	11	elisa	elisa	NOUN
easat-4305	197	12	with	with	ADP
easat-4305	197	13	enzyme	enzyme	NOUN
easat-4305	197	14	-	-	PUNCT
easat-4305	197	15	encapsulated	encapsulate	VERB
easat-4305	197	16	human	human	ADJ
easat-4305	197	17	serum	serum	NOUN
easat-4305	197	18	albumin	albumin	NOUN
easat-4305	197	19	nanoparticle	nanoparticle	NOUN
easat-4305	197	20	,	,	PUNCT
easat-4305	197	21	"	"	PUNCT
easat-4305	197	22	nano	nano	NOUN
easat-4305	197	23	convergence	convergence	NOUN
easat-4305	197	24	,	,	PUNCT
easat-4305	197	25	vol	vol	NOUN
easat-4305	197	26	.	.	PROPN
easat-4305	197	27	6	6	NUM
easat-4305	197	28	,	,	PUNCT
easat-4305	197	29	pp	pp	ADJ
easat-4305	197	30	.	.	PUNCT
easat-4305	198	1	1	1	NUM
easat-4305	198	2	-	-	SYM
easat-4305	198	3	7	7	NUM
easat-4305	198	4	,	,	PUNCT
easat-4305	198	5	2019	2019	NUM
easat-4305	198	6	.	.	PUNCT
easat-4305	199	1	https://doi.org/10.1186/s40580-019-0210-5	https://doi.org/10.1186/s40580-019-0210-5	NUM
easat-4305	199	2	https://creativecommons.org/licenses/by/4.0/	https://creativecommons.org/licenses/by/4.0/	PROPN
easat-4305	199	3	https://doi.org/10.17998/jlc.2024.03.13	https://doi.org/10.17998/jlc.2024.03.13	PRON
easat-4305	199	4	https://doi.org/10.3350/cmh.2023.0070	https://doi.org/10.3350/cmh.2023.0070	VERB
easat-4305	199	5	https://doi.org/10.3390/cancers14163997	https://doi.org/10.3390/cancers14163997	PROPN
easat-4305	199	6	https://doi.org/10.3390/cancers13194765	https://doi.org/10.3390/cancers13194765	PROPN
easat-4305	200	1	https://doi.org/10.69622/26763760	https://doi.org/10.69622/26763760	CCONJ
easat-4305	200	2	https://doi.org/10.1590/0074-02760160119	https://doi.org/10.1590/0074-02760160119	PROPN
easat-4305	200	3	https://doi.org/10.1016/s0022-1759(97)00163-4	https://doi.org/10.1016/s0022-1759(97)00163-4	PROPN
easat-4305	200	4	https://doi.org/10.1186/s40580-019-0210-5	https://doi.org/10.1186/s40580-019-0210-5	NUM
easat-4305	200	5	1018	1018	NUM
easat-4305	200	6	edelweiss	edelweiss	PROPN
easat-4305	200	7	applied	apply	VERB
easat-4305	200	8	science	science	NOUN
easat-4305	200	9	and	and	CCONJ
easat-4305	200	10	technology	technology	NOUN
easat-4305	200	11	issn	issn	PROPN
easat-4305	200	12	:	:	PUNCT
easat-4305	200	13	2576	2576	NUM
easat-4305	200	14	-	-	SYM
easat-4305	200	15	8484	8484	NUM
easat-4305	200	16	vol	vol	NOUN
easat-4305	200	17	.	.	PROPN
easat-4305	201	1	9	9	NUM
easat-4305	201	2	,	,	PUNCT
easat-4305	201	3	no	no	INTJ
easat-4305	201	4	.	.	NOUN
easat-4305	201	5	1	1	NUM
easat-4305	201	6	:	:	PUNCT
easat-4305	201	7	1010	1010	NUM
easat-4305	201	8	-	-	SYM
easat-4305	201	9	1018	1018	NUM
easat-4305	201	10	,	,	PUNCT
easat-4305	201	11	2025	2025	NUM
easat-4305	201	12	doi	doi	NOUN
easat-4305	201	13	:	:	PUNCT
easat-4305	201	14	10.55214/25768484.v9i1.4305	10.55214/25768484.v9i1.4305	NUM
easat-4305	201	15	©	©	PROPN
easat-4305	201	16	2025	2025	NUM
easat-4305	201	17	by	by	ADP
easat-4305	201	18	the	the	DET
easat-4305	201	19	authors	author	NOUN
easat-4305	201	20	;	;	PUNCT
easat-4305	201	21	licensee	licensee	PROPN
easat-4305	201	22	learning	learning	NOUN
easat-4305	201	23	gate	gate	NOUN
easat-4305	202	1	[	[	X
easat-4305	202	2	9	9	NUM
easat-4305	202	3	]	]	PUNCT
easat-4305	202	4	k.	k.	PROPN
easat-4305	202	5	m.	m.	PROPN
easat-4305	202	6	abdelwahab	abdelwahab	PROPN
easat-4305	202	7	,	,	PUNCT
easat-4305	202	8	w.	w.	PROPN
easat-4305	202	9	a.	a.	PROPN
easat-4305	202	10	ibrahim	ibrahim	PROPN
easat-4305	202	11	,	,	PUNCT
easat-4305	202	12	s.	s.	PROPN
easat-4305	202	13	a.	a.	PROPN
easat-4305	202	14	b.	b.	PROPN
easat-4305	202	15	saleh	saleh	PROPN
easat-4305	202	16	,	,	PUNCT
easat-4305	202	17	a.	a.	PROPN
easat-4305	202	18	a.	a.	PROPN
easat-4305	202	19	a.	a.	PROPN
easat-4305	202	20	elbarky	elbarky	PROPN
easat-4305	202	21	,	,	PUNCT
easat-4305	202	22	and	and	CCONJ
easat-4305	202	23	g.	g.	PROPN
easat-4305	202	24	a.	a.	PROPN
easat-4305	202	25	mohamed	mohamed	PROPN
easat-4305	202	26	,	,	PUNCT
easat-4305	202	27	"	"	PUNCT
easat-4305	202	28	evaluation	evaluation	NOUN
easat-4305	202	29	of	of	ADP
easat-4305	202	30	serum	serum	NOUN
easat-4305	202	31	thioredoxin	thioredoxin	PROPN
easat-4305	202	32	as	as	ADP
easat-4305	202	33	a	a	DET
easat-4305	202	34	hepatocellular	hepatocellular	ADJ
easat-4305	202	35	carcinoma	carcinoma	NOUN
easat-4305	202	36	diagnostic	diagnostic	ADJ
easat-4305	202	37	marker	marker	NOUN
easat-4305	202	38	,	,	PUNCT
easat-4305	202	39	"	"	PUNCT
easat-4305	202	40	egyptian	egyptian	ADJ
easat-4305	202	41	liver	liver	NOUN
easat-4305	202	42	journal	journal	NOUN
easat-4305	202	43	,	,	PUNCT
easat-4305	202	44	vol	vol	NOUN
easat-4305	202	45	.	.	PROPN
easat-4305	203	1	14	14	NUM
easat-4305	203	2	,	,	PUNCT
easat-4305	203	3	no	no	INTJ
easat-4305	203	4	.	.	NOUN
easat-4305	203	5	1	1	NUM
easat-4305	203	6	,	,	PUNCT
easat-4305	203	7	p.	p.	NOUN
easat-4305	203	8	3	3	NUM
easat-4305	203	9	,	,	PUNCT
easat-4305	203	10	2024	2024	NUM
easat-4305	203	11	.	.	PUNCT
easat-4305	204	1	https://doi.org/10.1186/s43066-024-00309-8	https://doi.org/10.1186/s43066-024-00309-8	PUNCT
easat-4305	205	1	[	[	X
easat-4305	205	2	10	10	NUM
easat-4305	205	3	]	]	X
easat-4305	205	4	j.	j.	PROPN
easat-4305	205	5	li	li	PROPN
easat-4305	205	6	et	et	PROPN
easat-4305	205	7	al	al	PROPN
easat-4305	205	8	.	.	PROPN
easat-4305	205	9	,	,	PUNCT
easat-4305	205	10	"	"	PUNCT
easat-4305	205	11	serum	serum	PROPN
easat-4305	205	12	thioredoxin	thioredoxin	PROPN
easat-4305	205	13	is	be	AUX
easat-4305	205	14	a	a	DET
easat-4305	205	15	diagnostic	diagnostic	ADJ
easat-4305	205	16	marker	marker	NOUN
easat-4305	205	17	for	for	ADP
easat-4305	205	18	hepatocellular	hepatocellular	ADJ
easat-4305	205	19	carcinoma	carcinoma	NOUN
easat-4305	205	20	,	,	PUNCT
easat-4305	205	21	"	"	PUNCT
easat-4305	205	22	oncotarget	oncotarget	NOUN
easat-4305	205	23	,	,	PUNCT
easat-4305	205	24	vol	vol	NOUN
easat-4305	205	25	.	.	PROPN
easat-4305	206	1	6	6	NUM
easat-4305	206	2	,	,	PUNCT
easat-4305	206	3	no	no	INTJ
easat-4305	206	4	.	.	NOUN
easat-4305	206	5	11	11	NUM
easat-4305	206	6	,	,	PUNCT
easat-4305	206	7	p.	p.	NOUN
easat-4305	206	8	9551	9551	NUM
easat-4305	206	9	,	,	PUNCT
easat-4305	206	10	2015	2015	NUM
easat-4305	206	11	.	.	PUNCT
easat-4305	207	1	https://doi.org/10.18632/oncotarget.3314	https://doi.org/10.18632/oncotarget.3314	NOUN
easat-4305	208	1	[	[	X
easat-4305	208	2	11	11	NUM
easat-4305	208	3	]	]	PUNCT
easat-4305	208	4	t.	t.	PROPN
easat-4305	208	5	sheta	sheta	PROPN
easat-4305	208	6	,	,	PUNCT
easat-4305	208	7	m.	m.	NOUN
easat-4305	208	8	selim	selim	PROPN
easat-4305	208	9	,	,	PUNCT
easat-4305	208	10	m.	m.	PROPN
easat-4305	208	11	sabry	sabry	PROPN
easat-4305	208	12	,	,	PUNCT
easat-4305	208	13	and	and	CCONJ
easat-4305	208	14	a.	a.	NOUN
easat-4305	208	15	saed	saed	NOUN
easat-4305	208	16	,	,	PUNCT
easat-4305	208	17	"	"	PUNCT
easat-4305	208	18	serum	serum	PROPN
easat-4305	208	19	thioredoxin	thioredoxin	PROPN
easat-4305	208	20	as	as	ADP
easat-4305	208	21	a	a	DET
easat-4305	208	22	diagnostic	diagnostic	ADJ
easat-4305	208	23	marker	marker	NOUN
easat-4305	208	24	for	for	ADP
easat-4305	208	25	hepatocellular	hepatocellular	ADJ
easat-4305	208	26	carcinoma	carcinoma	NOUN
easat-4305	208	27	in	in	ADP
easat-4305	208	28	cirrhotic	cirrhotic	ADJ
easat-4305	208	29	hepatitis	hepatitis	NOUN
easat-4305	208	30	c	c	NOUN
easat-4305	208	31	patients	patient	NOUN
easat-4305	208	32	,	,	PUNCT
easat-4305	208	33	"	"	PUNCT
easat-4305	208	34	medical	medical	ADJ
easat-4305	208	35	journal	journal	NOUN
easat-4305	208	36	of	of	ADP
easat-4305	208	37	viral	viral	ADJ
easat-4305	208	38	hepatitis	hepatitis	NOUN
easat-4305	208	39	,	,	PUNCT
easat-4305	208	40	vol	vol	NOUN
easat-4305	208	41	.	.	PROPN
easat-4305	208	42	5	5	NUM
easat-4305	208	43	,	,	PUNCT
easat-4305	208	44	no	no	INTJ
easat-4305	208	45	.	.	NOUN
easat-4305	208	46	2	2	NUM
easat-4305	208	47	,	,	PUNCT
easat-4305	208	48	pp	pp	ADJ
easat-4305	208	49	.	.	PUNCT
easat-4305	209	1	9	9	NUM
easat-4305	209	2	-	-	SYM
easat-4305	209	3	15	15	NUM
easat-4305	209	4	,	,	PUNCT
easat-4305	209	5	2021	2021	NUM
easat-4305	209	6	.	.	PUNCT
easat-4305	210	1	https://doi.org/10.21608/mjvh.2021.158271	https://doi.org/10.21608/mjvh.2021.158271	NOUN
easat-4305	210	2	https://doi.org/10.1186/s43066-024-00309-8	https://doi.org/10.1186/s43066-024-00309-8	NUM
easat-4305	210	3	https://doi.org/10.18632/oncotarget.3314	https://doi.org/10.18632/oncotarget.3314	NOUN
easat-4305	210	4	https://doi.org/10.21608/mjvh.2021.158271	https://doi.org/10.21608/mjvh.2021.158271	NOUN